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Human cytochromes P450 (CYP) constitute one of the most important and studied classes of 
phase I drug metabolizing enzymes. A small group of 6-7 isoforms of the 57 identified until 
now accounts for 90-95% of the metabolism of clinically used drugs and can contain mutations 
(single nucleotide polymorphisms) that, when located in the coding regions, can lead to absent, 
deficient or enhanced enzyme activity. Thanks to the development of pharmacogenetics and 
later on pharmacogenomics, the presence of these single nucleotide polymorphisms (SNP) has 
been associated to inter-individual and inter-ethnic variability in the response to several 
important therapeutic agents. Due to this direct correlation between polymorphism and efficacy 
of drug treatment, the pharmaceutical industry is particularly interested in developing new 
analytical tools for the determination of the cytochrome P450 in vitro metabolism to correlate to 
the in vivo situation. The use of amperometric sensing systems represents an interesting 
alternative to the traditional methods.  
 
In the present study an electrochemical characterisation of the human cytochrome P450 2C9 and 
its two main allelic variants the CYP2C9*2 and CYP2C9*3 have been performed. Different 
methods of immobilisation and electrodes have been used to investigate the conditions that are 
more suitable to maintain and guarantee the active state and biocatalytic response of an 
immobilised cytochrome P450.  
 
The CYP2C9 and its two main allelic variants CYP2C9*2 and CYP2C9*3 have been inserted 
into engineered constructs where the human cytochrome P450 gene is linked to artificial redox 
chains to regulate the electron flow from the electrode surface to the haem. All the constructs 
have been successfully expressed and purified in heterologous E.Coli cells, with the 
CYP2C9FLD chimeras showing higher yields.  
Preliminary spectroelectrochemical studies on semi-conductive and optically transparent tin-
dioxide allowed the combination of absorption spectroscopy and electrochemistry (cyclic 
voltammetry) to ascertain the native state of these P450 enzymes once immobilised. The results 
showed how the conversion from the active P450 form to the inactive P420 one can be achieved 
by modifying the surface with polycations with slightly different chemical properties. A proper 
characterisation of the two species was performed for the first time and, under certain 
conditions, the inactive P420 species appeared to dominate the cyclic voltammogram (CV). 
Similar findings have been observed when the CYP2C9 wild type have been electrochemically 
characterised on DDAB and PDDA modified glassy carbon electrodes. Electrocatalysis in 
presence of S-warfarin and FT-IR spectra of the CYP2C9/DDAB/GC electrodes revealed higher 
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catalytic activity and maintenance of the native secondary structure of the enzyme. 
Immobilisation of the CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD on DDAB modified 
glassy carbon electrodes showed well defined redox couples on the oxygen-free cyclic 
voltammograms (CVs) and mid point potentials of all enzymes were calculated. Electrocatalysis 
in presence of substrate and quantification of the product formed showed lower catalytic 
activities for the CYP2C9*3FLD and CYP2C9*2FLD compared to the wild type CYP2C9FLD 
as it was expected from literature data. When the CYP2C9FLD, CYP2C9*2FLD and 
CYP2C9*3FLD were immobilised on alkanethiol modified gold electrodes, the system was 
tested as both amperometric sensor and catalyser. Parameters such as the apparent Michaelis–
Menten constant Km and the Vmax were determined and the metabolic profile of S-warfarin was 
confirmed to be in line with literature findings.  
The fundamental knowledge acquired was then transferred to a commercial prototype sensor for 
testing the metabolic profile of known drugs. Encouraging results in line with the previous 







































Chapter 1: INTRODUCTION 
 




The cytochromes P450 (CYP) constitute a super-family of haem-thiolate enzymes present in 
almost all life forms, from bacteria through to plants and animals. They are monoxygenases 
whose activity can be associated with two main functional roles. The first is a protective role of 
degradation as they convert xenobiotics (molecules exogenous to the organism) to more polar 
and execrable compounds. The second function is the biosynthesis of signalling molecules 
crucial for controlling the development and homeostasis processes.  




where RH is the substrate molecule, ROH is the oxygenated metabolite and the two reducing 
equivalents are supplied by an external redox partner, which is usually an FAD and FMN 
containing NADPH oxidoreductase flavoprotein. 
The metabolic involvement of cytochromes P450 has attracted the attention of scientists in a 
variety of different disciplines (figure 1.1). Up-to date more than 15,000 cytochrome P450 
genes have been reported (PubMed database) and annotated on a variety of websites 
(http://drnelson.utmem.edu/CytochromeP450.html). Though only a dozen or so papers were 
published in 1966, the total number of works regarding cytochromes P450 stands to 61,867 as 



















Cytochromes P450 (CYP) were first discovered as pigments in rat liver homogenates more than 
half a century ago (Garfinkel, 1958; Klingeberg, 1958). They were referred to as “P450” 
(pigment 450) because they showed a unique absorbance at 450 nm when reduced with sodium 
dithionite and combined with carbon monoxide. Just a few years later the real nature of 
hemoproteins was revealed and the term “Cytochrome P450” was proposed (Omura and Sato, 
1964). The reaction with sodium dithionite and carbon monoxide represents an assay that is 
nowadays considered a specific method of identification of a cytochrome P450 with a correctly 




Several studies have been performed to further understanding the cytochromes P450’s 
phylogeny. The natural history of cytochromes P450 dates back perhaps three billion years and 
they occur variously in archaea, eubacteria and eukaryota (Nelson et al., 1996; Stegeman and 
Livingstone, 1998).  
Relationships between cytochromes P450 present in vertebrates and invertebrates were 
originally obscured because of evolutionary distance, independent duplications, gene conversion 
and gene loss. However, thanks to the discovery of new methodologies for their heterologous 
expression and crystallization, the structure and function of most of them have been determined 
and have revealed a unique and highly conserved fold. It has also been suggested that 
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eukaryotes and prokaryotes are immediate relatives with a unique ancestral gene dated at more 
than 3.5 billion years ago. The bacterial cytochromes P450 seem to be one of the first CYPs that 
most likely originated during early evolution to provide oxidative and peroxidative metabolism 
of important endogenous molecules and environmental chemicals utilized for energy. They then 
decreased their specificity as soon as they had to contend with a more diverse and hostile 
environment.  
The mammalian P450 gene family dates instead back about a billion years when it evolved from 
the bacterial CYP51 (lanosterol 14a-demethylase) of Ascomicete fungi (Nelson 1999). The 
xenobiotic metabolising activity of human CYPs evolved in a second step, about 600 million 
years ago when interactions between plants and animals started. While plants were evolving 
new biosynthetic pathways for their reproductive cycles and for defending themselves from 
animals and insect predators, animals were instead evolving new drug-metabolizing genes to 
cope with the ever changing plant toxic metabolites. Subsequent dietary pressure and 
environmental chemicals caused further diversifications (Ingelman-Sandeberg et al., 1999). 
Such diversifications are at the origin of the variety of polymorphic cytochromes P450 allelic 
variants. Nevertheless the question of whether the interethnic differences in the distribution of 




Because of the large number of discovered cytochromes P450, two nomenclature systems have 
been created, one for the genes and one for the proteins (Nebert et al., 1987). The P450 genes 
are indicated with the root symbol CYP for cytochrome P450 (“cyp” for mouse and 
Droshophila). The cDNA and genes are italicized, followed by an Arabic numeral designating 
the P450 family, a letter indicating the subfamily and an Arabic numeral representing the 
individual gene (isoform) within the subfamily, e.g., “CYP2C19”. The mRNA and enzyme in 
all species including mice have all capital letters without italics, e.g., “CYP2C9”. Genes within 
the same subfamily can share considerable sequence homology. However, where a single gene 
demonstrates variations, it is termed polymorphic. Polymorphic genes give rise to polymorphic 
enzymes with quite different enzyme activities and they are indicated by a further number 
following an asterisk, e.g. “CYP2C9*2”. This number refers to the chronological order of 
discovery of the allelic variants. 
Similar rules are applied for naming the proteins. Proteins with more than 40% of sequence 
identity are grouped in the same family (this percentage does not take into account the gaps and 
unmatched ends of the sequence alignment). The name assigned for the P450 family is CYP 
followed by a number which is usually a range assigned to the family. For example the bacterial 
family of the P450cam is designated CYP101 and belongs to the bacterial family. This family 
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includes all CYPs between CYP101 and CYP199. Sometimes new families are named 
according to their evolutionary association with previously named families. Fungal, yeast and 
other lower eukaryote families go from CYP51 to CYP69, plant gene families from CYP71 to 
CYP99, bacterial families start from CYP101. Once these sets are completed, it is suggested to 
continue from CYP201 for animals, CYP501 for lower eukaryotes, CYP701 for plants and 
CYP1001 for bacteria (Poulos et al., 2007a). The subfamilies show greater than 60% sequence 
identity and are indicated by letters followed by a number indicating the order of discovery.  
Before this standardised system they were named using different criteria, often according to the 
substrate specificity or the organism of origin. This non-systematic name is still widely used for 
some well-known studied bacterial cytochromes P450 like P450 BM3 from Bacillus 
megaterium (CYP102A1), P450cam (CYP101) from Pseudomonas putida (responsible for 
metabolism of camphor) and cytochrome P450 eryF (CYP107A1) from Saccharopolyspora 
erythraea (responsible for the biosynthesis of the antibiotic erythromycin). 
In addition to the standard nomenclature system, cytochromes P450 can be classified into three 
groups according to the nature of the intermediate electron carrier proteins that deliver the 
electrons required for activity. They are therefore split into class I, II and III (Omura, 1999). As 
shown in figure 1.2 class I receives electrons from NADPH via a FAD containing ferredoxin 
reductase and an iron sulphur cluster containing ferredoxin. This class includes enzymes found 
on the mitochondrial membrane (CYP17 α- hydroxylase) and bacterial P450s (CYP101 or 
P450CAM). In class II there are P450s anchored to the endoplasmic reticulum and the redox 
partner in this case is a single membrane-anchored protein known as NADPH dependent 
cytochrome P450 reductase (CPR). NADPH is directly oxidised by CPR, which then uses its 
FAD and FMN cofactors to shuttle electrons to the P450. Examples of this class include the 
human P450s. This classification system is not perfect as microsomal P450s can also receive 
their reducing equivalents from intermediates like cytochrome b5 (Bridges et al.,   1998). 
Cytochrome b5 can in turn be reduced by either CPR or cytochrome b5 reductase, a NADH 
utilising FAD containing protein. 
Class III is represented by enzymes catalytically self-sufficient single-polypeptide enzymes 
containing binding sites for haem, FAD and FMN. These enzymes require NADPH as a source 
of electrons and represent a fused system made up of the class II components but with the 
additional advantage of being self-sufficient. The bacterial cytochrome P450 BM3 (CYP102) 
gives an example. 
Class IV includes enzymes identified from the bacterial species Rhodococcus where an FMN 
containing reductase is fused in a single polypeptide chain with a ferredoxin-like centre and a 
CYP. An FMN centre and a [2Fe2S] ferredoxin-like component deliver the electrons to the 









1.1.2.1 Conservative P450 fold 
 
Cytochromes P450 belonging to different families and organisms share a high degree of 
structural conservation in their secondary and tertiary fold.  In all cytochromes P450 the overall 
structure is conserved to guarantee the unique haem-thiolate chemistry required for the 
functional activities like the oxygen activation, the binding of a redox partner and the 
stereochemical recognition of a substrate. This is evident by comparing the structures of the two 
most distantly related cytochromes P450: the cytochrome P450cam (CYP101) from 
Pseudomonas putida, which was also the first cytochrome P450 structure solved (Poulos et al., 
1987), and the mammalian membrane-bound CYP2C5 from rabbit (Williams et al., 2000) 
(figure 1.3). A part from the N-terminal region of the microsomal cytochromes P450 that helps 
anchoring the protein to the microsomal membrane, the main difference between the two 
structures is the presence of longer surface loops in the CYP2C5: the P450cam has 20 helical 





Figure 1.3 Illustration of the common three-dimensional fold of four known cytochromes P450. 
 
The subtle variation in the position of secondary structure elements and the lengths of 
interconnecting loop regions contribute to the rich diversity of their catalytic sites and resulting 
specificities.  
The overall structure consists of β domains and α helical domains which are split in the two N- 
and C-terminal halves. The common core structure is composed of eleven α-helices (A-K) and 
four β-pleated sheets (1-4) surrounding the generally hydrophobic catalytic site buried within 
the protein. The I- and L-helices responsible for bracketing the haem are in the C-terminal half.  
The majority of the β structures are on the C-terminal side, but far away from the haem. The N-
terminal half of the molecule surrounds the inner core of C-terminal residues closest to the 
haem. The zig-zag folding of this area defines how cytochromes P450 fold (figure 1.4).  
Within this core structure only small segments of the protein are involved in contacting the 
substrate and therefore influencing the catalytic reaction cycle. These limited regions include: 
the loop between the B- and C- helices positioned over the haem that is also known as substrate 
recognition site 1 or SRS1 (Gotoh 1992); the I-helix extending over the haem pyrrole ring B 
(SRS4); the amino terminus of  β-sheet 1-4 (SRS5); the β-turn at the end of β-sheet 4 (SRS6). 
Most of the species specific variations occur in the previously mentioned α-helices and β-
pleated sheets as well as in the external loops and the loop between the F- and G- helices 
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(between SRS2 and SRS3) that is involved in defining the substrate access and/or interactions 
with the endoplasmic reticulum membrane. 
Alignments of most of the crystal structures currently available for bacterial, mammalian and 
fungi have revealed that the most likely contributors to the diversity in substrate specificity 
among the cytochromes P450 are the B, the F-G and the β4 regions (Baudry et al., 2006).  
 
 
Figure 1.4 General structure of cytochrome P450. Representation of the α-carbon backbone of the 
cytochromes P450 in which the α-elices are shown in red, the β-sheets in yellow and coils in green. The 
haem is shown as red sticks. 
 
1.1.2.2 Cysteine ligand  
 
The most conserved elements of the cytochrome P450 structure centre on the haem-thiolate 
oxygen activation chemistry. A rigid architecture characterises the segment housing the Cys 
ligand, just prior to the L helix. This rigid architecture is required to both protect the Cys ligand 
and hold it in place in order to accept H-bonds from surrounding peptides that have no H-bond 
acceptors other than the thiolate ligand (Poulos et al., 2007a). These H-bonds regulate the haem 
redox potential that otherwise would be too low to favour the reduction of the haem iron by the 
redox partner (Ueyama et al., 1983; Ueyama et al., 1996). Thus the protein must provide a 
suitable electrostatic environment around the Cys ligand in order to maintain the redox potential 
in a physiologically accessible range. 
Another common feature is a group of propionates that anchor the haem in place and are usually 




1.1.2.3 Oxygen binding region 
 
The other highly conserved region involved in the oxygen activation is the portion of the helix I 
near the haem iron. In this region in P450cam there is a highly conserved Thr252 which is 
involved in a local helical distortion through donating a H-bond to carbonyl oxygen that would 
normally be involved in a α-helical H-bond. This local widening of the I helix enables the 
solvent to be positioned into the helical groove and the oxygen to start its activation process 
(Schlichting et al., 2000). This Thr252 is not conserved in all cytochromes P450 but it is 
substituted by other residues of similar properties like Ala and Asn in cytochrome P450eryF and 
P450cin respectively. The function of this arrangement is to guarantee a proper delivery of 
protons to the iron-linked oxygen required for the cleavage of the O-O bond thus generating the 
active Fe-O hydroxylating species (Vidakovic et al., 1998; Benson et al., 1997). 
 
1.1.2.4 Membrane binding 
 
One of the main differences between human and bacterial cytochromes P450 is the presence of 
an N-terminal membrane anchoring in the microsomal cytochromes P450. In particular the 
human cytochromes P450 are membrane-bound proteins mainly incorporated into the 
endoplasmic reticulum, but some of them are located on the matrix side of the mitochondrial 
inner membrane. The responsible of the membrane anchoring is a longer N-terminal 
polypeptide chain of 30-50 amino acids that precedes the catalytic domain. The mitochondrial 
cytochromes P450 loose this targeting sequence when they transfer into mitochondria (Omura et 
al., 1991), while for the microsomal cytochromes P450 the leader sequence is retained and 
inserted into the endoplasmic reticulum (Sakaguchi et al., 1993). The N-terminal sequence is 
not associated with function (Cosme et al., 2000). 
An important unknown to clarify is the interaction between the membrane and the cytochrome 
P450. Atomic force microscopy studies indicate that the cytochrome P450 extends about 35 Å 
above the membrane which means that in addition to the N-terminal membrane anchor, other 
regions of the protein must be embedded into the membrane (Bayburt et al., 2002). A model has 
been created after analysing all these findings. In this model the F/G loop and the substrate 
access channel are oriented towards the membrane. In such configuration the lipophilic 
substrate are partitioned between the membrane and the active site pocket. In the case of the 
human CYP3A4 the active site shows to be quite adaptable since it is able to metabolise almost 
half of all drugs nowadays used. The fact that this isoform is able to adapt to a variety of 
molecules indicates that the F/G loop area is quite flexible (Poulos et al., 2007b). Molecular 
dynamic simulations on CYP3A4 assign this flexility to a Phe cluster on the F/G loop (Park et 
al., 2005).   
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Also a proline rich motif at the N-terminus is linked to the catalytic domain through a short 
region of positively charged residues. A polypeptide chain between helices F and G close to the 
N-terminus of the catalytic domain forms a hydrophobic surface that could promote the transfer 
of hydrophobic substrates from the membrane to the cytochrome P450. Moreover this 
hydrophobic region could also orient the protein to facilitate interactions with the reductase, 
which is positioned along the surface of the reticulum endoplasmic (Poulos, 2005). 
 
1.1.3 Function: the catalytic cycle 
 
The cytochromes P450 are mixed-function monooxygenases able to catalyse the addition of one 
oxygen atom from molecular oxygen to a substrate using the reducing power of NADPH, as 
shown in the equation:  
RH + O2 + 2e - + 2H+      →       R-OH + H2O 
The active species of the enzyme is based on an iron ligated to a protoporphyrin IX macrocycle 
and two additional axial ligands: one, called proximal, is a thiolate from a cysteinate side chain 
of the protein and the other, called distal, is a variable ligand that changes during the cycle. 
When the distal group becomes an oxo group, the species becomes a reactive compound and 
one of the most potent oxidants known in nature. The catalytic cycle is schematically shown in 
figure 1.5. 
The resting state of the enzyme is a six-coordinate low-spin FeIII (1) that shows the porphyrin 
nitrogen donor atoms occupying the four equatorial positions, a proximal cysteine and a distal 
water molecule in the axial positions. Being six-coordinated, the d-block orbitals of the complex 
are split into the three-below-two molecular orbitals. Consequently, the five d-electrons of the 
complex occupy the lower orbital leading to a low spin species. 
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Figure 1.5 The cytochrome P450 catalytic cycle. The substrate is designated as RH and the oxidised 
product as ROH.  
 
Catalysis is initiated by substrate binding in the protein active site with displacement of the axial 
water and conversion of the six-coordinate low-spin FeIII haem to a five-coordinate high-spin 
complex (2). The spin state is due to the iron that pops out of the plane weakening the 
interaction of the d-orbital with the ligand. The five d-electrons occupy the d-block in a high-
spin fashion, and the complex becomes a good electron acceptor. The substrate binding is 
accompanied by a change in haem potential that varies according to the substrate but that in 
general is greater than +100 mV. This change in potential triggers a one-electron transfer from 
the reductase domain that reduces (2) to the RH FeII complex (3). The one-electron reduction to 
FeII allows dioxygen to bind to the iron, forming the FeII-O2 complex (4) (ferrous dioxygen 
complex). The rate-limiting step in the cycle is a second one-electron reduction that generates a 
peroxy complex, FeIII-OOH- complex (5) (ferric-dioxo complex). The ferric dioxo complex is a 
good Lewis base, and therefore undergoes protonation to give the ferric peroxide complex (6). 
The latter is still a good Lewis base able to undergo a second protonation and release a water 
molecule leading to the high valent iron-oxo complex (7) also referred to as compound I. The 
precise nature of this iron-oxo complex is not definitely known, although most likely it is a 
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FeIV=O unit coupled to a porphyrin cation radical. In the standard catalytic cycle this complex 
transfers the distal oxygen atom to the substrate, which is released and replaced by a water 
molecule.  
A significant impact on the cycle is made by the good electron donor ability of the proximal 
thiolate ligand that is referred to as the “push effect” (Dawson et al., 1976). A second important 
feature that guarantees the efficacy of the cycle is the hydrogen bonding interaction in the 
proximal side with the thiolate ligand in the cysteine loop. As shown by Poulos and 
subsequently by Schlichting in P450cam the sulphur ligand is hydrogen bonded to three amidic 
hydrogens of the side chains of Gln360, Gly359 and Leu358, while a fourth Gln360 donates 
hydrogen bond to the carbonyl group of the cysteine (Poulos et al., 1996; Schlichting et al., 
2000). 
 
1.1.3.1 Leakage in cytochrome P450 reactions 
 
The activity of cytochrome P450 is characterised according to its main reaction or substrate. 
However side reactions can occur because of the disturbed interplay of the haem and the 
protein.  
In order to metabolise a substrate two reactions need to occur: the electron delivery cycle and 
the cytochrome P450 cycle. In the first reaction electrons are provided from NADPH to redox 
proteins (flavin proteins) which transfer the electrons directly or via other redox proteins (e.g. 
cytochrome b5) to the cytochrome P450. Instead during the second reaction the oxygen and the 
substrate RH come together to form the product ROH.  
The efficiency of product formation can be diminished by five main protein-based phenomena. 
Three causes are assigned to the electrons that are inefficiently transported to cytochrome P450 
haem through being by-passed to another cycle, or because they are blocked in their transport to 
the haem or because of an improper interaction between the cytochrome P450 haem domain and 
the reductase. In the case of the electrons entering the catalytic cycle the product formation can 
still be reduced by the interaction with inhibitors or the formation of side products. This latter 
reaction is called uncoupling or leakage of the cytochrome P450 cycle.  
As shown as dashed lines in figure 1.6 there are three other possible redox active pathways that 
can lead to an undesired final product. These abortive reactions include:  
1- Autoxidation shunt - The autoxidation of the oxy-ferrous enzyme (4) to produce a superoxide 
anion and then return back to its resting state (2).  
2- Peroxide shunt - The formation of hydrogen peroxide through the peroxide shunt, where the 
coordinated peroxide (6) dissociates from the iron and, after protonation, forms hydrogen 
peroxide and then returns to its resting state (2). 
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3- Oxidase shunt - The oxidase uncoupling pathway, whereby the ferryl-oxo intermediate (7) is 
reduced to water by two additional electrons and protons. The compound returns again to its 
resting state (2). 
 
The supply of the necessary one or two protons for the generation of the proper active 
intermediates is essential to guarantee the correct “coupling” event. The spatial orientation of 
catalytic residues and the active-site water molecules may facilitate or suppress various 
branches of the microscopic pathways that contribute to the formation of the different oxygen 
intermediates. The hydrogen bonding network surrounding the haem iron has been implicated as 
the critical component of the mechanism that defines both the catalytic activity and the effective 
branching points between productive and non-productive pathways. The pathways of proton 
delivery can involve not only backbone and side-chain moieties from the protein structure, but 
also localized water molecules, which are stabilized in the active centre of the enzyme. 
One of the key components in this mechanism is the “conserved” Thr252. Two main roles have 
been assigned to this threonine such as the direct proton source for the peroxo species, or the 
indirect effect of stabilizing the critical hydrogen bonding and water placement that serves in 
proton delivery and dioxygen bond scission. For example in P450cam the uncoupled peroxide 
formation was avoided when the Thr residue was altered to a side chain that could participate in 
a hydrogen-bonding interaction (Shimada et al., 1991). Also mutagenesis studies on the Asp251 
in P450 CYP101 have provided additional evidence for its involvement in proton delivery 
(Vidakovic et al., 1998). 
 
Figure 1.6 The cytochrome P450 catalytic cycle. The substrate is designated as RH and the oxidised 
product as ROH. Possible routes of uncoupling are shown as red dashed lines. 
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1.1.3.2 The inactive P420 species 
 
The monooxygenase activity of cytochrome P450 has been primarily attributed to the presence 
of the proximal haem ligand, a thiolate sulphur donor provided by a cysteinate residue (Poulos 
et al., 1987). This Fe-S bond yields distinct physical characteristics that have been evaluated by 
a number of spectroscopic methods (Dawson et al., 1987). The presence of this thiolate bond is 
a constant in all the intermediates of the catalytic cycle (figure1.4) and is confirmed by the 
appearance of the characteristic absorbance peak at 450 nm when the iron is reduced and 
complexed with CO. However the cytochrome P450 can undergo a universal transition to a 
stable but inactive species known as cytochrome P420 because of the formation of an 
absorption peak at 420 nm rather than at 450 nm. Chemical and physical techniques, including 
increased temperature or pressure, variations in pH, exposure to salts, denaturants, or organic 
solvents, can convert the P450 to P420 (Yu et al., 1974).  
Different theories about the structure of P420 have been formulated around the proximal haem 
iron ligand: a conformational change could substitute histidine for the proximal cysteine, 
yielding a myoglobin-like haem coordination structure; the proximal thiolate might be 
protonated, resulting in a weak thiol ligand (Collman et al., 1976); the Fe-S bond might be 
weakened by lengthening (Jung et al., 1979). The first hypothesis derives from a comparison 
between the P450cam and chloroperoxidase that also contains a proximal thiolate ligand and 
undergoes a P420-type transition. While chloroperoxidase contains a histidine in the distal 
pocket as a potential ligand to the haem iron, there are no histidines near the haem iron of 
P450cam (Martinis et al., 1996). It is therefore more probable that the proximal thiolate ligand 
is altered by protonation or by stretching the iron-sulphur bond upon reduction. 
An investigation into the ability of P420cam to bind substrates suggests that conversion to the 
P420 form involves a conformational change, which restricts the substrate-binding site and /or 
alters the ligand access channel. The stability of the P420 form seems to be due to 
conformational rearrangements, which increase surface-exposed regions and P420-P420 
interaction sites (Davydov et al., 1999). 
 
1.1.4    Human cytochromes P450 
 
To date 57 human cytochrome P450 genes have been identified, each having different site of 
tissue expression, sub cellular localization and reaction. In particular most of them are expressed 
primarily in the smooth endoplasmic reticulum of hepatocytes and only 6 are located 
exclusively in the mitochondria.  
Of these 57 isoforms, 14 are involved in steroidogenesis, 4 are involved in the metabolism of 
vitamins (A and D), 5 are involved in eicosanoid metabolism, 4 in fatty acids metabolism and 
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15 catalyze transformation of xenobiotic chemicals (table 1.1). The latter are mainly in families 
1-3, and levels of these vary considerably in humans. 75% of the drugs can be oxidized by 3 
cytochromes P450 (3A4, 2D6, 2C9) and a set of 6-7 account for 90-95% of all drug 
metabolisms (figure 1.7) (Rendic et al., 2002; Evans et al., 1999). The relative contributions of 
these xenobiotic-metabolizing cytochromes P450 are a function of the relative abundance and 
each of them is characterised by high substrate specificity (figure 1.8). 
 
Table 1.1 Classification of human cytochromes P450 based on major substrate class. 
 
Sterols Xenobiotics Fatty acid Eicosanoids Vitamins Unknown 
1B1 1A1 2J2 4F2 2R1 2A7 
7A1 1A2 4A11 4F3 24 2S1 
7B1 2A6 4B1 4F8 26A1 2U1 
8B1 2A13 4F12 5A1 26B1 2W1 
11A1 2B6  8A1 26C1 3A43 
11B1 2C8   27B1 4A22 
11B2 2C9    4F11 
17 2C18    4F22 
19 2C19    4V2 
21A2 2D6    4X1 
27A1 2E1    4Z1 
39 2F1    20A1 
46 3A4    27C1 
51 3A5     
















Figure 1.7 Contribution of individual human cytochromes P450 to the metabolism of all drugs (Rendic 








Figure 1.8 Schematic representations of the major human cytochromes P450 involved in drug 
metabolism, including major substrates and inhibitors. The sizes of the cubes indicate the mean 
percentages of the total hepatic percentages. 
 
According to table 1.1 about one-quarter of the human cytochromes P450 are clearly involved 
in the metabolism of sterols. Most of these are essential and levels of these enzymes do not 
usually vary to any great extent. In contrast the levels of cytochromes P450 listed as involved in 
xenobiotics metabolism vary considerably and are also known as polymorphic variants. 
New insights into the structure and function of human cytochromes P450 have been investigated 
thanks to the resolution of new crystal structures. Table 1.2 shows a list of chemical structures 
of human cytochromes P450 deposited onto the Protein Data Bank. 
  
Table 1.2 List of some of human cytochrome P450 structures solved and deposited on the Protein Data 
Bank website. The PDB ID indicates the Protein Data Bank Identifier of the deposited structure. 
 
PDB ID HUMAN P450 ISOFORM Resolution 
(Å) 
Reference 
1R90 CYP2C9 with flurbiprofen 
bound 
2 Wester et al., 2004 
10G5 CYP2C9 with warfarin bound 2.55 Williams et al., 2003 
1PQ2 CYP2C8 2.70 Scoch et al., 2004 
1WOE CYP3A4 2.8 Williams et al., 2004 
2JOD CYP3A4 with erythromycin 
bound 
2.75 Ekroos et al., 2006 
2JOC CYP3A4 with ketoconazole 
bound 
2.80 Ekroos et al., 2006 
2F9Q CYP2D6 3 Rowland et al., 2006 
1Z11 CYP2A6 with methoxsalen 2.05 Yano et al. 2005 
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1Z10 CYP2A6 with coumarin bound 1.90 Yano et al., 2005 
2FDW CYP2A6 with inhibitor 
(5(pyridin3Yl)furan-2-yl) 
methanamine bound  
2.05 Yano et al., 2006 
1B1C FMN binding domain of human 
cytochrome P450 reductase 
1.93 Zhao et al., 1999 
2HI4 CYP1A2 with alpha-
naphtoflavone 
1.95 Sansen et al., 2007 
2P85 Human Lung Cytochrome P450 
2A13 with indole  
2.35 Smith et al., 2007 
3E6I 2E1 in complex with the 
inhibitor indazole 
2.20 Porubsky et al., 2008 
3DAX CYP7A1 2.15 Strushkevich et al., 2008 
 
Examination of the chemical structure and physical-chemical properties of the various drugs 
metabolised by the major forms CYP2D6, CYP2C9 and CYP3A4 gives general rules for 
substrate preference: the CYP2D6 metabolises arylalkylamines (basic) with site of oxidation 5-7 
Å from protonated nitrogen; CYP2C9 interacts with lipophilic, neutral or acidic molecules with 
site of oxidation 5-8 Å from a hydrogen bond donor heteroatom; CYP3A4 metabolises 
lipophilic, neutral or basic molecules with site of oxidation favoured by ease of electron or 
hydrogen atom abstraction, such as tertiary amines (N-dealkylation) or allylic positions (Smith 
et al., 1998). 
The importance given to studies on the human cytochromes P450 increased consistently in the 
last ten years. Identification of the individual human cytochromes P450 responsible for the 
metabolism of new drug candidates is routinely carried out in the pharmaceutical industry as the 
Food and Drug Administration requires this information for every new drug application. 
Nowadays in routine practice reactions of the tested drugs with recombinant human 
cytochromes P450 associated with NADPH-P450 reductase are conducted. Activity results 
obtained with several recombinant cytochromes P450 are compared to each other and to those 
obtained with tissue microsomes. Assays are performed at different substrate concentrations to 
derive thermodynamic parameters and assign the level of interaction of the drug with the 
specific cytochrome P450 isoform (Lu et al., 2003).  
 
1.1.4.1 The human cytochrome P450 2C9 (CYP2C9) 
 
The human cytochrome P450 2C is a complex subfamily and CYP2C9 is one of its most 
important and studied isoforms. CYP2C9 metabolizes a number of therapeutically important 
drugs such as the narrow therapeutic index (NTI) agent warfarin, phenytoin and other routinely 
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prescribed compounds such as losartan, irbesartan, tolbutamide, glipizide, torsemide and 
various non-steroidal anti-inflammatory agents. 
Some endogenous compounds found normally in our body are metabolized by CYP2C9, 
including linoleic acid (epoxidation) and vitamin A (all-trans-retinoic acid, 4-hydroxylation), 
although the physiological significance is unknown (Draper et al., 2000; McSorley et al., 2000). 
CYP2C9 is primarily expressed in the liver where its level of expression is one of the highest 
(figure 1.6) but it has also been recognised in the small intestine (Obach, 2001). Similarly to all 
the other cytochrome P450 2C enzymes, the CYP2C9 is absent in fetal livers (Umbenhauer et 
al., 1987) and rise quickly in the first month after birth (Treluyer et al., 1997), while the hepatic 
level does not change with age (Brenner et al., 2003).  
The catalytic activity of CYP2C9 has been widely investigated and specific aspects have been 
identified. For instance it has been observed that 1% (v/v) of acetonitrile inhibits the catalytic 
activity of this enzyme (Tang et al., 2000). Another observation is the enhancement of the 
catalytic activity in the presence of cytochrome b5 (Yamazaki et al., 2002) or substrates like 
dapsone and analogs (Hutzler et al, 2002). The ability of CYP2C9 to use two binding sites in 
the interaction with substrates has been recognised, but the mechanism remains to be elucidated 
(Hutzler et al., 2003). 
Several studies have tried to examine the roles of a number of amino acids in the active site. 
Arg97 and Arg108 affected the activity towards diclofenac in a yeast recombinant system 
(Ridderstrom et al., 2000). Asp293 has been shown to have a relatively general structural role by 
bonding to a partner amino acid or amide (Flanagan et al., 2003). Studies with coumarins have 
suggested two substrate binding sites, one for the II-stacking of aromatic rings and another ionic 
for organic anions (He et al., 1999), as expected from this isoform whose main ligands have an 
anionic charge (Mancy et al., 1997). A comparison with the crystal structure of rabbit 
cytochrome P450 2C5 suggests that residues I99H, S220P, P221T, S286N, V292A and F295L 
are influencing the packing of substrate-binding sites and substrate-access channels (Tsao et al., 
2001). Residues 292, 295, 331 and 399 plus residues 231-288 (substrate-binding sequence 
[SRS]) have been recognized as important in CYP2C9 activities (Niwa et al., 2002). Mansuy’s 
laboratory identified residues 476, 365 and 114 as being important in diclofenac and 
sulfaphenazole binding (Melet et al., 2003). 
Sulfaphenazole has been recognized as a highly selective competitive inhibitor of CYP2C9 as 
well as other warfarin analogs (Veronese et al., 1990). Tienilic acid is instead a mechanism-
based inactivator because of S-oxygenation and unstable product reactions (Dansette et al., 
1992). 
Several models of CYP2C9 have been published. Some of these take experimental binding 
studies into consideration while others are based only on sequence homology. However in 2003 
Williams and co-workers first solved the crystal structure of human CYP2C9 (Williams et al., 
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2003) introducing an N-terminal modification and seven amino acid substitutions within the 
F/G helix and loop region. They crystallized both the warfarin-bound (PDB ID: 10G5, figure 
























Figure 1.9 The crystal structures of warfarin-bound CYP2C9 determined by Williams and co-workers 
(PDB ID: 1OG5). The haem co-factor is shown in red, the warfarin in blue (Williams et al., 2003). 
 
 
Later Wester and co-workers (Wester et al., 2004) solved the X-ray structure of the 
flurbiprofen-bound enzyme just modified at the N-terminal region to a resolution of 2.0 Å (PDB 
ID: 1R90).  
The overall structure of these two crystals is quite similar, apart from some differences due to 
the modifications introduced for crystallisation. Helices F’ and G’ are only evident in the 10G5 
structure, probably because of the substitutions introduced in the F/G loop region. The distance 
of the substrate bound from the haem iron is also different: warfarin in the 10G5 structure is 
located at about 10Å away from the haem iron, whereas flurbiprofen, in the 1R90 structure, is 
located at about 4.9Å. In both structures Arg97 plays a role of stabilization of the haem cofactor 
forming a hydrogen bond with the haem propionates. Val113 is involved in hydrophobic 
interactions, while Phe114 and Phe476 form π-π stacking interactions with the substrates.  
In the 1R90 structure the carboxylate side chain of flurbiprofen forms a salt bridge with Arg108 
and a hydrogen bond with Asn204. Arg108 is stabilised in the active site through hydrogen bonds 
with two residues on the helix I, Asp293 and Asn289. The presence of basic residues like Arg108 
within the active site explains the interaction with generally small acidic lipophilic compounds. 
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1.1.4.2 The human cytochrome P450 reductase (CPR) 
 
Cytochrome P450 reductase (CPR) is a membrane bound flavoprotein, containing two cofactors 
able to transfer electrons from NADPH to cytochrome P450. It is a 76 KDa protein with a N-
terminal membrane binding domain (Wang et al., 1997a) that comprises the FMN-binding 
domain, the linker domain, the FAD and NADPH-binding domains (Porter et al., 1986). No 
structure of the entire human CPR (hCPR) has been determined, but instead it has been solved 
the structure of the single FMN-binding domain (Zhao et al., 1999). The N-terminally truncated 
cytochrome P450 reductase from rat has been described at a resolution of 2.6 Å (Wang et al., 
1997a) (figure 1.10). Dissection of rat CPR into its FMN binding domain and its FAD binding 
domain, shows that the FMN domain exhibits great similarity to short chain flavodoxins such as 
that from Desulfovibrio vulgaris (Watt et al., 1991), the FMN binding domain of CYP102 
reductase (P450BM-3 reductase ) (Sevrioukova et al., 1999), and the FMN binding domain of 
human CPR (Zhao et al., 1999). Similarly the FAD domain of rat CPR displays a structural 
similarity to ferredoxin reductases such as the pea ferredoxin reductase (Deng et al., 1999) 
The crystal structure of FMN-binding domain of hCPR (Zhao et al., 1999) has been 
demonstrated to be very similar to the corresponding domain of the rat cytochrome P450 
reductase, with a common central fold made of five-stranded β-sheet flanked on either side of 
the helices (figure 1.11). The 125 residues linker has a predominant structural role, since it 
connects the two-flavin binding domains without being involved in cofactor binding (Gutierrez 
et al., 2003). The interaction between cytochromes P450 and CPR is indeed largely 
electrostatic, but a study showed that hydrophobicity plays an equally important role (Bridges et 
al., 1998).  
However, since the FMN co-factor of CPR is buried and not clearly accessible, binding of the 
cytochrome P450 requires a conformational change by the CPR. It has been postulated that to 
allow binding of cytochromes P450, the FMN domain moves through a flexible linker or “hinge 



























Figure 1.10 The crystal structures of the NADPH cytochrome P450 reductase from rat (PDB ID: 1AMO). 
The FMN co-factor is shown in red, the FMN in blue and the NADPH in yellow (Wang et al., 1997a). 
The FMN and FAD are in direct contact but they probably need to separate to enable the FMN domain to 
























Figure 1.11 Comparison between the crystal structures of the FMN binding domain of the NADPH 
cytochrome P450 reductase from rat (grey) (PDB ID: 1AMO) and the FMN binding domain of the human 
cytochrome P450 reductase (CPR) (light blue) (PDB ID: 1B1C). The FMN co-factor is shown in blue 




The electrons released from NADPH are first released to the FAD domain and then transferred 
to the FMN cofactor and the haem iron centre of the cytochrome P450.  
The two flavin isoalloxazine rings can exist in three oxidation states: the oxidised quinone, the 
one-electron semi reduced semiquinone and the completely reduced hydroquinone state 
(Ludwig & Luschinski, 1992). The sequence of steps involved in the transfer of electrons from 
NADPH via CPR to the haem iron of the cytochrome P450 was determined by Coon and co-
workers (Oprian and Coon, 1982; Vermilion et al., 1981; Vermilion and Coon, 1978). In recent 
years a similar scheme was proposed for human CPR (Munro et al., 2001). The transfer of 
hydrides from NADPH through FAD, FMN and then the double transfer of a single electron to 






In the resting state of CPR a stable FMNH (semiquinone) and FAD (quinone) are present. Upon 
the transfer of two electrons (in the form of a hydride anion) from NADPH, FAD is fully 
reduced to its hydroquinone form. The FAD then transfers a single electron to FMNH to give 
FMNH2, the fully reduced hydroquinone. The transfer of this electron is made 
thermodynamically favourable by the fact that the redox midpoint potential of the 
FADH/FADH2 couple is more negative (-365 mV) than that of the FMNH/FMNH2 couple (-270 
mV). At this point a single electron is transferred to the cytochrome P450 (step 2 to 3 of the 
catalytic cycle, figure 1.5) leaving both the FMN and FAD in their semiquinone forms. Once 
again the transfer of this electron is due to thermodynamic favourability since the 
FMNH/FMNH2 has a more negative redox midpoint potential compared to the substrate bound 
mammalian cytochrome P450 (Sligar et al., 1979) (around -237 mV for substrate bound 
compared to –300 mV for substrate free). Upon utilisation of the first electron by the 
cytochrome P450, the process is repeated and a second electron is then transferred to the FMNH 
by FADH. This second electron is in turn transferred to the cytochrome P450 (steps 4 to 5 of the 
cytochrome P450 catalytic cycle, figure 1.5) thereby leaving the FMNH and FAD quinone 
couple back in their initial state. 
The change in redox midpoint potential of the haem iron upon substrate binding and the change 
in spin state of the haem iron are therefore important mechanisms by which the transfer of 
electrons from CPR to the cytochrome P450 is regulated. Electron transfer is instead thought not 
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1.1.5 The bacterial cytochrome P450 BM3 (CYP102)  
 
The flavocytochrome P450 BM3 (CYP102) is a fatty acid hydroxylase from Bacillus 
megaterium in which the cytochrome P450 haem domain is fused to its mammalian-like di-
flavin NADPH-P450 reductase in a single 119 KDa polypeptide. The holoenzyme is constituted 
by a 55 KDa NH2-terminal P450 domain (BMP), which binds the substrate and a 66 KDa 
COOH-terminal reductase, which contains, in order, FMN and FAD (BMR). The FAD domain 
also contains the NADPH binding site (Govindaraj and Poulos, 1997). More specifically the 
cytochrome P450 domain contains residues 1-455 (Li and Poulos, 1997), with residues 460-475 
forming a short linker region (Govindaraj and Poulos, 1997). The exact amino acids in the 
linker have not been determined and neither has the starting point of the reductase. Residues 
471-664 and 664-1048 constitute the FAD and FMN domains respectively. 
The cytochrome P450 BM3 uses an FAD/FMN containing system similar to the mammalian 
membrane bound enzymes. However unlike those systems, the CYP102 is a soluble and 
catalytically self-sufficient fatty acid monoxygenase able to hydroxylate a wide range of fatty 
acids most frequently at the ω-2 position (Narhi et al., 1986). The catalytic activity is one of the 
highest determined for a cytochrome P450 monoxygenase (17,999 mol/min/mol of enzyme for 
arachidonic acid) (Noble, 1999) and is probably due to the efficiency in the electron transfer 
system covalently associated with the cytochrome P450.  
After the identification (Matson et al., 1977) and discovery of its activity (Miura and Fulco, 
1974), cytochrome P450 BM3 was difficult to study because of its low expression levels. The 
expression was then greatly improved by the discovery that the addition of phenobarbital (a 
known inducer of cytochromes P450 in rabbits) to the growth media increased its expression 
level up to 28-fold (Narhi and Fulco, 1982). Thanks to these discoveries, it is now possible to 
express the recombinant protein, both as the complete system and as separate domains (Munro, 
1993). 
The crystal structure of the entire holoenzyme has not yet been solved, whereas the X-ray 
stucture of the haem domain in the substrate-free (Ravichandran et al., 1993) (figure 1.12), 
palmitoleate bound (Li and Poulos 1997) and then complexed with the FMN are known 
(Sevrioukova et al., 1999) (figure 1.13). The catalytic domain has a triangular prism shape and it 
consists of an α and β domains, which are separated by the haem through an extended loop of 
28 residues with two 310 helices. The α and β domains account for about 70 and 22 percent of 
the entire structure respectively. The active site is accessible through a long hydrophobic 








Figure 1.12 The crystal structure of the haem domain of cytochrome P450BM-3 in the substrate-free 




Figure 1.13 The crystal structure of the complex of the haem and FMN-binding domains of the bacterial 
cytochrome P450 BM3 (PDB ID: 1BVY) (Sevrioukova et al., 1999). In red is shown the haem cofactor 




The substrate bound structure shows that there is a conformational change upon binding: the F 
and G helices are able to slide as a unit over the L helix, which leads to the open/close motion 
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for the entering of the substrate and the leaving of the product. In addition there may also be a 
proper reshaping of the active site guaranteed by the F/G loop and B’ helix mobility. The 
solvent accessible surface also changes: in the substrate free structure there is a channel that 
would allow substrate access, while in the palmitoleate bound structure this channel is closed to 
bulk solvent. 
The structure of the reductase FMN domain in complex with the haem domain has been widely 
criticized since it is considered an artefact of crystallisation (Sharp and Chapman, 1999). 
However it allowed study of the fold of the FMN domain and discovery that it is very similar to 
the FMN domain of the NADPH dependent cytochrome P450 reductase from rat (Wang et al., 
1997a) and human (Zhao et al., 1999), and to another family of FMN containing electron 
transfer proteins, the flavodoxins.  
The passage of electrons from NADPH to substrate in cytochrome P450 BM3 was elucidated by 






The FAD-cofactor is first fully reduced to its hydroquinone form by a molecule of NADPH. 
This species is less thermodynamically favourable than the semi reduced flavin cofactors. Then 
a hydride anion is transferred to FMN so that an electron can now be passed to the cytochrome 
P450 for the catalytic cycle (step 2 to 3 of the catalytic cycle, figure 1.4). Another hydride is 
then transferred from the FAD to form the semiquinone FMNH before the final electron transfer 
to the haem (step 4 to 5 of the catalytic cycle, figure 1.4). 
It is important to understand the basis of this transfer since it is responsible for the high turnover 
of this enzyme (Munro et al., 1999, 2002). In order to prevent unwanted electron transfer, 
cytochrome P450 BM3 has a thermodynamic “gate”. The redox potential of the haem in the 
substrate free form, when the iron is in a low spin state, is far more negative (-370mV vs NHE) 
than the substrate bound form (-250mV). In cytochrome P450 systems this change in potential 
should favour electron transfer from the reductase. However the redox potential of FMN/FMNH 
couple in the cytochrome P450 BM3 reductase domain is –213 mV, making the transfer of 
electrons to the haem appear thermodynamically unfavourable. The difference in redox potential 
is not the only driving force, but instead there is another electron tunnelling effect which is 
equally important (Munro et al., 2002). The iron spin state is another important factor for 
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is close to the haem thiolate ligand (cysteine 400) was shown to accelerate the haem reduction 




Flavodoxins are small flavoproteins found in microorganisms and eukaryotic algae where they 
function as electron carriers in oxidation-reduction reactions. They are able to replace 
ferredoxin in a number of electron transfer reactions including pyruvate catabolism, nitrogen 
fixation and sulphate reduction (Dubourdieu et al., 1975; Simondsen and Tollin, 1980).  
They consist of five-stranded parallel β sheet with α helices on each side of the sheet, and a 
molecule of FMN bound strongly but not-covalently between two loops on one side of the 
molecule.  
They can be divided into two main groups according to their size: long and short chain 
flavodoxin. The Flavodoxin from Desulfovibrio vulgaris used in this work belongs to the short 
chain category (15-17KDa) and Watenpaugh and co-workers solved its X-ray structure in 1972 
(figure 1.14) (Watenpaugh, 1972) at a 2.5Å resolution. The resolution was improved to 2 Å one 
year later (Watenpaugh et al 1973) and recently to 1.3 Å (Artali et al., 2002). 
The FMN cofactor is capable of both 1e- and 2e- electron transfer, resulting in the formation of 
the singly reduced semiquinone and doubly reduced hydroquinone states. The second low-
potential transition is considered physiologically the most significant (Simondsen and Tollin, 
1980). The reduction potentials of the quinone to semiquinone (E2) and semiquinone to 
hydroquinone (E1) have been calculated to be –143 and –440 mV vs NHE (Curley et al., 1991). 
However when free in solution FMN undergoes a two-electron reduction with a potential of –
205 mV (Draper and Ingraham, 1968). The single electron transitions have been found to have 
potentials of –172 mV for E1 and –238 mV for E2 (Draper and Ingraham, 1968). The 
semiquinone reduction is coupled to a proton uptake and therefore displays a pH dependent 
reduction potential (Dubourdieu et al., 1975). The shift in the redox potential of the 


























Figure 1.14 Structure of Flavodoxin from Desulfovibrio vulgaris in the oxidised form (PDB ID: 1J8Q). 
The FMN cofactor is shown in red stick (Watenpaugh et al 1973). 
 
 
The proton uptake stabilises the semiquinone form so that it can work as a low potential one-
electron transfer protein and avoid wasteful cycling to the unimportant quinone form (Astuti et 
al., 2004). 
The absorbance spectrum of oxidised flavodoxin has peaks at 397 and 458 nm due to the FMN 
cofactor. The spectrum of the semiquinone is dominated by a broad absorbance centred around 
580 nm and without the peaks at 397 and 458 nm. The hydroquinone does not absorb strongly, 
it has modest peaks at 365 and 450 nm and is colourless. 
 
1.3 PHARMACOGENOMICS: THE PROMISE TO 
PERSONALISED MEDICINE 
 
There is great heterogeneity in the way individuals respond to medications, in terms of both host 
toxicity and treatment efficacy. Many non-genetic factors including age, organ function, 
concomitant therapy, drug interactions and the nature of the disease seem to influence the 
effects of medications; however there are now numerous examples of cases in which inter-
individual differences in drug response are due to sequence variants in genes encoding drug-
metabolising enzymes like the cytochromes P450 (Evans et al., 2003; Weinshilboum et al., 
2003; Ingelman-Sundberg et al., 2001).  
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Two separate investigators, Lucien Cuenot, working with coat colours in mice, and his 
contemporary Archibald Garrod, studying alcaptonuria in humans, anticipated the connection 
between enzymes and genes. Garrod’s work on alcaptonuria in 1902 constituted the first proof 
of Mendelian genetics in humans. As a result of these studies, he advanced the hypothesis that 
genetically determined differences in biochemical processes could be the cause of adverse 
reactions after the ingestion of drugs. He suggested that enzymes were implicated in the 
detoxification of foreign substances and that in some cases this mechanism might fail for lack of 
the required detoxifying enzyme. These conclusions presaged our current concept of genetically 
controlled inter-individual variation in the response to foreign substances (Garrod 1902).  
Clinical observations of such inherited differences in drug effects were first documented in the 
1950s (Kalow et al., 1956; Evans et al., 1960), giving rise to the field of pharmacogenetics, that 
carries the promise of explaining how the individual’s make-up of genes determines drug 
efficacy and toxicity.  
Since 2001 when almost the entire human genome sequence became known and accessible, the 
term pharmacogenetics evolved to pharmacogenomics, i.e. the study of the entire spectrum of 
genes that determine drug response, including the assessment of the diversity of the human 
genome sequence and its clinical consequences (Licinio et al., 2003). 
In general all the variations of specific genes are called genetic polymorphisms and are defined 
as monogenic variations that exist in the normal population with a frequency of more than 1% 
(Meyer, 1991).  
Another important aspect of pharmacogenetics is the realization that all pharmacogenetic 
variations studied to date occur at different frequencies among subpopulations of different 
ethnic and racial origin. For example, some mutations of the cytochromes P450 occur uniquely 
in certain ethnic subpopulations and trace the origins and movements of populations on this 
planet. This ethnic diversity, also called pharmacoantropology, implies that population 
differences and ethnic origin have to be considered in pharmacogenetic studies and in 
pharmacotherapy. 
Rapid sequencing and single nucleotide polymorphisms (SNPs) will play a major role in 
associating sequence variations with heritable clinical phenotypes of drug or xenobiotic 
response. SNPs occur approximately once every 300-3,000 base pairs and their number is 
always increasing (http://www.ncbi.nlm.aih.gov/SNP/) and even if the majority do not have any 
function, some of them are located in the coding regions (cSNPs) causing alteration in amino 
acids that may lead to absent, deficient or enhanced enzyme activity. Once a large number of 
these SNPs and their frequencies in different populations are known, they can be used to 
correlate an individual’s genetic fingerprint with the probable individual drug response. 
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Four phenotypes can be therefore identified in a population: poor metabolizers (PMs), who lack 
the functional enzyme; intermediary metabolizers (IMs), who are eterozigous for one deficient 
allele that causes reduced activity; extensive metabolizers (EMs), who have two normal alleles; 
and ultra rapid metabolizers (UMs), who have multiple gene copies (figure 1.15) (Ingelman-
Sundberg et al., 2004). 
 
 
Figure 1.15 Significance of unexpected metabolism of a drug. Panel B shows the extensive metabolizers 
pattern (majority of the population). Panel A and C show unusual low metabolism and high metabolism 
that occur in poor metabolizers and ultra rapid metabolizers. In the graph arrows indicate multiple doses 
(Guengerich et al., 2003). 
 
Nowadays medicine still targets therapy to the broadest patient population that might possibly 
benefit from a certain drug and predicts therapeutic effects in individual patients through 
statistical analysis of the population’s response. The choice of drug and appropriate dosage is 
based on information derived from population averages. 
However it has been demonstrated that this therapeutic approach often fails to be curative and 
may in fact cause substantial adverse effects because of inter-individual differences in drug 
response. Any given drug can be therapeutic in some individuals but ineffective in others, and 





Figure 1.16 Schematic representation of different therapeutic approaches. 
 
The recognition of these inter-individual differences in drug response is an essential step 
towards optimizing therapy. Since much evidence has indicated that a substantial portion of this 
variability is genetically determined, medical doctors should account for different patterns of 
drug response among geographically and ethnically distinct populations before prescribing any 
medications. 
Thanks to the development of pharmacogenomic research, which determines an individual’s 
unique genetic profile in respect to disease risk and drug response using DNA analysis, the “one 
drug fits to all approach” could evolve into an individualized approach where optimally 
effective drugs are matched to a patient’s unique genetic profile. Classifying patients according 
to their genetic variations associated with disease drug response or both can lead to a more 
efficacious and less toxic drug therapy. In this way the drugs administered to different patients 
for the same medical condition may not be the same and could be tailored to each individual in a 
way that would maximize the chance of having benefits and minimize the chance of having side 
effects and toxicity (Mancinelli et al., 2000). 
Until recently, the only way to identify patients with a genetic risk of adverse drug reactions 
was with “phenotyping test”, that means administration of a specific marker drug or test 
substance and subsequent biochemical analysis. The Human Genomic Project and advanced 
technology in DNA analytical devices can enable the rapid and unequivocal determination of a 
pharmacogenetic profile or genotype of a patient. Pharmacogenetic testing may provide a 
mechanism whereby DNA based testing can be applied to populations to detect genetic 
variations that have an effect on the metabolism of certain drugs (Sadèe et al., 2005). The first 
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test of this kind for clinical applications is the AmpliChip CYP450 test from Roche Diagnostics 
(figure 1.17), which was launched in Europe in the autumn of 2004. The test combines Roche's 
patented polymerase chain reaction (PCR) amplification technology and Affymetrix high-
density micro array technology on glass chips no bigger than a thumbnail arrayed with tens of 














The chip contains more than 15,000 different oligonucleotide probes for the analysis of sense 
and anti-sense strains of an amplified target of sample DNA. The test is capable of 
differentiating between 29 different polymorphisms of the CYP2D6 gene including gene 
duplication and deletion as well as two important polymorphisms of the CYP2C19 gene. The 
ability to identify sensitive individuals, either before drug treatment or after an adverse drug 
response has also an economic importance as it allows matching the most appropriate drug at its 
optimal dose for each patient reducing hospitalisation and costs arising from adverse drug 
reactions. 
Pharmaceutical drug discovery and development of small molecules is a risky, expensive and 
time-consuming process of about 10-12 years (figure 1.2) (Kuhlmann 1999; Craig et al., 1997). 
The time from discovery to market is very stable, but the number of drugs that arrive on the 
market is very low (figure 1.18). Due to the high risk of adverse drug reactions observed in 
individuals carrying polymorphic allelic variants, the pharmaceutical industry is obviously 
interested in following pharmacogenomic approaches and technologies for drug discovery and 
drug development (Kalow et al., 2001). As a consequence, until now pharmaceutical companies 
have preferred to develop drugs for which several cytochromes P450 have a contribution to 
Figure 1.17 AmpliChip CYP450 Test (picture taken from Roche website). 
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metabolism and drop other development candidates that are metabolized exclusively by a highly 
polymorphic P450 (e.g. 2D6, 2C9). 
 
 
Figure 1.18 Schematic representations of the drug research and development steps. 
 
The understanding of genetic factors that determine our response to drugs may also allow drugs 
to be designed that are specifically targeted towards particular populations or that avoid genetic 
variability in therapeutic response. Due to the high cost of the drug discovery process, 
pharmaceutical companies are now interested in introducing pharmacogenetic clinical trials in 
which a specific drug is tested on a small target patient population of a certain ethnicity or with 
rare diseases. The first example of personalized drug entered on market in 2005 was Bidil, a 
drug for the treatment of heart failure in black patients. The approval of Bidil was based in part 
on the results of trials performed on a general population of severe heart failure patients where 
the only benefit was observed in a small black population. Because of these results, a 
subsequent African-American Heart Failure Trial was performed demonstrating a 43% 
reduction in death and a 39% decrease in hospitalization for heart failure. The approval of a 
drug to treat a specific disease in a small population is a striking example of how a treatment 
can benefit some patients even if it does not help all patients. 
Another advantage of pharmacogenomics could also be the enhancement of the value of 
currently approved drugs with limited market share because of significant toxicity or limited 




1.3.1  Cytochrome P450 polymorphism 
 
One of the most important and studied phase I drug metabolising class of enzymes is the 
cytochrome P450, whose main isoforms are polymorphic. Nowadays the level of interest 
towards human P450s has advanced to the point where the Food and Drug Administration 
typically expects for each New Drug Application a statement concerning its relationship to the 
P450s and their allelic variants (Guengerich et al., 2003). According to Phillips et al., 56% of 
drugs that are cited in ADR studies are metabolized by polymorphic phase I enzymes, of which 
86% are P450s (Phillips et al., 2001). 
The central role of the cytochrome P450 in drug metabolism has prompted detailed searches for 
polymorphisms in most human P450 genes. Polymorphisms have now been described in all the 
main cytochrome P450 that contribute to metabolism of drugs and other xenobiotics 
(http://www.imm.ki.se/CYPalleles).  
Many of these polymorphisms are functionally significant, often resulting in altered activity or a 
complete absence of enzyme. Drugs with a low therapeutic index are the most dangerous since 
minor variations in concentrations caused by polymorphisms may be crucial. Other effects such 
as the activity of the product of the enzymatic reaction and multiple metabolic pathways may 
instead neutralize or abolish the clinical significance of a genetic polymorphism. 
A recent review of the clinical practice of the main polymorphic drug-metabolizing enzymes 
has tried to determine which drugs are affected to a clinically important extent by a significant 
change in AUC (area under the plasma concentration time curve) of the active moiety (Gardiner 
et al., 2006). 
The major families responsible for the oxidative metabolism of drugs and environmental 
chemicals are CYP1, CYP2 and CYP3, with CYP2D6, 2C9 and 2C19 being involved in the 
metabolism of molecules having a proven clinical effect from P450 polymorphisms. The 
CYP2D6, CYP2C9 and CYP2C19 play also a critical role in genetically determined responses 
to a broad spectrum of drugs. 
Patients who are homozygous for the CYP2D6 null alleles exhibit a poor metabolizer 
phenotype, with impaired degradation and excretion of many drugs, and they are more likely to 
exhibit adverse drug reactions (Touw et al., 1997). The frequency of this recessive trait ranges 
from 1% to 2% in Asians, to approximately 5% in African Americans, to 6% to 10% in 
Caucasian populations (Evans et al., 1993). More than 40 drugs used in clinical practice in the 
areas of cardiovascular diseases and psychiatric disorders are involved in genetically modified 
CYP2D6 metabolism (Buchert et al., 1993; Dahl et al., 1993). Determination of a patient’s 
CYP2D6 phenotype/genotype becomes useful in treatment with antipsychotic drugs. To date 61 
different allelic variants have been identified. 
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The CYP3A family is composed by four members: CYP3A4, CYP3A5, CYP3A7 and 
CYP3A43. The 3A4 and 3A5 are the most important regarding drug metabolism since they are 
responsible for the transformation of about half of the clinically used drug in the liver. CYP3A4 
accounts for approximately 30 % of the total hepatic CYP content, and in African populations 
CYP3A5 is suggested to reach almost the same levels. CYP3A7 is not expressed in adults, but it 
is the major CYP3A isoform in fetal liver. CYP3A43 is expressed at very low levels and is a 
pseudo gene without functional activity (Westlind-Johnsson et al., 2003). 
There are quite a number of allelic variants of both CYP3A4 and CYP3A5, but most of them 
are rare. The CYP3A5*3, *6 and *8 are all associated with low protein expression and their 
frequencies vary considerably among populations (Lamba et al., 2002; He et al., 2005). 
The CYP2C subfamily has four known human members, CYP2C8, 2C9, 2C18 and 2C19, which 
are mainly located in the liver (Lapple et al., 2003). CYP2C9 and 2C19 have been studied 
intensively since they have important therapeutic consequences. CYP2C18 does not seem to 
have an important impact on drug metabolism in humans. 
Patients with allelic variants of the CYP2C19 are highly sensitive to omeprazole, diazepam, 
propranolol, mephenytoin, amitriptyline, hexobarbital and other drugs (Touw et al., 1997).  The 
CYP2C19 poor metabolizer phenotype comprises 2% to 5% of Caucasian and 3% to 23 % of 
Asians, resulting from a single base pair mutation (A-G) in exon 5 of the coding region 7. The 
truncated mutant protein lacks the haem-binding region and is enzymatically inert (de Morais et 
al., 1994). Many different variant alleles of CYP2C19 have been detected, several of them 
(CYP2C19*2-CYP2C19*8) being null-alleles with no enzyme activity at all. The most common 
variants are the *2 and *3, which show a large interethnic variation. Poor metabolizers of 
CYP2C19 substrates are more common among Asian populations than among Caucasians, with 
a frequency of approximately 20% and 3% respectively (Klotz et al., 2004). The relevance of 
CYP2C8 polymorphisms with paclitaxel, rosiglitazone and amodiaquine remains to be 
established (Hichiya et al., 2005). The occurrence of the CYP2C8*2 allele is about 18% among 
African populations, but very rare in Caucasians, while the opposite is true for the *3 (Cavaco et 
al., 2005). The CYP2C8*4 allele frequency is very low, among both Caucasians and Africans. 
In total there are ten different alleles of CYP2C8, five of them CYP2C8*6-*10 were only 
recently discovered in Japanese individuals at a very low frequency (Hichiya et al., 2005). 
CYP2C9 is the isoform considered in this project. It is the most abundant isoform comprising 
one-third of the total hepatic P450 content (Lasker et al., 1998). Its gene contains quite a few 
variant alleles, both in the exons and the 5’flanking region. Up to now there have been 30 
different alleles identified (CYP2C9*1-CYP2C9*30) (www.imm.ki.se/CYPalleles) most of 
which result in decreased enzyme activity, at least in vitro.  
The two main allelic variants of CYP2C9 are the *2 and *3 (table 1.3), located in exon 3 and 7 
respectively, show a generally lower catalytic activity and serious adverse drug reactions with 
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low therapeutic index drugs such as (S)-warfarin, acenocumarol, tolbutamide and others (table 
1.4). In vitro studies show that *3 is associated with a lower intrinsic clearance of substrate 
drugs than *2 (Yamazaki et al., 1998a; Yamazaki et al., 1998b; Rettie et al., 1999; Yasar et al., 
2001) and this has also been demonstrated in vivo. The role of *2 is less clear with only some 
CYP2C9 substrates (e.g. warfarin and phenytoin) being affected in vitro. 
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In the case of CYP2C9*2, the R144 (figure 1.19) is positioned in the D helix that is not a known 
substrate recognition sequence. The mutation seems to affect the interaction of the enzyme with 
the CYP450 reductase so that the maximum rate of metabolism (Vmax) is reduced to around 50% 















Figure 1.19 Structure of the wild-type CYP2C9 (PDB ID: 1OG5) and the simulated substitution of the 
residue R144 (this work). The haem co-factor is shown in black, the warfarin in blue, the wild-type amino 
acid in green and the polymorphic amino acid in yellow. 
 
In the case of CYP2C9*3, the I359 residue (figure 1.20) is located within a distal substrate 
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binding domain (SRS5), causing, in the case of (S)-warfarin 7-hydroxylation, a fivefold 
decrease in the apparent Vmax for and a fivefold increase in the apparent Km because of a 
















Figure 1.20 Structure of the wild-type CYP2C9wt (PDB ID: 1OG5) and the simulated substitution of the 
residue I359 (this work). The haem co-factor is shown in black, the warfarin in blue, the wild-type amino 






























 Table 1.4 List of drugs that are affected by CYP2C9 allelic variants to a clinically important extent. 
(Clearance: Vmax/ Km; AUC: area under the plasma concentration time curve). (Gardiner et al., 2006). 
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2C9*3/*3 AUC 2.3 
folds higher 
than wt 
Niemi et al., 
2002 
2C9*1/*3 AUC 2.7 
folds higher 
than wt 

























 2C9*1/*3 AUC 1.5 
folds higher 
than wt 
Niemi et al., 
2002; Wang 
et al., 2005 
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1.4 Amperometric biosensors 
 
Biosensors are analytical devices that use the specificity of a biological element in sensing the 
target molecule. Several industries are interested in the development of biosensors because of 
their capability of giving continuously and reversibly a selective and fast response continuously 
and reversibly. They combine the power of analytical detection techniques with the specificity 
of a biological recognition system. 
According to the IUPAC definition, a biosensor is a self-contained integrated device, capable of 
providing specific quantitative or semi-quantitative analytical information using a biological 
recognition element, which is kept in direct special contact with a transduction element. 
A biosensor consists of three different but strictly connected elements: a selector, which binds 
and recognises the target molecule; a transducer, which converts the signal generated by the 
selector (biological response) into a physically measurable signal; a detector that permits 
amplification, processes and displays the chemico-physical signal in a suitable form (figure 
1.21). 
 
Figure 1.21 Schematic representation of a biosensor. 
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Different disciplines coexist in the bio-sensing event: biochemistry, which is useful in 
improving the selectivity and sensitivity of the biological components, physics, electrochemistry 
and engineering technology, which provide the information for the transduction system.  
In general sensors can be divided into physical, chemical and biochemical. Physical sensors 
measure traditional parameters such as temperature, pressure, humidity or flow rate. Chemical 
sensors are miniaturised compact devices that transform chemical information, such as a 
variation of concentration, into a measurable signal. Biochemical sensors have instead a 
biological recognition system such as an enzyme, a receptor protein, an antibody that translates 
the information from a biochemical domain into a chemical or physical output signal. They can 
detect and follow the catalytic transformation of a substrate in product, the activity of enzyme 
inhibitors or mediators. 
Biochemical sensors can also be classified according to the mode of signal transduction. 
Amperometric sensors are based on the measurement of the current resulting from the oxidation 
or reduction of an electro active species upon application of a potential at the working electrode. 
Potentiometric sensors involve the determination of the potential difference between an 
indicator and a reference electrode without significant flowing of current. In this case the 
transducer may be an ion selective electrode, e.g. pH electrode, ion or gas electrode. Other 
enzyme reactions can be monitored as conductance or impedance differential measurements in 
conductometric or impedimetric devices. 
Amperometric sensors are the most diffuse ones and they can be further distinguished into first, 
second and third generations according to the different mechanism of the electronic transport 
(Thevenot et al., 1999). In the first-generation, the transduction is based on the detection of the 
electroactive substrates or the products of the enzyme. A good example is the traditional glucose 
biosensor where the hydrogen peroxide produced in the oxidation process of glucose oxidase is 
detected by the electrode (Clark and Lyons 1962; Updike and Hiks 1967). In the second-
generation devices the contact between the enzyme and the electrode occurs through mediators 
either free in solution or immobilized with the bio-molecule (Scheller et al., 1991). Example of 
mediators includes redox couples such as ferrocene, ferrocene derivatives and bipyridil 
complexes. In the third generation biosensors, the enzyme is directly coupled to the electrode 
leading to a direct electron transfer response (Ghindilis et al., 1997). This format offers better 
selectivity as it operates in the potential range close to the redox potential of the enzyme itself 
and it avoids interfering reactions such as the generation of active oxygen species. 
 
The present study investigates the electrochemical properties of the human cytochrome P450 
2C9 immobilised on differently modified electrochemical surfaces. As explained in the previous 
sections, cytochromes P450 are redox enzymes that require electrons to perform their catalytic 
activity. The reducing equivalents originated from a NADPH cofactor are delivered to the redox 
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centre via an electron transport domain, the NADPH-cytochrome P450 reductase.  The electrode 
on which the enzyme is directly immobilised acts as the electron transport system. In the 
presence of oxygen and substrate the reduced enzyme reacts with the specific substrate and a 
change in catalytic current consumed can be recorded and correlated to the concentration of 
substrate added. No recognition of target molecules is performed, but rather a monitoring of the 
change in current. For this reason the system here investigated cannot be considered as a 
traditional biosensor, but rather an amperometric sensor.   
 
1.4.1 The electrochemistry of immobilised cytochrome P450 
 
The transfer of electrons between and within proteins is a fundamental step to guarantee 
important physiological processes such as biological energy transfer, metabolism and enzymatic 
catalysis (Bistolas et al., 2005). Electrochemistry can be used to observe this transfer of 
electrons in real time and obtain important information on the electrochemical properties of the 
redox enzymes and their mechanism.  
As explained in the previous sections, cytochromes P450 are redox enzymes that require 
electrons to perform their catalytic activity. These reducing equivalents coming from an external 
cofactor, the NADP(H), are delivered to the redox centre by an electron transport chain.  During 
the catalytic cycle, the electrons and an available oxygen molecule are used to form a high-
energy oxidizing species that hydroxylates a substrate.  
The electroactive component that receives the electrons is an iron-protoporphyrin IX (haem), 
which is positioned within a long folded polypeptide chain. When the haem iron is in substrate-
free, low-spin conformation, it is esa-coordinated with the four lateral nitrogen atoms of the 
tetrapyrrole macrocycle, with a proximal sulphur atom of a thiolate (cysteine) group and a distal 
weakly bound water molecule. This primary coordination environment and the factors 
influencing it, together with the dielectric setting of the haem, are the factors defining the level 
of electronic energy required to activate the enzyme. 
In the catalytic cycle two electrons are consumed. The first electron reduces the haem iron and 
initiates the binding of the co-substrate oxygen. The second electron reduces the oxygenated 
haem, leading to the active oxidant “Compound I”. 
The first one-electron reduction process can be electrochemically described under equilibrium 
via the half-cell reaction: 
 
where E0 is the reversible potential versus a reference electrode, and Fe (III) and Fe(II) refer to 
the oxidized and reduced forms of the cytochrome P450 haem with or without a substrate 
bound. Though this equation does not take into account the phase of the enzyme (solution or 
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solid), differences in the protonation levels of the oxidized or reduced forms, or the presence or 
absence of substrate. The reference half-cell reaction that completes the electrochemical cell is 
assumed to be the standard hydrogen electrode (SHE), which is assumed to be reversible under 
all operating conditions and assigned a value of 0 Volt under standard conditions (25˚C, unit 
activity of H+(aq) and H2(g).: 
 
In practice the reference electrode is either Ag/AgCl or saturated calomel electrode (SCE) 
whose potential is accurately known versus SHE.  
Assuming that the reference half-cell has a potential of 0V, the P450 process can be described 
by a standard potential, E0 measured as voltage versus SHE. Though experimentally standard 
conditions are impossible to obtain for enzymes, so a reversible formal potential E0’
 
rather than 
E0 is usually reported. Differences between E0’ and E0 arise from terms such as junction 
potentials, non-unity activities and non-standard temperatures.  
The electrochemistry of immobilized cytochromes P450 has been investigated on different 
surfaces like metal electrodes (Au, Pt, Tin-dioxide) and non-metal electrodes (glassy carbon, 
pyrolytic graphite, edge-plane graphite, carbon cloth). Several methods for confining the P450 
enzymes to an electrode surface have been attempted to improve the electron transfer of 
cytochromes P450 that show a haem redox centre buried inside the protein structure and 
surrounded by amino acid chains necessary to guarantee a hydrophobic environment for 
catalysis. These methods of confining P450 enzymes have been attempted to improve the 
Faraday current signal of the protein compared to the one coming from the low background 
non-Faraday current. The intensity of the current signal is important as the potential at which 
the peak of reduction current Ec and oxidation current Ea occur are used to calculate the 
midpoint potential and hence the Emid. 
The first report of direct electrochemistry of a P450 enzyme was that of P450cam with an 
unmodified edge-plane graphite electrode (Kazlauskaite et al., 1996). The response was based 
on the electrostatic interaction between negatively charged groups of the electrode material and 
positive charges on the protein surface. The Emid values given in the absence and presence of 
substrate were consistent with that reported previously by potentiometric methods. Subsequent 
works in the same laboratory on the camphor-bound wild-type and mutant of the P450cam 
showed comparable data (Lo et al., 1999). Other attempts to directly immobilize other 
cytochromes P450 did not give the same results. Electrochemistry of CYP2E1 could also be 
seen with bare GC electrodes but with quite a low heterogeneous electron transfer rate and more 
positive potentials compared to those calculated on mammalian’s P450 with potentiometric 
methods (Fantuzzi et al., 2004).
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Another concern is the stability of the protein structure once immobilized. P450scc deposited 
directly onto an indium-tin oxide (ITO) electrode showed a Faraday response inconsistent with 
the data provided and probably correlated to the haem domain (Paternolli et al.,2004). 
Although direct electron transfer has been observed on bare electrodes, modified electrodes with 
polymers or polyelectrolyte were used in order to attain native structure and appropriate 
orientation for increased electron transfer.  
Since CYP are located in a hydrophobic environment in the endoplasmic reticulum of cells, a 
number of groups have used phospholipids able to create stable vesicular dispersions which 
mimic biological membrane. The molecules used to form such films consist of insoluble (in 
water) surfactants or lipids, such as DDAB, DDAPSS and DMPC. These compounds are able to 
form lamellar phases within which the P450 enzyme can remain stable, diffuse and undergo 
reversible electron transfer. However, regardless of the fact that several bacterial and human 
P450s have been immobilized with the same modification DDAB, different Emid values have 
been recorded. It appears that even slight experimental differences with parameters such as pH, 
electrolyte, temperature, buffer, reference electrodes, method of midpoint potential 
determination, etc., may influence on the final Emid value measured. In general the Emid is more 
positive compared with those observed with potentiometric titrations and it is difficult to 
identify the real factors responsible for these changes. 
 
Another entrapment method that resulted in a voltammetric P450 response is a layer-by-layer 
approach where multilayer of a polyion and the P450 enzyme should guarantee the formation of 
layers of stable, ordered and active enzyme. P450cam showed Faraday response once embedded 
in poly(styrenesulfonate) (PSS) and deposited on gold electrodes negatively charged by a MPS 
layer (Lvov et al., 1998). The same enzyme showed a significant electrochemical signal when 
alternate layers of enzyme and poly(ethyleneimine) (PEI) were deposited on PG electrodes 
(Munge et al.,2003). In a similar way human P450 1A2, 2E1 and 3A4 have been immobilized in 
layers containing PSS (Estavillo et al., 2003) and PDDA (Joseph et al., 2003; Fantuzzi et al., 
2004). In all cases catalysis of specific substrates were demonstrated. 
Catalysis of styrene as well as benzaldehyde oxidation was also observed on protein-polyion 
modified carbon cloth (CC) electrodes (Zu et al., 1999). All turnover numbers were calculated 
after product analysis using GC-MS. However addition of catalase decreased the turnover 
suggesting that the catalysis is carried out through H2O2. The fluoxetine product was obtained 
when CYP2D6 was immobilized on a polyaniline-doped GC electrode (Iwuoha et al., 2005). 
Clay-modified electrodes also revealed encouraging results. A significant response was shown 
by P450cam absorbed onto sodium montmorillonite-modified GC electrodes, where positive 
shifts were observed in the presence of substrate and CO (Lei et al., 2000). The addition of a 
detergent such as Tween 80 dramatically improved the electron transfer to P4502B4 probably 
for the ability to monomerize the microsomial enzyme (Shumyantseva et al., 2004). 
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Recently several studies have been performed on carbon electrodes modified with gold 
nanoparticles. CYP2B6 has been immobilised on GC electrodes modified with colloidal gold 
nanoparticle-chitosan and direct and reversible electron transfer was observed as well as 
bioelectrocatalytic reduction current in presence of substrate (Liu et al., 2008). 
Biocatalytic response was observed on human CYP2D6 immobilised on poly (8-anilino-1-
naphtalene sulphonic acid) nanotubes deposited on gold electrodes. Analysis of the biosensor 
response curve for sertraline gave apparent Michaelis-Menten constant values (Iwuoha et al., 
2007). 
However in order to obtain physiologically relevant parameters the achievement of a monolayer 
coverage of oriented enzyme should be attempted. In this way the controlled orientation of the 
enzyme would guarantee a readily accessible binding pocket for substrates molecules. 
An investigation on a mutant of the haem domain of cytochrome P450 BMP in which two 
exposed cysteines were left on the surface showed the possibility of achieving an oriented 
immobilisation of the protein and a consequent improved electron transfer response (Ferrero et 
al., 2008). 
Previously the human cytochrome P450 2E1 immobilised on cysteine-malemide modified gold 
electrode showed improved electrochemical and bioelectrocatalytic response compared to the 
same protein immobilised on polymer modified glassy carbon electrodes (Fantuzzi et al., 2004).  
However direct electrochemistry does not allow control over whether CYP remains native when 
interacting with electrodes. At this purpose spectroelectrochemistry plays an important role as it 
gives an insight into structural changes accompanying the electrochemical redox cycling. 
Spectroelectrochemistry of wild-type CYP101 has been carried out by using mediator (Reipa et 
al., 1997) and mediator-free (Bistolas et al., 2004) electrode systems proving that the CYP101 
remains in the native state during electrolysis. Ivanov and Archakov have constructed an optical 
biosensor to study binary and ternary complex formation of CYP2B4, CYP101 and CYP11A1 
with their redox partner (Ivanov et al., 1999).  
 
1.4.2 Improving the direct electrochemistry of immobilised cytochromes P450 
 
Cytochromes P450, because of their direct involvement in the metabolism of a large number of 
drugs and xenobiotics, are an example of attractive electrochemical sensor targets (Bistolas, 
2005). As previously observed the success of a P450 based amperometric sensor depends on the 
efficient interaction of the target protein with the electrode surface as well as on the stability of 
the enzyme in non-physiological conditions. The poor coupling between the biochemical 
material and the transducer can affect the selectivity, sensitivity and stability of the current 
response. 
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The selection of appropriate combinations of materials, such as the enzyme, the electron 
transport mediator, the binding and encapsulation materials, the conductive support matrix and 
the solid support, governs the efficiency of the electrode in terms of electron transfer kinetics, 
mass transport, stability and reproducibility.  
The main components are the enzyme and the electrode material. The electrode material is 
chosen according to its conductivity and its hardness. Therefore the electrode is usually made of 
solid supports such as gold, (foil and rod), platinum (foil and rod) or carbon (paper, rod, paste, 
metalized carbon, glassy carbon, carbon fibre, nanotube film). Biocompatibility and low cost of 
mass production are some of the important features but conductivity remains one of the main 
requisite to ensure rapid electron transfer.  
Though the stability of an efficient interaction between the electrode and the enzyme can be 
improved at two levels: 
-  modifying the enzyme at genetic level through protein engineering   
-  modifying the electrode surface  
 
1.4.2.1 Protein engineering: the molecular lego approach 
 
The use of proteins as a component of electrochemical sensors has many advantages including 
low costs in design and synthesis, the fact that proteins are soluble in water and finally, with the 
progress of molecular genetics, the possibility of improving/changing some of the properties of 
the proteins by genetic manipulation.  
Protein engineering is emerging as a possible strategy to improve the performance of native 
enzymes. The two main strategies in protein engineering are rational design, which combines 
site directed mutagenesis with the detailed knowledge of enzyme structures and functions, and 
directed evolution, which is based on the random synthesis of a pool of mutated enzymes and 
the subsequent selection by an iterative process (Wong et al., 2003). Working at these levels it 
is possible to obtain better electrochemical sensors because of more sensitive enzymes, new 
enzyme immobilisation techniques or enhanced electron transfer (Campàs et al., 2009). 
The most common strategy to achieve more sensitive and selective enzymes is to increase the 
affinity for the target analyte favouring the accessibility of the active site. An example is 
provided by genetically engineered acetylcholinesterase (AchEs) that has been applied in an 
inhibition-based biosensor for the detection of pesticides (Sotiropoulou et al., 2005). The 
replacement of specific amino acids in the active site increased the level of interactions and 
therefore the inhibition constants towards certain compounds. Since some structural changes 
caused by the genetic mutations may imply variations in the enzyme functionality, also the 
operational and storage stabilities of the biosensors can be affected. Usually enzyme are 
therefore engineered taking into account the location and the type of mutation, selecting those 
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mutations that may imply a benefit for the stability of their functionality in terms of time, 
temperature and pH (Ferapontova et al., 2002).  Immobilisation methods such as adsorption, 
covalent binding, entrapment within a polymeric matrix and cross-linking may involve 
multiple-point attachment, loss of bio molecule activity, bio molecule leaking, random molecule 
orientation and large diffusion barriers, which render biosensors poorly sensitive, unstable and 
with longer response times. New trends focus on the oriented immobilisation of the enzyme 
through specific functional groups located at their surface. In this way, active sites may be faced 
towards the target analytes and the product can freely diffuse in the biological layer. The 
mutations regarding new immobilisation strategies are usually located far away from the active 
site to avoid denaturation and steric impediments during the bio-recognition event. An example 
is the insertion of cysteine (Cys) residues into the protein sequence for the immobilisation of the 
enzyme by the formation of self-assembled monolayer (SAM) (Ferrero et al., 2008). 
Finally another approach is to modify the electron transfer kinetics rather than the active site 
accessibility and the enzyme orientation. A similar approach can be achieved with the 
“molecular lego” method where protein domains are genetically linked in order to build 
artificial redox chains with desired electrochemical properties from building blocks (Valetti et 
al., 1998; Sadeghi et al., 2000; Sadeghi et al., 2001; Gilardi et al., 2002) (figure 1.22). The 
linkage between building blocks can be achieved by fusion at genetic level or by disulphide 
bonds, via introduced cysteine residues if necessary.  
 
 
Figure 1.22 Schematic representation of the Molecular Lego technique. The artificial redox chain may be 
composed of two or more proteins, which can be linked by disulphide bonds via natural or introduced 
cysteine residues. Alternatively, the protein can be joined at the genetic level, giving rise to a fusion 
protein. Electrons pass from the electrode to the redox centre of the first protein (blue rectangle), then to 
the redox centre of the second (red rectangle), before finally being incorporated into the substrate. The 
redox centres may be a haem, flavin, an iron-sulphur cluster, a copper site etc. 
 
 
1.4.2.2 Modification of the electrode surface 
 
As previously stated the stability of the immobilised protein is an important factor to control. 
When directly immobilised, the protein tends to adsorb strongly on the electrode surface and to 
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denature because of a change in the forces that usually favour the native folded conformation of 
the proteins. Modification or functionalization of the electrode surface has been demonstrated to 
be a suitable way to minimise the protein denaturation.  
Different approaches can be pursuant to enzyme immobilization: physical adsorption at a solid 
surface, entrapment in polymeric gel or cross-linked bi-functional reagents and covalent binding 
to a reactive insoluble support. Adsorption tends to be less disruptive to enzyme protein than 
chemical methods of attachment. Binding forces are due to hydrogen bonds, multiple salt 
linkages, Van der Waals’s forces and the formation of electron transition complexes. The 
entrapment in a polymeric gel can be applied to any enzyme since the protein molecule is 
trapped within a three-dimensional lattice, but substrate and product diffusion through the 
membrane and loss of enzymes through the pores can be limiting. Covalent bonding between 
the enzyme and the support matrix is accomplished through functional groups in the enzyme, 
which are not essential for its catalytic activity.  
Apart from the stability of the immobilised protein, another important factor in guaranteeing the 
electronic coupling of the redox protein to the electrode is the orientation of the immobilised 
redox protein on the surface of the sensor. The immobilisation method used can control the 
orientation of the immobilised protein and therefore the optimal configuration for the electron 
transfer. Cysteine residues located on the external protein structure can form covalent sulphur-
gold bonding to achieve a monolayer of molecules with determined orientation. Covalent 
bonding has also the great advantage that the enzyme is unlikely to be released. Different 
methods for the immobilization of redox proteins are summarized in table 1.5 (Gilardi and 
Fantuzzi, 2001). Immobilization is an important aspect in the construction of nanodevices as 
sensitivity might depend on the concentration of the enzyme at the surface as well as specific 
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Table 1.5 Methods for the immobilisation of redox proteins. 
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1.5 Aims and objectives 
 
As observed in the previous sections human cytochromes P450 are redox enzymes mainly 
involved in the metabolism of 90-95% of clinically used drugs. The pharmaceutical industry is 
continuously looking for new analytical tools for the determination of the cytochrome P450 in 
vitro metabolism to correlate to the in vivo situation. The currently used assays consist of 
reactions in solution between the tested drugs and recombinant human cytochromes P450 
associated with NADPH-P450 reductase. However, the use of expensive NADPH or NADPH 
regeneration systems as well as the need to identify and quantify the formed metabolite with 
complex chromatographic methods make these assays time consuming, expensive and relatively 
low throughput. The use of amperometric sensing systems in which the enzyme is immobilised 
on an electrode can represent an interesting alternative: the electrons are supplied directly from 
the electrochemical surface to the haem iron and the metabolic parameters of interest are 
extrapolated from the correlation between the catalytic current consumed and the concentration 
of substrate added. Aim of this project is to perform a detailed study of the steps necessary to 
develop a similar P450 based amperometric sensor. 
The human cytochrome P450 2C9 has been chosen as subject of the investigation because of its 
primary involvement in the metabolism of widely used low therapeutic index drugs such as the 
anticoagulant warfarin. The electrochemical characterisation of CYP2C9 immobilised on 
electrodes differently modified would be performed. An investigation on the consequences of 
the immobilisation process on the active state of the enzyme would be carried out by 
spectroelectrochemical studies. Moreover to improve the electrochemical response of the 
immobilised enzyme, the heam domain would be genetically fused with external electron 
transfer modules able to modulate the transfer of electrons from the electrode to the haem. 
Once defined the right conditions of immobilisation, the two main allelic variants of CYP2C9, 
the CYP2C9*2 and CYP2C9*3, would be electrochemically and enzymatically characterised. 
The development of an amperometric sensor with human P450 allelic variants would pave the 
way to the creation of a new tool to use with the pharmacogenomic chips already available on 
the market. While the currently used genotyping assays would allow grouping patients 
according to their genetic pattern, instead the amperometric sensor would allow defining the 
correct dosage to be administered to each group.       
With this aim in mind, the following objectives were set: 
• Construction, expression and purification of chimeras consisting of the human 
CYP2C9, CYP2C9*2 and CYP2C9*3 haem domain fused at genetic level with either 
the reductase domain of the bacterial P450 CYP102 (P450BM-3) or D. vulgaris 
flavodoxin (FLD). 
 73 
• Spectroelectrochemical characterisation of the active/inactive state of a cytochrome 
P450 enzyme immobilised on optically transparent and semiconductive tin-dioxide 
electrodes. 
• Electrochemical and enzymatic characterisation of the different CYP2C9, CYP2C9*2 
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Chapter 2: MATERIALS AND METHODS 
 




General chemicals were purchased from Sigma-Aldrich or ICN Biomedicals. Substrates of 
human cytochrome P450s were purchased from Sigma-Aldrich. Chemicals such as ampicillin, 
IPTG, NADPH, δ-aminolevulinic acid and DTT were purchased from Melford Labs Ltd. 
Restriction enzymes, Vent DNA polymerase, dNTPs and enzyme buffers were purchased from 
New England Biolabs and Promega Ltd. Oligonucleotides were obtained from Thermo 
Scientific at a 0.02 µmole scale, purified using HPLC. Plasmid purification and DNA gel 
extraction was performed using kits from Qiagen Ltd. Chromatographic resins and pre-cast 
SDS-Page gels were purchased from Amersham Biosciences. The E. coli strains DH5αF’ were 
obtained from Invitrogen.  
 
2.1.2 Bacterial growth media 
 
The Luria Bertani medium (LB) contained 1% w/v trypton, 0.5% w/v yeast extract and 1% w/v 
sodium chloride. Tryptone and yeast extract serve as a source of nitrogen, sulphur and carbon 
while yeast extract also contains vitamin B complex. Sodium chloride provides sodium ions for 
the membrane transport and maintains osmotic equilibrium of the medium. The reagents were 
dissolved by stirring with a magnetic stirrer and the pH was adjusted to a value of 7.3 using 10 
M NaOH. The medium was sterilized by autoclaving at 121°C for 20 min. 
To prepare the plates for solid growth of bacteria 1.5% w/v of bacto-agar was added to all of 
above ingredients. The solution was autoclaved for 20 min at 121°C and sterile filtered 
ampicillin was added when the flask was cool enough to be held (around 50°C) to a final 
concentration of 100 µg/ml. The solution was then poured into Petri dishes and allowed to 
solidify under sterile condition. When the agar solidified, the plates where inverted (to avoid 
contamination) and stored at 4°C. 
Terrific broth (TB) was made using 12 g of tryptone, 24 g of yeast extract and 8 mL of glycerol 
in 900 mL of water. Potassium salts used to buffer the TB were autoclaved separately and 
contained 2.31 g of potassium di-hydrogen orthophosphate (KH2PO4) and 12.54 g of di-
potassium hydrogen orthophosphate (K2HPO4) in 100 mL of water. After autoclaving the media 





2.1.3   General chemical stocks 
 
Ampicillin stocks, stored at –20°C when not in use, contained 100 mg/ mL of ampicillin in 
distilled water and were used at final working concentrations of 100 µg/mL. DTT stocks 
contained 1 M DTT, 3 g in 20 mL of distilled water, and were stored at –20°C when not in use. 
IPTG stocks contained 1 M IPTG, 1.2 g in 10 mL of distilled water and were stored at –20°C 
when not in use.  
 
2.1.4 Competent Escherichia coli cells preparation and transformation 
 
Competent Escherichia coli DH5αF’ cells were prepared using the rubidium chloride method 
(Hanahan et al., 1995). To make frozen competent cells using the rubidium chloride method, 
cells of Escherichia coli DH5αF’ from a glycerol stock were streaked onto a LB-agar plate and 
incubated at 37 °C for 16 hours. A single colony from the plate was picked and grown in 5 mL 
of LB for 16 hours at 37 °C. The overnight culture was then diluted 40 times into 200 mL of LB 
and grown at 37 °C to an optical density at 600 nm of 0.3-0.5 (around 2-3 hours). The LB 
culture was then incubated on ice for 5 minutes and harvested by centrifugation at 8000g for 10 
minutes at 4 °C. The cells were re-suspended in 80 mL of transformation buffer I (Tfb I), 
incubated on ice for 1 hour and then harvested by centrifuged at 8000g for 10 minutes at 4 °C. 
The cell pellet was then re-suspended in 8 mL of transformation buffer II (Tfb II) and incubated 
on ice for 2-3 hours.  After 2-3 hours, the cells were flash-frozen on dry ice in 100 µl aliquots 
and stored at –80 °C until use.  
Transformation buffer I (Tfb I) contained per litre 2.94 g of potassium acetate, 1.209 g of 
rubidium chloride, 2.19 g of calcium chloride hexahydrate, 9.9 g of manganese chloride 
hexahydrate and 150 mL of glycerol. The final pH was adjusted to 5.8 with 200 mM acetic acid 
and the solution filter sterilised prior to storage at –20 °C. Transformation buffer II (Tfb II) 
contained per 200 mL 0.42 g of MOPS, 0.24 g of rubidium chloride, 3.29 g of calcium chloride 
hexahydrate and 30 mL of glycerol. The final pH was adjusted to 6.5 using 1 M potassium 
hydroxide and the solution filter sterilised prior to storage at –20 °C. 
Competent cells were transformed with plasmid DNA using the procedure developed by 
Mandel and Higa (Sambrook and Russell, 2001). First 100 µL of competent cells were thawed if 
necessary and incubated on ice with up to 100 ng of plasmid for 30 minutes (typically 1 µl for 
plasmid or 10 µl for ligation mixtures). The cells were then transferred from the ice to a water 
bath at 42 °C for 90 seconds and returned to the ice for 2 minutes. 800 µL of LB was then added 
to the cells and grown at 37 °C for 45 minutes. After 45 minutes, the cells were harvested by 
centrifugation at 8000g for 15 minutes. The cells were re-suspended in 100 µL fresh LB and 
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plated onto a LB agar plate containing the appropriate antibiotic. The LB agar plate was then 
incubated at 37 °C for 16 hours. 
 
2.1.5 Plasmid mini-prep purification 
 
A single colony of E.coli DH5a cells transformed with the recombinant plasmid was grown over 
night in 5ml LB containing ampicillin (100 µg/ml) shaking at 37°C. The plasmid was isolated 
from the bacterial chromosomal DNA using the purification procedure suggested in the 
miniprep kit supplied by Qiagen that uses the commonly known alkaline lysis method. The 
bacteria were centrifuged and then resuspended in an alkaline solution with detergent (0.2 M 
NaOH, 1% SDS) and RNase A (to degrade RNA). The detergents serve to lyse cells and 
denature proteins and the alkaline conditions denature chromosomal DNA, plasmid DNA, and 
proteins. The solution was neutralized and adjusted to high salt conditions (necessary for 
binding to a column) while proteins, chromosomal DNA, and cell debris precipitate, plasmid 
DNA remains in solution. Following centrifugation, the plasmid was further purified and 
concentrated from the supernatant using a small column containing silica gel that binds DNA in 
high salt conditions and elutes DNA in low salt conditions. 
 
2.1.6 Restriction enzyme digestion of DNA 
 
A variety of restriction enzymes were used through out the project to digest DNA. Generally 
restriction enzymes were used at a concentration of 1-10 units per 50 µL of sample along with 
the appropriate restriction enzyme buffer. Enzymatic digests typically contained 2-3 µg DNA 
for analytical digests and 10 µg of DNA for sub-cloning procedures. Reactions were usually run 
for 2 hours at 37°C after which time the sample was heated at 80°C for 10 minutes to inactivate 
the restriction enzyme and run on an agarose gel. 
 
2.1.7 DNA agarose gel electrophoresis 
 
DNA agarose gels were run on a GNA 100 system (Amersham) and typically gels run on the 
system contained 1-2% agarose dissolved in 1xTAE buffer, made from a 50x stock which was 
made using per litre 242 g of Tris base, 57.1 mL of acetic acid and 100 mL of 0.5 M EDTA pH 
8. Ethidium bromide was also added to the gel before pouring to a final concentration of 0.5 
µg/mL. Before loading on the gel DNA samples were mixed with the loading buffer, the 6x 
stocks of which contained: 0.25% bromophenol blue, 0.25% xylene cyanol and 15% ficoll. 
Mass Ruler DNA Ladder mix (Fermentas) was used as DNA standard. After loading the gel was 
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then run at 200V and 250mA for 20 to 25 minutes. Once the run had finished the gel was placed 
on a UV trans-illuminator and a picture taken if required.  
 
2.1.8 DNA ligation 
 
Cohesive end ligations usually contained 100 ng of vector DNA and 10x as much insert and 
were done using 0.2-0.4 Weiss units of DNA ligase in the presence of 1x ligase buffer. 
Cohesive end ligations were then incubated at 4°C overnight and then the mixture used for 
transformation 
 
2.1.9 PCR amplification and mutagenesis 
 
PCR amplifications were carried out in a Techne thermal cycler. As a standard protocol 
reactions were performed in a 50 µL volume containing 36 µL of sterile water, 5 µL of 
Thermopol buffer 10x, 5 µL of dNTPs (2mM), 1µL of template DNA (0.5 µg), 1µL of each 
primer (50pmol/µL) and 1 µL of Vent polymerase (2 units/µL). The general PCR conditions 
applied consisted of an initial denaturation at 94°C for 2 minute followed by 30 cycles of a 
denaturation at 94°C for 1 minute, an annealing Tm °C for 1 minute (Tm= the estimated melting 
temperature of the primer) and extension at 72°C for X minutes (X= length of fragment to be 
generated) and a final extension of 2x minutes at the end of the 30 cycles. In order to control the 





Sequencing was carried out using the dye terminator method on an ABI 373A machine 
(Imperial College facility) using specific FW and RV primers able to anneal the entire gene of 
interest. 
 
2.1.11 Protein SDS-Page 
 
SDS-Page of protein samples was carried out on a PHAST gel electrophoresis system 
(Amersham). The sample mixture loaded on the gel consisted of 1 part of protein samples and 1 
part of PHAST gel loading buffer composed by 4.8 mL of distilled water, 1.2 mL of 80 mM 
Tris-HCl pH 6.8, 1 mL of glycerol, 2 mL of 10 % SDS and 0.5 mL of 0.1 % bromophenol blue. 
This mixture was then heated at 95 ºC for 5-10 minutes. The protein samples were then loaded 
onto the PHAST system and run on a pre-cast homogenous 7.5 % gel or a gradient 8-25 % SDS-
Page PHAST gel. At the end of the run the gel was placed to stain in a filtered coomassie 
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solution for 30-45 minutes. The coomassie solution was obtained by diluting the stain stock (1 
PHAST gel coomassie stain tablet dissolved in 80 mL distilled water and 120 mL of methanol) 
with an equal part of 20 % acetic acid. The gel was then destained overnight in a destain 
solution containing 30 % methanol and 10 % acetic acid. Once destained, the gel was placed in 
a preserving solution that contained 13 % glycerol and 10 % acetic acid for 10 minutes. Markers 
routinely used during SDS-Page were the low or high molecular weight. SDS-Page markers 
from Amersham Biosciences. 
 
2.1.12 Construction of the allelic variants CYP2C9*2BMR and CYP2C9*3BMR 
 
The construction of the BMR allelic variants was carried out using the four primers mutagenesis 
method. According to this technique (figure 2.1) using two first separate PCR reactions (PCR1 
and PCR2) it is possible to amplify the two halves of the fragments containing the mutation. 
Then in a second step the products obtained in PCR1 and PCR2 are runned together in PCR3 























Figure 2.1 A schematic representation of the standard PCR four-primer methods. Arrows and 
numbers indicate the single primers. 1 correspons to the FW N-terminal primer 1, 2 to FW mutated 
primer 2, 3 to RV mutated primer 3 and 4 to RV C-terminal primer 4. The crosses represent the 
mutations inserted. 
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The primers designed for this method are listed in table 2.1 together with their melting 
temperatures. In particular primers 2 (Q2C9R144C.FW and Q2C9I359L.FW) and 3 
(Q2C9R144C.RV and Q2C9I359L.RV) were designed in order to have the specific mutation in the 
middle of their sequence. 2C9*2BMR and 2C9*3BMR were constructed by inserting the 
mutation in the 2C9 gene delimited by the NdeI and AvrII restriction enzyme sites. The mutated 
gene was then ligated back into the original BMRpCW fragment also pre-digested with the 
NdeI and AvrII restriction enzyme sites. The original 2C9BMR palsmid was used as template. 
The PCR sample composition was the one described in section 2.1.9. 
 
Table 2.1 Oligonucleotides used for the construction of the CYP2C9*2BMR and CYP2C9*3BMR 





Q2C9R144C.FW 5′-AGGAGCATTGAGGACTGTGTTCAAGAGGAAGCC-3′ 79.1°C 
Q2C9R144C.RV 5′-GGCTTCCTCTTGAACACAGTCCTCAATGCTCCT-3′ 79.1°C 
Q2C9I359L.FW 5′-CGAGGTCCAGAGATACCTGGACCTTCTCCCCAC-3′ 79.8°C 
Q2C9I359L.RV 5′-GTGGGGAGAAGGTCCAGGTATCTCTGGACCTCG-3′ 79.8°C 
2C9Nde.FW 5′-GGAGGTCATATGGCTCGACAATCT-3′ 63°C 
2C9Avr.RV 5′-CTTTGACCTAGGAATGAAGCACAGCTGGTAGAA-3′ 57°C 
 































Figure 2.2 Cycling conditions used fro the construction of the 2C9*2BMR allelic variant. 
 




















Figure 2.3 Cycling conditions used fro the construction of the 2C9*3BMR allelic variant. 
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2.1.13 Construction of the allelic variants CYP2C9*2FLD and CYP2C9*3FLD 
 
The FLD mutants were constructed using the same four primers method described in section 
2.1.12 (figure 2.1). 
The primers designed for this method are listed in table 2.2 together with their melting 
temperatures. In particular primers 2 (Q2C9R144C.FW and Q2C9I359L.FW) and 3 
(Q2C9R144C.RV and Q2C9I359L.RV) were the same used for the construction of the BMR 
mutants. In this case the mutations were inserted in the entire 2C9FLD gene delimited by the 
NdeI and HindIII restriction enzyme sites. The mutated gene was then ligated back into the 
original FLDpCW fragment pre-digested between the NdeI and HindIII restriction enzyme sites. 
The original 2C9FLD plasmid was used as template. The PCR sample composition was the one 
described in section 2.1.9. 
 
 
Table 2.2. Oligonucleotides used for the construction of the CYP2C9*2FLD and CYP2C9*3FLD 
plasmid. Single mutations are shown in red. 
 
 





Q2C9R14.FW 5′-AGGAGCATTGAGGACTGTGTTCAAGAGGAAGCC-3′ 79.1°C 
Q2C9R144C.RV 5′-GGCTTCCTCTTGAACACAGTCCTCAATGCTCCT-3′ 79.1°C 
Q2C9I359L.FW 5′-CGAGGTCCAGAGATACCTGGACCTTCTCCCCAC-3′ 79.8°C 
Q2C9I359L.RV 5′-GTGGGGAGAAGGTCCAGGTATCTCTGGACCTCG-3′ 79.8°C 













Figure 2.4 Cycling conditions used fro the construction of the 2C9*2/FLD allelic variant. 
Figure 2.5 Cycling conditions used fro the construction of the 2C9*3/FLD allelic variant. 
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2.1.14 Expression of CYP2C9, CYP2C9BMR, CYP2C9*2BMR, CYP2C9*3BMR, 
CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD 
 
The vectors pCW2C9BMR, pCW2C9*2BMR, pCW2C9*3BMR, pCW2C9FLD, 
pCW2C9*2FLD and pCW2C9*3FLD were used for the expression of human cytochrome 
P450s in Escherichia coli DH5a. An overnight culture was performed with 5mL of LB + 100 
µg/mL ampicillin and 1 colony of cells transformed and grown at 37o C. The day after the liquid 
culture was inoculated in 2L flask containing 500mL of TB and 100 µg/mL of ampicillin. The 
culture was grown at 37o C, 180 rpm shaking until an optical density at 600 nm of 0.4-0.6 was 
observed. Then a final concentration of 0.5 M ∂-ALA (∂-aminolevulenic acid) was added to the 
culture, the temperature was decreased to 28o C and cells were grown for a further hour at 180 
rpm shaking. The protein expression was induced by addition of IPTG at final concentration of 
1mM and 100 µg/mL of ampicillin was added again. The induced cells were grown for 48 hours 
at 28o C, 180 rpm shaking. 
After this procedure, cells were harvested, by centrifugation at 8,000 g for 20 minutes at 4o C 
and stored at -20 0C until use. 
 
2.1.15 Purification of CYP2C9BMR, CYP2C9*2BMR and CYP2C9*3BMR 
 
Purification of CYP2C9BMR, CYP2C9*2BMR and CYP2C9*3BMR was carried out using an 
ionic exchange chromatography step and a hydroxylapatite chromatography step. 
The harvested cells were resuspended in 100 mM potassium phosphate buffer (pH 8), 
containing 1mM DTT, 0.1 mM EDTA, 0.1 mM PMSF, 2.5% IGEPAL. EDTA reduces 
oxidation damage and chelates metal ions, PMSF is a trysin and chimotripsin inhibitor and DTT 
maintains –SH groups in the reduced form. Then lysozyme was added at a final concentration of 
1mg/mL and the cell suspension was stirred for 1h at 4oC. The suspension was then sonicated 
(Misoni Incorporated Ultrasonic Processor XL) on ice using ten bursts of 30 seconds each with 
1 minute of rest and then stirred again for 1 h at 4o C. After this step the lysate was centrifuged 
at 38,000 rpm for 1 hour at at 4o C (Beckman 28-60M).  
Purification of CYP2C9 chimeras was performed using ion exchange chromatography. Ion 
exchange chromatography (IEX) separates molecules according to net charge. Charged sample 
molecules adsorb to ion exchangers of the opposite sign. The interaction is a dynamic 
equilibrium that can be influenced by pH or salt concentration.  
The supernatant was loaded on a DEAE column (150 mL bed volume) pre-equilibrated with 5 
volumes of 100 mM potassium phosphate buffer (pH 8), containing 1 mM DTT. The column 
was washed with 5 volumes of 100 mM potassium phoshate buffer (pH 8) containing 1 mM 
DTT and then with 5 volumes of 200 mM potassium phosphate buffer (pH 8) containing 1 mM 
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DTT and 0.1% IGEPAL. Elution was carried out using 500 mM potassium phosphate buffer 
(pH 8) containing 1 mM DTT and 0.1% IGEPAL and 5 mL fractions were collected. Fractions 
containing P450 were pooled and concentrated using a Vivaspin 20® with a 30 KDa cut-off. 
The elution buffer was exchanged 3 times with a 50 mM potassium phosphate buffer (pH 8) 
containing 1mM DTT. The protein was loaded then onto a hydroxylapatite (20 mL bed volume) 
pre-equilibrated with 50 mM potassium phosphate, 1mM DTT (pH 8). The column washed with 
20 column volumes of 100 mM potassium phosphate, 1 mM DTT (pH 8) to remove detergent 
and impurities still present. The protein was eluted with 500 mM potassium phosphate buffer 
(pH 8) containing 1 mM DTT and 5 mL fractions were collected. Fractions containing 
CYP2C9BMR, CYP2C9*2BMR and CYP2C9*3BMR were concentrated using a 30 KDa cut-
off membrane (Vivaspin 20®). Different steps of dilution and concentration were carried out 
using 50 mM potassium phosphate buffer (pH 8), containing 1mM DTT. Prior storage, a SDS-
page gel of purified proteins was run and the presence of CYP2C9BMR, CYP2C9*2BMR and 
CYP2C9*3BMR was investigated by using the UV-vis spectrophotometric CO-binding assay 
(section 2.1.19). The protein was then stored at -20o C upon addition of 50% glycerol.  
 
2.1.16 Purification of the CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD 
 
Purification of the CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD chimeras was carried 
out using an anion exchange chromatography step followed by a Nickel ion affinity 
chromatography step. The harvested cells were re-suspended in lysis buffer containing 50 mM 
potassium phosphate, 0.1 mM PMSF and 5 mM β-mercaptoethanol at pH 8. Lysozyme was 
added to a final concentration of 2 mg/ mL. The suspension was stirred for 1 hr at 4 °C followed 
by sonication on ice (ten bursts of 30 seconds each with 1 minutes rest) to lyse the cells. The 
soluble and membrane fractions were separated by centrifugation at 38,000 rpm (100,000g) for 
60 minutes at 4 °C. Membrane bound proteins were then solubilised by re-suspension of 
membrane pellet in buffer containing 50 mM potassium phosphate, 5 mM β-mercaptoethanol 
and 2.5% Igepal at pH 8 using a dounce homogeniser and stirring for 2 hours at 4 °C. The 
suspension was then centrifuged again at 38,000 rpm (100,000g) for 60 minutes at 4 °C. 
The final supernatant was loaded onto a DEAE column (200 mL bed volume) pre-equilibrated 
with 5 column volumes of 50 mM potassium phosphate containing 5 mM β-mercaptoethanol 
(pH 8). Initial washing was carried out with 10 column volumes of 50 mM potassium phosphate 
containing 5 mM β-mercaptoethanol (pH 8). Impurities were removed by washing with 5 bed 
volumes of 200 mM potassium phosphate containing 5 mM β-mercaptoethanol and 0.1% 
IGEPAL (pH 8). Elution was achieved by a linear gradient from 200 mM potassium phosphate 
containing 5 mM β-mercaptoethanol and 0.1% IGEPAL (pH 8) to 500 mM potassium 
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phosphate containing 5 mM β-mercaptoethanol and 0.1% IGEPAL (pH 8) with 5 mL fractions 
collected. Fractions with an absorbance at 420 nm were pooled and concentrated using a 
centrifugal concentrating device with a 30 kDa cut-off membrane (Vivaspin 20). 
The concentrated protein was loaded onto a Nickel chelating sepharose FF column (20 mL bed 
volume) that was pre-equilibrated with 500 mM potassium phosphate pH 7.4 containing 20 % 
glycerol and 5 mM β-mercaptoethanol. The column was then washed with 10 column volumes 
of this pre-equilibration buffer to remove any aspecifically bound protein. A further wash with 5 
column volumes of 50 mM potassium phosphate pH 7.4 buffer containing 20 % glycerol, 500 
mM sodium chloride and 5 mM β-mercaptoethanol and 2 column volumes of 50 mM potassium 
phosphate pH 7.4 buffer containing 20 % glycerol, 500 mM sodium chloride, 5 mM β-
mercaptoethanol and 1 mM histidine were performed. The low concentration of histidine was 
used to remove any protein bound to the resin through weak affinity towards the nickel ion. The 
column bound P450 was then eluted using 50 mM potassium phosphate pH 7.4 buffer 
containing 20 % glycerol, 500 mM sodium chloride, 5 mM β-mercaptoethanol and 40 mM 
histidine. The high concentration of histidine resulted in the displacement of the nickel ion from 
the resin and the subsequent elution of the cytochrome P450.  
The cytochrome P450 containing fractions were pooled and concentrated using a centrifugal 
concentrating device with a 30 kDa cut off membrane (Vivaspin 20). A series of dilution and 
concentration steps were carried out using 50 mM potassium phosphate pH 7.4 buffer 
containing 20 % glycerol, 500 mM sodium chloride and 1 mM DTT in order to remove the 
histidine and exchange the β-mercaptoethanol with DTT. Prior to storage an SDS-Page gel of 
the purified protein was run and the UV-visible spectra of the oxidised, reduced and reduced-
carbon monoxide bound forms of the protein were recorded as described in section 2.1.19. The 
protein stock was typically concentrated to 0.3-0.6 mM of P450 and centrifuged at 13,000g to 
remove any aggregates. Glycerol was added to the protein to a final concentration of 50 % and 
the protein stock was stored at -20° C. 
 
2.1.17 Expression of BMP 
 
BL21 (DE3) competent cells were transformed with the pT7BMP plasmid and plated onto LB 
agar plates containing 100µg/ml of ampicillin. One colony was picked from the plate and grown 
in 5ml of LB- solution over night at 37°C in a shaker (200rpm) to set up the initial culture. One 
ml of the culture was added to 100 ml of LB spiked with ampicillin at a concentration of 
100µg/ml. The culture was grown until an optical density (OD) of 1 was observed at 600 nm. 
This value was reached in 3-3.5 hours. The culture was then diluted again (1:100) to a final 1 
litre volume of LB containing ampicillin and incubated at 37°C shaking (200rpm) until the OD 
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at 600 nm was 0.7. At that point the expression was induced by adding 1 mM of IPTG. The E. 
Coli BL21 (DE3) cells contain a single copy of the T7 polymerase on the chromosome in a 
lambda lysogen (DE3) under control of the Lac-UV5 promoter. In absence of lactose (as in the 
case of LB broth), the lac repressor (lacI) binds to the lac operator and prevents transcription 
from the lac promoter. When IPTG is added it binds to the repressor and induces its dissociation 
from the operator, permitting transcription of T7 polymerase. The induced cells were grown for 
18 hours at 28°C. They were harvested by centrifugation at 4000rpm for 20 minutes, 
supernatant was discarded and pellet was stored at –20°C until use.  
 
2.1.18 Purification of P450 BM3 haem domain  
 
Stored cells were thawed on ice and re-suspended in an ice cold buffer made of 30mM 
potassium phosphate pH7.4, 0.1mM EDTA, 0.1mM PMSF, 2mM DTT (5ml/g) (buffer A). The 
solution was supplemented with Lysozyme (0.2mg/ml) and stirred for 30 minutes at 4°C. The 
re-suspended cells were then sonicated on ice with ten 30 second bursts with 1 minutes rest on 
ice between each burst to minimise proteolytic activity. Complete sonication was confirmed by 
the decreased viscosity of the suspension. The lysed cells were then stirred for a further 30 
minutes at 4°C. The latter was centrifuged at 100,000g for 1 hour at 4°C to remove lipids and 
particulate matter. 
After ultracentrifugation the supernatant was loaded onto a Q-Sepharose fast flow column 
(150ml bed volume) pre-equilibrated with three bed volumes of buffer A. Q Sepharose Fast 
Flow is a strong anion exchanger that remains charged and maintains consistently high 
capacities over the entire working range, pH 2-12. The column was washed with 5 column 
volumes of the same buffer and P450 BMP was eluted with a 1 litre linear gradient from 0.1 to 
0.3 M sodium chloride, collecting 8 ml fractions. The P450 BMP containing fractions with a 
420 nm / 280 nm ratio greater than 0.1 were then pooled and concentrated  using a 30 KDa cut-
off membrane (Vivaspin 20®). The sample was then concentrated and diluted 3 times with 
buffer A. After doing this the sample was loaded onto a DEAE fast flow column (150 ml bed 
volume) pre-equilibrated with buffer A. DEAE Sepharose Fast Flow is a weak anion exchanger. 
The protein was washed with buffer A until the absorbance at 280 nm of the wash was equal to 
that of the applied buffer (around 3 column volumes). P450 BMP was then eluted with a 1 litre 
linear gradient of 0.1 to 0.2 M sodium chloride, collecting 5 ml fractions. P450 BMP containing 
fractions with a 420 nm / 280 nm greater than 1 were then pooled and concentrated. If the 
sample was not pure enough the fractions were concentrated to a final volume of 5ml and 
loaded onto a S200HR gel filtration column (200ml bed volume) pre equilibrated with the same 
buffer. The protein was then eluted using a flow rate of 1 ml / min and 5 ml fractions were 
collected. Fractions with a 420 nm /280 nm ratio greater than 1.3 were pooled and concentrated 
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and exchanged into 50mM HEPES pH 8 buffer and 20% of glycerol to help protein maintain its 
correct conformation. The protein was aliquoted in 0.5 ml aliquots and stored at –20°C. 
 
2.1.19 CO binding assay  
 
The presence of cytochrome P450 was investigated by using a UV-Vis spectrophotometric 
assay. The assay is based on the shift of the maximum of absorbance of the protein from 420 
nm, which represents the maximum absorbance of oxidased heme (FeIII), to 450 nm, which 
represents the maximum absorbance of heme upon reduction with a crystal of dithionite and 
bubbling of carbon monoxide in the solution for 1 minute. The spectrum of reduced form was 
subtracted to the spectrum of the reduced-CO bound form. The resulting spectrum was used to 
calculate the concentration of the cytochrome P450 by using the extinction coefficient ε = 
91,000 M-1cm-1. The assay was used in this project to investigate the presence of th cytochrome 
P450 for CYP2C9BMR, CYP2C9*2BMR CYP2C9*3BMR, CYP2C9FLD, CYP2C9*2FLD 
and CYP2C9*3FLD chimeras.  
 
2.1.20 Substrate binding studies on 2C9FLD and 2C9*3FLD 
 
Substrate binding studies were performed on 2C9FLD and 2C9*3FLD using the marker 
substrates ibuprofen and flurbiprofen. The spectral increase in absorbance at 390 nm and the fall 
in absorbance at 420 nm were followed on a a Hewlett-Packard 8453 diode array 
spectrophotometer equipped with a peltier temperature control device. Titrations of substrate 
into protein were carried out in 50 mM potassium phosphate pH 7.4 buffer containing 10 % 
glycerol, 500 mM sodium chloride and 0.1 % IGEPAL at a temperature of 28 °C with the 
protein concentration being around 0.5 to 2.0 µM in a 1000 µL volume. 
The substrate stock solutions used were 10 mM ibuprofen and 10mM flurbiprofen in 50 mM 
potassium phosphate pH 7.4. Volumes of 0.5-2.0 µL of the substrate stock solution were added 
to the protein solution and mixed prior recording the spectra.  
The dissociation constant KD was calculated by fitting the obtained data, using non-linear 
regression analysis on the Sigma Plot 5.0 program (Systat Inc.), to the rectangular hyperbolic 
equation: 
Y= AX / (B+X)  
Where Y= (∆A392-∆A420), X= [S] free, A = ∆Amax = (∆Abs392-∆Abs420) max and B= KD 
and 
[S] free = ([S] added  - [ES]) and [ES] = [(∆Abs392-∆Abs420) x [P450]] /  (∆Abs392-∆Abs420) max. 
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2.2.1.1 Cyclic voltammetry 
 
Electrochemical methods consist of holding constant certain parameters of the electrochemical 
cell and observing how other factors vary as a consequence. Voltammetry is a dynamic electro-
analytical technique in which the potential (“volt-”) of an electrode is varied while the current 
(“amm-”) induced is simultaneously monitored. This occurs as a result of the electrode being 
polarized, that is, its potential is forced away from its equilibrium value.  
Cyclic voltammetry is one of the most commonly encountered techniques for studying dynamic 
electrochemistry of immobilised enzymes (Armstrong et al., 2000).  
In a cyclic voltammetric event the potential of the working electrode is ramped from an initial 
potential Ei to a switch potential value Eλ at a certain scan rate (ν). The direction of the potential 
scan is then reversed back to the starting point and each cycle is repeated n times (figure 2.6). 
The resultant trace of the measured current against the applied potential is termed a cyclic 









The cyclic voltammogram shown in figure 2.8 is typical for an electroactive compound that is 
wholly reversible. This situation would be expected from a simple reversible one-electron 
oxidation process where both the reactant (A) and the product (B) are fully soluble. Under these 
conditions oxidation and reduction peaks of similar shape and magnitude are observed in both 












Figure 2.6 Potential time profile for cyclic voltammetry. 
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Figure 2.7 Schematic diagram of a cyclic voltammogram. CV recorded in absence of oxygen, where both 
reduction and oxidation occur between the electrode surface and the electron transfer protein. 
 
 
The magnitude of the current is proportional to the concentration of the electro-modified 
material. The potential of the cathodic peak is Epc, while the potential of the anodic peak is Epa. 
Provided that the couple is fully reversible, the two peaks are positioned on either side of the 
formal electrode potential E0’ of the analyte redox couple, as follows: 
(Epa + Epc) / 2 = E0’ 
This formal potential or formal redox potential is similar to the standard electrode potential, E. 
The CV will look like that shown in figure 14 only if the ratio of activities of the oxidized and 
reduced forms of the redox couple satisfies the Nernst equation for the potential of the working 




1. ipc = ipa 
2. Epc and Epa are independent of the scan rate ν 
3. E0’ is positioned midway between Epc and Epa 
4. ip is proportional to ν1/2 
5. The separation between Epc and Epa is 59 mV/n for an n-electron couple 
(pc, cathodic peak; pa, anodic peak). 
 
In the case of immobilised protein the system is not homogeneous. The two species A and B are 
not soluble but rather in a thick-solid or thin-film format attached to an electrode surface which 
is in contact with a solvent (electrolyte) solution phase. Figure 2.8 shows an idealized diagram 
of a layer of redox active protein adsorbed onto an electrode surface (Armstrong et al., 1997).  
 
Table 2.3 Criteria for the electrochemical reversibility of a redox couple in solution, carried out by 
using cyclic voltammetry 
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Figure 2.8 Idealized diagram of a layer of redox active protein acsorbed onto an electrode surface. All 
centres are assumed to have the same [Ef0]surf value and exhibit identical electron transfer characteristic 
(Amstrong F.A. and Hirst J., University of Oxford – Bond 2002 ). 
 
Assuming that the entire thin-film layer consists of redox active species with the same single 
reversible potential [Ef0]surf  and the charge-transfer rate constants for oxidation kox and reduction 
kred are equal, the potential of the electrode with surface attached material will be governed by 
Nernst equation in its surface-attached form. Thus 
E = [Ef0]surf  + RT/nF ln {Γox / Γred} 
where Γox  is used to denote the fraction of the oxidized form of the compound, and Γred is the 
fraction of the reduced form of the compound. This is equivalent to state that the activities of 
red and ox are proportional to their mole fractions in the ideal thin film.  
For a diffusionless reversible (Nernstian) reaction involving the simultaneous transfer of n 
electrons at the same potential, the equilibrium current is simply given by the rate of change of 
the redox state of the redox centers as follows: 
i = nFA dΓox / dt    or     i = nFA dΓred / dt 
Figure 2.10A shows a reversible voltammogram for a surface confined ideal one-electron thin-
film reaction. Under these ideal conditions the peak separation is expected to be zero and the 
peak heights [Ip]surf for oxidation and reduction can be calculated from the expression 
[ip]surf = (n2F2 / 4RT) n AΓtot 
Furthemore the areas under the peaks are related to the total number of electrons transferred (or 
number of adsorbed molecules): 
Area under peak/ n = nFAΓtot 
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Figure 2.9 (A) A reversible and
 
(B) non-reversible voltammogram for a surface confined ideal one-
electron thin-film reaction at 0˚C (Amstrong F.A. and Hirst J., University of Oxford – Bond 2002 ). 
 
When equilibrium cannot be maintained the thin-film voltammetric process is no longer 
reversible but rather irreversible or quasi-reversible (figure 2.9B). This situation arises when the 
scan rate is increased or when the electron transfer rate is too slow for equilibrium to be 
maintained. Since the rate of change of potential is now faster than the rate of adjustment of the 





Spectroelectrochemistry consists of the combination of optical and electrochemical techniques 
for studying the redox chemistry of inorganic, organic and biological molecules. During a 
spectroelectrochemical experiments the oxidation states of the species at the electrode are 
changed by addition or removal of electrons while spectral measurements on the solution 
adjacent to the electrode are made simoultaneously. Such a combination of electrochemical 
perturbations with the molecular specificity of optical monitoring successfully addresses the 
limited structural information available from the current response. It can be extremely useful for 
the elucidation of reactions mechanisms, and for the delineation of kinetic and thermodynamic 
parameters. 
This technique was developed by the availability of optically transparent electrodes (OTEs), 
which enable the passage of light trough them and adjacent solution. The optically transparent 
electrode can be: 
- a thin metal film on a transparent substrate. The thickness must not exceed 100 nm for 
the film to remain transparent and this can results in high electrical resiresistance 
- a glass plate with a thin film on an optically transparent, conducting material 
- a thicker, free-standing metal mesh 
The most commonly used conductive materials are Pt, Au, SnO2, C or Hg-coated Pt deposited in 
form of thin films (100-5000 Å) on transparent substrates such as glass or plastic (visible), 
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quartz (UV-visible) or Ge (infrared) depending on the spectral region of interest. The film 
thickness is often selected as a compromise between its electrical conductivity and optical 
transmission. 
In a typical experiment, one measures absorption changes resulting from species produced (or 
consumed) in the redox process. The change in absorbance is related to concentration and 
optical path length. Evaluation of the temporal absorbance response (A-t curve) during the 
electrochemical generation (or consumption) of an optically active species can yield useful 
insight on reaction mechanisms and kinetics. 
Observation of a thin layer of solution (≤ 0.2 mm) confined next to a transparent electrode is 
one of the most useful spectroelectrochemical techniques. The optical beam of the 
spectrophotometer is passed directly through the transparent electrode and the solution. 
Thin layer spectroelectrochemistry offers a simple way of controlling the oxidation state of 
species in a very small volume of solution for simultaneous spectral observation. The redox 
potential of the thin layer of solution is adjusted by the applied potential as determined for the 
reversible system  
O + e- ↔ R 
by the Nernst equation 
E = E°O,R + 0.059 / n log [O]/[R] 
The applied potential, E, controls the ratio [O]/[R] at the electrode surface, but the ratio in the 
thin solution layer quickly adjusts to the same ratio by electrolysis. 
A spectropotentiostatic technique has been developed for obtaining spectra, formal reduction 
potentials (E°) and electron stoichiometries (n-values) of redox couples. The redox couple is 
converted incrementally from one oxidation state to another by a series of applied potentials for 
which each corresponding value of [O]/[R] is determined spectrally. Each potential is 
maintained until electrolysis ceases so that the equilibrium value of [O]/[R] is established as 
defined by the Nernst equation. By doing a nernstian plot of the E values and the corresponding 
value of [O]/[R] determined spectrally, it is possible to calculate the theoretical reduction 
potential from the intercept and slope. 
In semi-infinite diffusion spectroelectrochemistry the cell has an electrode in contact with a 
electrolyte solution thicker than the diffusion layer adjacent to the electrode such that a 
condition of semi-infinite diffusion exists for the electroactive species.Consider the situation in 
which species O is present in an unstirred solution that is contacting an optically transparent 
electrode through which a light beam is passed. Species R is electrogenerated from O by the 
potential applied to the transparent electrodeaccording to equation 1. If the wavelength is such 
that R absorbs light, an absorbance time response is obtained. The increase in absorbance 
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reflects the generation of R at a rate determined by the diffusion of O at the electrode surface. 
This absorbance-time behaviour is described by  
A = (2/Π1/2) εR CºO D1/2O t1/2 
where εR is the molar absorptivity of the optically monitored species r and CºO and DO are the 
solution concentration and diffusion coefficient, respectively, of the species O from which R is 
being electrogenerated. 
Differentiation of both sides of this equation with respect to time then yields to data that 
measured as a function of applied potential give a differential cyclic voltabsorptogram whose 
shape is directly analogous to a voltammogram. Depending upon the molar absorptivity of the 
monitored species, the derivative optical response may afford a more sensitive tool than the 
voltammetric one. This concept is also not prone to charging-current background contributions 
and holds considerable promise for mechanism diagnosis and kinetic characterization of 
coupled chemical reactions. 
 
2.2.2 Materials and equipment 
 
All the chemicals used for the different immobilisation methods were purchased from Sigma-
Aldrich with the exception of 6-hexanethiol and the 7-mercapto heptanoic acid that were 
purchased from Dojindo. All chemicals were of reagent grade and all solutions were prepared 
using distilled, deionized water of resistance 10 MΩ 
Glassy carbon electrodes were purchased from BAS (3 mm diameter). Gold electrodes 
evaporated on silicon wafer were provided by RAL (Rutterford Analysis Laboratory, UK). The 
evaporated gold electrode had an area of 15 mm2 and 200 nm thickness). The prototype of the 
array was provided by Nanobiodesign Ltd (spin out company of Imperial College). The tin-
dioxide electrodes for the spectro-electrochemical experiments were provided by Prof. Durrant 
(Chemistry Department, Imperial College) and consisted of a nanocrystalline, porous SnO2 
paste (15-nm-sized particles) deposited on fluorine-doped tin-oxide coated (TEC15) glass with a 
sheet resistance of 15 Ω sq and purchased from Hartford Glass (Hartford City, Indiana, U.S.A.). 
The surface area determined by BET analysis was of 89 m2 per g, corresponding to a 
macroscopic film area of 1 cm2. 
All the electrochemical experiments on the N-terminally modified CYP2C9, CYP2C9BMR, 
CYP2C9*2BMR, CYP2C9*3BMR, CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD 
immobilised on glassy carbon electrodes were carried out in the cell shown in figure 2.10 and 
consisted of a chamber housing the working and counter electrodes and a chamber housing the 
reference electrode. The reference electrode chamber and the working electrode chamber were 
connected via a capillary that contained 1% agarose and 3 M potassium chloride to act as a salt 
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bridge. The reference electrode used was the saturated calomel electrode (SCE E° +242 mV vs. 




Figure 2.10 Bi-compartment electrochemical cell. 
 
Electrochemical and spectroelectrochemical experiments were performed on an Autolab PGStat 
12 potentiostat connected to a three-electrode cell with quartz windows. The 
spectroelectrochemical cell (figure 2.11) comprised a 3 mL compartment, in which the SnO2 
film was used as the working electrode, a platinum mesh flag as the counter electrode and an 
Ag/AgCl in 3.5 M KCl as the reference electrode. All potentials measured in this work are with 
reference to this electrode (203 mV vs NHE).  The electrolyte used during the electrochemical 
experiments was an aqueous solution 0.02 M KPi pH 8 saturated with argon after bubbling for 
20 min. Argon was then continuously flowed over the solution at ambient temperature in order 
to maintain the anaerobic environment. Way of access for the Ag/AgCl reference electrode and 
platinum counter electrode were available on the plastic holder. 
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Figure 2.11 One-compartment electrochemical cell 
 
Measurements in the absence of oxygen were carried out in a nitrogen filled glove box with 
oxygen level less than 2 ppm (Belle technology) and all cyclic voltammograms were recorded 
using a PGSTAT 10 potentiostat (Autolab). 
 
2.2.3 Immobilisation of BMP on tin-dioxide electrodes 
 
Prior to immobilization, the protein storage buffer was exchanged to 20 mM KPi pH 8 so that a 
final 25-30 µM solution was obtained. 20-25 µM of PEI and PDDA solutions were prepared in 
the same 20 mM KPi pH 8 buffer. All the dirt and any adsorbed water were removed from the 1 
cm2 area of a SnO2 electrode by heating the electrode at 450 °C for 20 min. The electrode was 
then cooled down at room temperature and modified by immersion in the PDDA or PEI 
solutions for 4 hours. The electrode was then rinsed with 20 mM KPi pH 8 buffer and immersed 
in the BMP solution for 5-12 hours at 4 °C. The amount of protein adsorbed onto the film was 
monitored at room temperature by recording the UV-vis absorption spectra of the treated film 
using a standard Shimadzu UV-1601 spectrophotometer. Prior measurements, films were rinsed 
again with buffer in order to remove the excess of un-bound protein. Contributions to the 
spectra from the SnO2 films alone were subtracted by the use of protein-free reference 
electrodes. 
 
2.2.4 Cyclic voltammetry of BMP on tin-dioxide electrodes 
 
The protein modified electrode was inserted in the cell illustrated in figure 2.12. The cell was 
then inserted into the sample compartment of a standard Shimadzu UV-1601 spectrophotometer 
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and the optical absorbance spectra were recorded. For kinetic studies chronoabsorptometry was 
performed. Different fixed potentials in a range between 0 and -0.9 V until either the reduction 
and CO binding or the oxidation and CO dissociation from the enzyme reached equilibrium. 
The sample optical absorbance was monitored at the single wavelengths of interest (450nm or 
420nm). Cyclic voltammetry (measurement of the current as a function of potential) and cyclic 
voltabsorptometry (measurement of the optical absorbance as a function of potential) were 
conducted simultaneously. Cyclic scans between 0 and -0.75V were performed at scan rate of 
0.005V/sec. Differential cyclic voltabsorptometry data were obtained for differentiation of the 
CVA data, followed by smoothing with a fast Fourier transform smoothing algorithm.  
 
2.2.5 Immobilisation of the proteins on glassy carbon electrodes. 
 
Glassy carbon electrodes were cleaned with small size polishes (alumina paste of 0.015 µm) by 
using PAN-W cloths manufactured by Kemet International. The electrode surface was rinsed 
and then sonicated in Milli-Q water for 15 min in order to remove alumina particles. Electrodes 
were rinsed again with Milli-Q water and let dry out. For the immobilisation of the CYP2C9 
protein in didodecyldimethylammoniumbromide (DDAB), 7 µl of concentrated protein (80µM) 
(protein storage buffer: 50 mM potassium phosphate pH 8 containing 500 mM sodium chloride, 
10 % glycerol and 1 mM DTT) were mixed with 3 µl of a 5mM DDAB aqueous solution and 
loaded onto electrode surfaces. For the immobilisation of the CYP2C9 protein in 
polydiallyldimethylammonium chloride (PDDA molecular weight 100,000-200,000), 5 µl of a 
10 % w/v aqueous solution of PDDA were mixed with 5 µL of protein in 50 mM potassium 
phosphate pH 8 containing 500 mM sodium chloride, 10 % glycerol and 1 mM DTT. The 
electrodes were left at the room temperature overnight to allow the vaporisation of water from 
the polymer. After immobilisation the electrodes were washed with the electrolyte buffer (50 
mM potassium phosphate pH 7.4 containing 500 mM sodium chloride) and inserted in the 
electrochemical cell for the cyclic voltammetric experiments. Control electrodes were routinely 
prepared by depositing a mixture of 7 µl of the protein storage buffer and either 3 µl of the 
DDAB aqueous solution or 3 µl of the PDDA aqueous solution. 
The CYP2C9FLD/DDAB/GC electrodes used for the electrocatalytic titration where further 
covered with a drop (5 µl) of aqueous solution Nafion®117 (Sigma) and left dry for a couple of 
hours. In order to change of the ion exchange capability of the layer 28 µL of 
tetraethylammonium bromide 50% was solved in 472 µL of ethanol and then mixed with 500 
µL of Nafion. In order to check the change in porosity, cyclic voltammetric scans were 




2.2.6 Immobilisation of the proteins on the polycrystalline and sputtered gold 
electrodes. 
 
Evaporated gold electrodes were cleaned with multiple washes in ethanol and acetone solvents, 
followed by plasma cleaning treatment for 30 minutes. After the plasma cleaning treatment, the 
electrode was left immersed in ethanol for 20 minutes in order to remove the formed gold oxide.   
The electrode surface was then rinsed with ethanol and immersed in an ethanolic solution of the 
mixed spacers 6-hexanethiol and the 7-mercapto heptanoic acid (1mM:1mM). The electrodes 
were heated up to 60 ˚C for 20 minutes and then left in incubation at room temperature for up to 
48 hours to allow the formation of the SAM monolayer. At the end of the incubation, the 
electrode was rinsed with ethanol, Milli-Q water and MES, which is the buffer used to solubilise 
EDC (1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and NHS (N-Hydroxysuccinimide). 
The electrode was then immersed for 15 min in the EDC/NHS solution. Immediately after the 
electrode was washed with water and then 30 µL of the protein solution (5µM) were deposited 
and the electrode was left at 4˚C for one hour.  
The same protocol was used for the modification of the array with the exception of the heating 
step at 60˚C because of the instability of the glue and plastic holder with consequent leakage of 
the electrolyte buffer. 
 
2.2.7 Cyclic voltammetric experiments 
 
All the electrochemical experiments on the N-terminally modified CYP2C9, CYP2C9BMR, 
CYP2C9*2BMR, CYP2C9*3BMR, CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD 
immobilised on glassy carbon or gold electrode were carried out at 25 °C and in 50 mM 
potassium phosphate pH 7.4 containing 500 mM potassium chloride. 
Cyclic voltammetry experiments were carried out in glove box (Bell Technology) under a 
nitrogen atmosphere with an oxygen level less than 2 ppm. Measurements were carried out with 
a PGSTAT 10 potentiostat (Autolab). Cyclic voltammograms were recorded at 25°C using a 
two compartment electrochemical cell containing oxygen free buffer (50 mM potassium 
phosphate pH 7.4, 500mM potassium chloride). A potential was cyclically applied from 0 V to -
0.65 V for all the CYP2C9 proteins immobilised on C6C7 modified gold electrodes and from 
0.25 to -0.85 for all the CYP2C9 proteins immobilised on DDAB (didecyldimethylammonium 
bromide) and PDDA (polydiallyl dimethylammonium chloride) modified glassy carbon 





2.2.8 Measurements in the presence of carbon monoxide 
 
Measurements in the presence of carbon monoxide were carried out in the absence of oxygen in 
a nitrogen filled glove box with oxygen level less than 2 ppm (Bell technology). The buffer (50 
mM potassium phosphate pH 7.4 containing 500 mM potassium chloride) was saturated with 
carbon monoxide and introduced into the working electrode compartment of the cell inside the 
glove box. The cyclic voltammograms of the proteins were then measured to assess the binding 
of carbon monoxide to the haem iron. 
 
2.2.9 Electrocatalytic experiments  
 
A cyclic voltammetric scan was performed in oxygen free environment to evaluate the amount 
of electroactive protein immobilised. The area of the reduction peak measured in anaerobic 
conditions gave the amount of charge transferred on the reduction of the protein. The surface 
concentration of the electroactive enzyme on the electrode was estimated by assuming one 
electron transfer using Faraday’s Law: 
Q=mF 
where Q is the charge, m is the mass of electroactive species (mol) and F is Faraday’s constant 
(96485 C/mol).  
Electrocatalytic experiments were performed in 500 µL of fresh buffer was introduced into the 
working electrode chamber and a saturating concentration of S-warfarin (250mM) was added to 
evaluate the ability of the immobilised protein to convert it to 7-hydroxy warfarin. Catalase 
(CAT) and superoxide dismutase (SOD) where added in a concentration of 100 units/500µL to 
control the contribution of reactive oxygen species to the formation of metabolites. Superoxide 
dismutase catalyzes the dismutation of superoxide into oxygen and hydrogen peroxide, 
while catalase decomposes the hydrogen peroxide formed to water and molecular oxygen. The 
solution was stirred and a potential more negative than the redox potential of the haem iron of 
the protein (-0.550V) was applied for 30 minutes. After 30 minutes the reaction mixture was 
removed, extracted using solid phase extraction into 50 µL methanol and spiked with 1 µL of 10 
mM acetylsalicilic acid (internal standard). The catalysis reactions were repeated at least 4 times 
and catalysis reactions using baseline (no protein) electrodes were always carried out on each 
occasion. 25 µL of the spiked reaction mixture was injected onto a Agilent 1200 LC system 
equipped with a quaternary pump, diode array detector and ChemStation® LC management 
software. A LiChroCART® 250-4 LiChrospher® 100 RP-18 (5 µm) cartridge (Merck Chemicals, 
UK) was used and gradient from 90:10 / water: acetonitrile to 75:25 / water: acetonitrile at a 
flow rate of 1.2 mL min-1 was used as the mobile phase. Elution was monitored at a wavelength 
 100 
of 306 nm that is the maximum of absorbance of the 7-hydroxywarfarin. The 7-hydroxywarfarin 
formed in the reactions was calculated from a standard curve of authentic standards. Using the 
quantity of electroactive protein, the rate of product formation (min-1) at a 250 µM of S-warfarin 
concentration was determined (Vmax).  
2.2.10 Titration reactions  
 
Electrocatalytic titrations were studied under aerobic conditions with stirring to ensure a 
constant dissolved oxygen concentration. The potential was cycled between 0 and - 0.65 V for 
the CYP2C9 proteins immobilissed on C6C7/Au electrodes and between 0.25 and -0.75 V for 
the CYP2C9FLD/Nafion/DDAB/GC electrodes. Increasing volumes of the substrate stock were 
added. The change in bioelectrocatalytic current at - 0.45 V was recorded until the current signal 
reached saturation. The values of current at -0.450V were plotted against the concentration of 
substrate added and fitted using non-linear regression analysis to a rectangular hyperbolic 
equation to obtain values of Km. A minimum of four electrodes were titrated for each protein.  
Controls involving the titration of substrate in the absence of immobilised protein were also 
perfomed.  
 
2.2.11 FT-IR measurement 
 
Infrared spectroscopy has long been recognised as a powerful method for the characterisation of 
materials. The technique measures changes in vibrational and rotational states of the molecules 
after a sample being irradiated by infrared light. The resulting absorption frequency depends on 
the vibrational frequency of the molecules, whereas the absorption intensity depends on how 
effectively the infrared photon energy can be transferred to the molecule. The molecule absorbs 
infrared light only if there is a change in the dipole moment upon molecular vibration.  The plot 
of the intensity of light absorption versus the frequency of the light is called the infrared 
spectrum. 
Most of the chemical compounds show infrared spectra with sharp peaks at certain frequencies 
that correspond to the vibrational frequencies of specific functional groups or bonding 
arrangements. These specific spectra can be used as fingerprints to identify compounds.  
In a FT-IR system a polychromatic radiation is sent onto a sample through an interferometer. In 
the interferometer the light passes through a beam-splitter, which sends the light in two 
directions at right angles. One beam goes to a stationary mirror, the other to a moving mirror. A 
path difference between the beams is introduced whereupon they are allowed to recombine. In 
this way, interference between the beams is obtained and the intensity of the output beam from 
the interferometer can be monitored as function of path difference using an appropriate detector. 




Figure 2.12 Scheme of interferometer. 
 
 
The final recombined beam passes then through the sample. The sample absorbs the 
wavelengths characteristic of its spectrum and those wavelengths are therefore subtracted from 
the interferogram.  The detector records the variation in energy versus time for all wavelengths 
simultaneously.  A reference signal is given by a superimposed laser beam. 
The mathematical function called Fourier transform allows to convert an intensity-vs.-time 
spectrum into an intensity-vs.-frequency spectrum. The final peak position (vibration frequency) 
is therefore given as wavenumber (cm-1), which corresponds to the frequency divided by the 
speed of light.  
For the FT-IR measurements, the CYP2C9BMR and CYP2C9FLD were immobilised on an 
evaporated gold electrode cleaned as described in section 2.2.2. A negatively charged surface 
was prepared by coating with MPS 1mM. The deposition of MPS 
(mercaptopropyltrimethoxysilane) was done immersing in the aqueous solution for 48 hours. A 
film of protein mix to DDAB and PDDA in the same proportions used for the glassy carbon 
immobilisation was deposited on the surface and left at 4˚C overnight. The film was then dried 
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3.1 Introduction  
The human cytochromes P450 (CYP450) are enzymes located primarily in the endoplasmic 
reticulum of liver microsomes and involved in drug metabolism. The binding to the membrane 
renders them not soluble and therefore difficult to handle when located in their native 
environment. 
First characterisations of the CYP450 catalytic activity towards drugs was carried out in in vivo 
experiments on tissue samples. Extraction and purification of the single CYP450 isoforms were 
attempted, but the procedure still required the constant presence of detergents to be removed 
prior to the enzymatic characterisation (Beaune et al., 1979; Wang et al., 1983). 
The development of recombinant DNA technology opened new directions as it allowed the 
expression of cDNAs of single human P450s in host systems such as bacteria (Larson et al., 
1991; Guengerich et al., 1996). Since then the engineering of cytochromes P450 has been 
performed with several purposes such as crystallization and structure determination. Site-
directed mutagenesis of the active site has allowed studies on the enzyme activity and structure-
function relationship (Gillam et al., 2008). 
The constructs considered in this study provide a further example of possible applications of 
engineered enzymes. In particular the investigated recombinant constructs consisted of the 
human cytochrome P450 CYP2C9 fused to an external redox partner to develop P450 
derivatised electrodes for biocatalytic and amperometric sensing applications. As it will be 
discussed more into details in the next chapters, aim of the fusion was to obtain engineered 
enzymes with improved solubility and electron transfer properties (Sadeghi et al., 2000; Gilardi 
et al., 2002).  
In the present chapter the expression, purification and biochemical characterisation of three 
constructs of the CYP2C9 have been described: the N-terminally modified CYP2C9 gene fused 
at genetic level with the reductase domain of the cytochrome P450 BM3 (BMR) from Bacillus 
megaterium, the N-terminally modified CYP2C9 gene fused at genetic level with the small 
electron transfer protein flavodoxin (FLD) from Desulfovibrio vulgaris and the N-terminally 
modified CYP2C9 gene on its own. Moreover, as the human CYP2C9 is well known to show 
polymorphisms with altered enzymatic activity, the single nucleotide mutations corresponding 
to the allelic variants CYP2C9*2 and CYP2C9*3 have been inserted in the two chimeras 
CYP2C9BMR and CYP2C9FLD.  
The chapter also presents the expression, purification and biochemical characterisation of the 
haem domain of the bacterial cytochrome P450 BM3 (CYP102), a model enzyme that has been 
used for the spectroelectrochemical investigations described in chapter 4.  
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3.2 Cloning, expression and purification of protein engineered human 
cytochromes P450 2C9 and its allelic variants 
 
3.2.1 Large scale expression and purification of N-terminally modified human 
CYP2C9 
 
3.2.1.1 Large scale expression of the CYP2C9 
 
The N-terminally modified CYP2C9 clone was expressed in Escherichia coli cells and then 
electrochemically characterised to be compared to the engineered fusion proteins.  
The expression of the human cytochrome P450 in bacteria required optimization because of the 
the different codon preferences between bacterial and mammalian cells. The CYP2C9 clone 
used contained N-terminal modifications to greatly increase its expression levels in a 
heterologous system like the bacterial Escherichia coli. Moreover the hydrophobic N-terminal 
aminoacids that form an anchor of binding to the membrane cell was truncated to favour the 
solubilisation of the enzyme and its subsequent purification (Dodhia 2006). 
The CYP2C9 gene was inserted into the expression vector pCWori+ between the unique Nde I 
and Hind III sites uniquely present in both the CYP2C9 gene and the pCW vector (figure 3.1). 
This vector has already shown to promote high levels of expression of active human 
cytochrome P450s (Barnes, 1996). The CYP2C9 gene also contained a four-residue histidine 
tag at the end of the gene for the purification process.  
 
 
Figure 3.1 Plasmid map of the pCWori+ vector. The plasmid is shown as digested between the unique 
NdeI and HindIII sites. 
 
The expression vector CYP2C9/pCW was transformed in competent cells of Escherichia coli 
(section 2.1.4). Although a number of systems can be employed for the heterologous expression 
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of cytochromes P450, Escherichia coli offers the advantages of easy manipulation and low cost 
of culture. A large-scale expression (3 litres) was then set up in Terrific Broth (TB) medium 
containing ampicillin for the selection of the ampicillin resistant CYP2C9 plasmid (section 
2.1.16). The isopropyl thiogalactoside (IPTG) was used as artificial inducer of the protein 
expression. The haem precursor δ-amino levulinic acid (δ-ALA) was added to stimulate an 
over-expression of the heam cofactor and guarantee the formation of holo-enzyme (Richardson, 
1995). 
The increased haem content in the cell allowed the production of more holo protein not only 
because of an increased haem availability, but also for an increased stability of the protein with 
the incorporated co-factor (Kery et al., 1995). 
After 48 hours expression, the cells were harvested and resulted in the production of 
approximately 539 nmoles per litre of culture (29 mg per litre of culture). This value is closed to 
the one reported in the literature for CYP2C9 grown in presence of δ-ALA (Richardson et al., 
1995). 
 
3.2.1.2 Purification of the CYP2C9 
 
The N-terminally modified CYP2C9 was purified according to the protocol described in 
section 2.1.16. The modification at the N-terminus did not abolish the membrane association 
completely. The protein was extracted from the membrane by using a buffer containing 
detergent and glycerol to avoid aggregation and stabilize the protein in solution.  
The purification process was performed according to the method described by Guengerich and 
co-workers (Guengerich, 1996). It involved the use of two chromatographic steps after the 
isolation and solubilisation of the membrane fraction. The first chromatographic separation was 
performed on a DEAE anion exchange column. The CYP2C9 like all the other human 
cytochromes P450 isoforms has a high theoretical pI (8.18) that keeps the protein positively 
charged at the experimentally used pH 6-7. After loading the protein on the column and 
washing with buffer at pH 6, the positively charged P450 2C9 flowed through, while the 
negatively charged bacterial impurities stayed bound to the column.   
Due to the presence of the four-residue histidine (His-tag) engineered at the end of the CYP2C9 
gene, a second metal ion affinity chromatography (IMAC) step was carried out. The protocol 
used (section 2.1.14) was similar to the one used for the purification of the histidine tagged 
modified CYP2C5 (Wester et al., 2002). The sepharose resin was charged with Nichel ions that 
bind selectively the histidines of the protein. Usually the proteins bound to a Nickel charged 
resin are eluted with imidazole that displaces the His-tag from Nickel co-ordination. However, 
since imidazole is also a known inhibitor of cytochromes P450 with its direct coordination to 
the haem iron (type II ligand), elution was carried out using histidine at high concentrations 
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(Schenkman et al., 1981; Ahlstrom et al., 2008). Multiple exchanges of the pooled fractions 
buffer were carried out at the end of the purification to completely remove the excess of 
histidine from the pooled purified protein. 
Figure 3.2 shows the SDS-Page gel of the fractions containing the pure CYP2C9 at the end of 
the nickel column. Lanes 4-7 show the band at 54 KDa that corresponds to the CYP2C9 protein 
at a high level of purity at the end of the two purification steps. The gel demonstrates how the 
second step successfully removed all the impurities that were present after the first DEAE 
column. The identity of the P450 enzyme was confirmed through spectroscopic measurement of 
the reduced CO complexed P450 species (section 3.4). 
 
Figure 3.2 SDS-Page Phast gel 8-25% gradient of the CYP2C9 purification process. Lanes 2-3 show the 
elute from the first DEAE column 4-7 shows the pooled, concentrated Nickel chelating column eluate. 
Lane 1 is the molecular weight marker with band sizes as shown.  
 
 
The purification process also resulted in good yields of pure protein. The final yield of the 
purified protein was approximately 20 mg of P450 per litre of culture compared to the starting 
P450 content of 29 mg per litre of culture (table 3.1). In conclusion the protocol used for the 
purification of the N-terminally modified CYP2C9 resulted in high yields of pure holo protein 
that could be used for further studies.  








Expression yield 537 nmol/L culture 
Purification yield 370 nmol/L culture 
Total percentage yield 69 % 
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3.2.2 Cloning, large scale expression and purification of the BMR fusion protein of 
CYP2C9 and allelic variants  
 
3.2.2.1 Cloning of CYP2C9*2BMR and CYP2C9*3BMR 
 
The CYP2C9BMR is a fusion protein where the CYP2C9 haem domain is fused at genetic level 
with the reductase domain of the bacterial P450 BM3 (BMR) (Narhi et Fulco, 1986). The 
bacterial CYP102 (or P450 BM3) is the only cytochrome P450 where the haem domain is fused 
at genetic level with the reductase domain in a unique polypeptide chain. It is one of the 
cytochromes P450 with the highest catalytic turnover and it is soluble in the cytoplasm.  
The aim of the fusion protein is to obtain a chimera with improved electron transfer and 
catalytic activity suitable for immobilisation on the electrode. It is hoped that once the system is 
immobilised on an electrode, the reductase domain would regulate the flow of electrons from 
the electrode to the haem.  
The CYP2C9*2 and CYP2C9*3 are the two main allelic variants of the wild type CYP2C9 also 
called CYP2C9*1. Several studies have demonstrated that the catalytic turnover of the two 
allelic variants is lower than the one of the wild type. The different catalytic activity is assigned 
to two single nucleotide mutations located within the CYP2C9 gene. In the case of CYP2C9*2, 
the arginine in position 144 within the D helix is substituted by a cysteine. Experiments have 
shown how this mutation seems to affect the interaction of the enzyme with the CYP450 
reductase so that the maximum rate of metabolism (Vmax) is reduced to around 50% (Crespi et 
al., 1997). 
In the case of CYP2C9*3, an isoleucine is substituted by a leucine in position 359, which is 
located within a distal substrate binding domain (SRS5). This causes a fivefold decrease in the 
maximum rate of metabolism and a fivefold increase of the Michaelis Menten constant (Km) 
which defines the substrate affinity (Haining et al, 1996). 
In order to compare the electrochemical and functional properties of the wild type CYP2C9 
with those of the allelic variants CYP2C9*2 and CYP2C9*3, the single nucleotide 
polymorphism (SNP) of the two allelic variants have been inserted in the investigated chimeras 
CYP2C9BMR. The mutants will be then immobilised on electrodes and characterised in order 
to find a correlation between the in vitro data of the proteins in solution and that of the 
immobilised.  
The two domains of the CYP2C9BMR are joined through a three aminoacid linker Pro-Arg-Ser. 
The same group of aminoacids has been used successfully in the construction of a mammalian 
P450/BMR fusion protein (Helvig and Capdevila, 2000). The aminoacid sequence Pro-Arg-Ser 
encodes the AvrII restriction site that is unique within all of the human cytochrome P450 gene 
CYP2C9, the reductase domain BMR and the pCW vector. The uniqueness of the site allowed 
 108 
further cloning experiments by cutting out and linking back the DNA strands to modify. As 
previously described, the N-terminally modified CYP2C9 gene contained the expression codon 
preferences of mammalian cells and the absence of the membrane anchor (Dodhia 2006). 
A schematic representation of the CYP2C9BMR/pCW is given in figure 3.3.  
. 
 
Figure 3.3 A schematic representation of the CYP2C9BMR chimera 
 
 
The individual CYP2C9*2BMR/pCW and CYP2C9*3BMR/pCW have been generated with the 
standard PCR four-primer method. Explanation and schematic representation of this technique 
are shown in section 2.1.12.  
In this method four primers are used in three different PCR steps to insert single mutations in a 
desired DNA fragments. The 1500 base pair long CYP2C9 gene was extracted from the original 
plasmid CYP2C9BMR/pCW and used as vector during the PCR runs. The mutated fragment 
was then digested with NdeI and AvrII restriction enzymes and inserted back into the original 
BMR/pCW fragment. The product of the ligation was then transformed in DH5α Escherichia 
coli cells and grown in an agar plate with ampicillin. The plasmid was then extracted from the 
colonies. 
Digestion of the plasmid with NdeI and AvrII restriction enzymes showed fragments with the 
expected dimensions and thus indicated that the mutated fragment was correctly inserted back 
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into the original BMR/pCW vector (figure 3.4). The extracted plasmids were then sent to DNA 
sequence analysis to confirm the insertion of the right mutation (figure 3.5). 
 
Figure 3.4 Agarose gel (1%) of the ≈ 1.5kb fragment of the 2C9*2BMR/pCW and 2C9*3BMR/pCW 
ligation product digested with NdeI and AvrII restriction enzymes. M Marker; Line 1 undigested 
fragments; Line 2 2C9*2BMR digested fragment; Line 3 2C9*3BMR digested fragment. 
 
The results confirmed the success of the cloning method applied. Moreover an advantage of this 
technique is that the PCR reactions are runned on a selected fragment thus limiting the risk of 
inserting extra undesired mutations. 
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Figure 3.5 Sequencing results of the 2C9*2BMR and 2C9*3BMR mutants 
 
 
3.2.2.2 Large scale expression and purification of CYP2C9BMR, CYP2C9*2BMR 
and CYP2C9*3BMR  
 
The CYP2C9BMR/pCW, CYP2C9*2BMR/pCW and CYP2C9*3BMR/pCW expression vectors 
were transformed in Escherichia coli DH5α competent cells. A large-scale expression of the 
chimeras was set up according to the protocol described in section 2.1.15. After 48 hours of 
expression ≈ 20 grams of cell paste per litre of culture was obtained for the wild type and the 
two allelic variants constructs. Like for the protocol used for the CYP2C9, the haem precursor 
δ-amino levulinic acid (δ-ALA) was added to stimulate the over-expression of the haem 
cofactor and therefore the production of more holo-protein. The high concentration of the haem 
cofactor increased the correct folding of the protein that was less susceptible to protease 
degradation. 
A final yield of about 584, 550 and 545 nmoles of CYP2C9BMR, CYP2C9*2BMR and 
CYP2C9*3BMR per litre of culture was calculated from the absorbance at 450 nm of the 
reduced and complexed with carbon monoxide species (section 3.4).  
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The CYP2C9BMR, CYP2C9*2BMR and CYP2C9*3BMR proteins were then purified in the 
presence of detergent and glycerol. The detergent prevented the aggregation of the protein while 
the glycerol stabilised the solubility of the construct (section 2.1.15).  
The need of detergent suggested how the association to the membrane is not only due to the N-
terminal anchor, but also to interactions between the hydrophobic surfaces of the protein and the 
membrane. 
The sample was then loaded onto a first anion exchange DEAE column with a bed volume of 
150ml. The same concentration of detergent and glycerol were maintained during the 
purification steps to avoid aggregation and unfolding of the protein structure.  
At pH 8, the CYP2C9BMR, which has a theoretical iso-electric point of 5.6, was negatively 
charged and able to bind the anion exchange column. Most of the positively charged impurities 
were instead removed by washing with a medium ionic strength buffer.  
The bound protein was eluted by gradually increasing the ionic strength of the elution buffer. As 
the eluted fractions still contained impurities, a second hydroxyl-apatite column was used. Only 
after extensive washing through the column with a detergent free buffer, the CYP2C9BMR, 
CYP2C9*2BMR and CYP2C9*3BMR resulted pure. Figure 3.6 shows the final pure band of 
the size of ≈ 120 KDa, which corresponds to the dimension of CYP2C9BMR. 
 
 
Figure 3.6 SDS-PAGE gel of the purified of the CYP2C9BMR (lane 1), CYP2C9*2BMR (lane 2) and 
CYP2C9*3BMR (lane 3). M is the molecular weight marker with band sizes as shown. 
 
 
The gel showed in figure 3.8 demonstrates how all the three proteins were highly pure after the 
two purification steps. The hydroxyapatite column removed all the impurities that were present 
after the DEAE ion exchange chromatography step. The identity of the P450 enzymes was 
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confirmed through spectroscopic measurement of the reduced CO-complexed P450 species 
(section 3.4).  
Table 3.2 summarises the yield of purification of the CYP2C9BMR, CYP2C9*2BMR and 
CYP2C9*3BMR. The allelic variants mutations did not influence the level of expression and 
purification of the BMR fusion chimeras. It appears that the mutations of the allelic variants did 
not influence the level of expression and purification of the CYP2C9*2BMR and 
CYP2C9*3BMR variants. The yield of purification was slightly lower than those observed for 
the CYP2C9. The difference in the final amount of protein obtained could be assigned to the 
multiple purification steps rather than to a difference in the expression.  
 




3.2.3 Cloning, large scale expression and purification of the fld fusion protein of 
CYP2C9 and allelic variants  
 
3.2.3.1 Cloning of CYP2C9*2FLD and CYP2C9*3FLD 
 
The CYP2C9FLD is a fusion protein where the CYP2C9 haem domain is fused at genetic level 
with an external reductase, the small electron transfer protein flavodoxin (FLD) from 
Desulfovibrio vulgaris. Aim of this fusion is to obtain a chimera with improved electron transfer 
and catalytic activity once the enzyme is immobilised on the electrode. The FLD is a small and 
independent electron transfer protein and therefore it should regulate the flow of electrons going 
from the electrode to the haem redox centre (Dodhia 2006). 
The CYP2C9*2FLD and CYP2C9*3FLD were constructed to compare the electrochemical and 
functional properties of the wild type CYP2C9 and the two allelic variants CYP2C9*2 and 
CYP2C9*3 once inserted into this engineered fusion system. 
The CYP2C9FLD/pCW clone is formed by the N-terminally modified CYP2C9 described in the 
previous section (3.2.1.1) linked at genetic level to the FLD through the three aminoacids long 
linker Pro-Arg-Ser that encodes for a unique restriction enzyme site AvrII. Codon preferences of 
the mammalian cells are located at the start of the gene to increase the expression level of a 
human enzyme in bacteria. Moreover the N-terminal anchor to the membrane is truncated to 
favour the extraction, solubilisation and purification of the enzyme (Dodhia 2006). 
As mentioned in section 3.2.2.1, the allelic variants CYP2C9*2 and CYP2C9*3 contain single 
nucleotide mutations able to alter the catalytic turnover of the two allelic variants compared to 
Protein 2C9BMR 2C9*2BMR 2C9*3BMR 
Expression yield 584 nmol/L culture 550 nmol/L culture 545 nmol/L culture 
Purification yield 350 nmol/L culture 320 nmol/L culture 330 nmol/L culture 
Total percentage yield 60% 58% 61% 
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the wild type.  
A schematic representation of the used wild type plasmid CYP2C9FLD/pCW is shown in figure 
3.7.  
 
Figure 3.7 A schematic representation of the CYP2C9FLD chimera 
 
Similarly to the CYP2C9BMR variants, the individual CYP2C9*2FLD/pCW and 
CYP2C9*3FLD/pCW have been generated with the standard PCR four-primer method (figure 
2.1).  
In order to construct the CYP2C9*2FLD/pCW and CYP2C9*3FLD/pCW, the 1890 base pair 
long fragment containing the CYP2C9 gene and the FLD was extracted from the original 
plasmid by digestion with the NdeI and HindIII restriction enzymes. The fragment was then 
used as vector of the PCR runs. The product of the PCR was further digested and ligated back 
into the original pCW vector. After ligation the plasmids of the colonies grown in presence of 
ampicillin were extracted and screened through digestion with NdeI and HindIII. Five digested 
plasmids showed fragments with the right expected size. These results indicated that the 
mutated CYP2C9*2 and CYP2C9*3 genes were correctly inserted into the FLD/pCW (figure 
3.8). The plasmids extracted from the selected colonies were then sent to sequence and 





Figure 3.8 Agarose gel (1%) of the ≈ 1.9kb fragment of the 2C9*2FLDpCW ligation product digested 
with NdeI and HindIII restriction enzymes. M Marker; Line 1 digested fragments; Line 2 undigested 
fragment 
 
Also for the CYP2C9FLD/pCW, CYP2C9*2FLD/pCW and CYP2C9*3FLD/pCW the results 
confirmed the success of the cloning method applied.  
 
Figure 3.9 Sequencing results of the 2C9*2FLD and 2C9*3FLD mutants 
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3.2.3.2 Large scale expression and purification of CYP2C9FLD, CYP2C9*2FLD and 
CYP2C9*3FLD 
The expression vectors CYP2C9FLD/pCW, CYP2C9*2FLD/pCW and CYP2C9*3FLD/pCW 
were transformed in Escherichia coli DH5α competent cells and a large-scale expression of the 
chimeras was set up (typically 3 litres) in Terrific Broth. After 48 hours expression, the cells 
were harvested and resulted in the production of about ≈25 g of cell paste per litre of culture for 
all the constructs. Also for these chimeras the haem precursor δ-amino levulinic acid (δ-ALA) 
was fundamental for the holoenzyme expression.  
The N-terminal modification and the fusion with the soluble and negatively charged flavodoxin 
were not able to abolish the membrane association of the proteins. As described in the 
purification protocol in section 2.1.16, the CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD 
chimeras were purified in the presence of detergent. Spectroscopic analysis of the extracted 
supernatant showed a final yield of about 610, 595 and 609 nmoles of CYP2C9FLD, 
CYP2C9*2 FLD and CYP2C9*3 FLD per litre of culture. 
The solubilised fraction was loaded onto a first anion exchange DEAE Sepharose column. The 
CYP2C9FLD as well as the allelic variants CYP2C9*2FLD and CYP2C9*3FLD have a 
theoretical isoelectric point of 5.70. The experimental pH buffer used gave a net negative charge 
to the chimeras of interest and therefore they bound the positively charged functional groups of 
the anion exchange resin. Most of the positively charged impurities were removed by first 
washing with a low ionic strength buffer. Since the protein appeared to be tightly bound to the 
column, a high ionic strength buffer with detergent was used for the elution of CYP2C9FLD, 
CYP2C9*2FLD and CYP2C9*3FLD. The detergent and residual impurities were then removed 
using a nickel chelate affinity chromatography step. The protocol used was the same applied for 
the CYP2C9. Histidine rather than imidazole was used for the protein elution because of 
inhibitory effect of imidazole (Schenkman et al., 1981). Extensive washing of the column with 
detergent free buffer resulted in the final pure ≈ 70.4 kDa CYP2C9FLD, CYP2C9*2FLD and 
CYP2C9*3FLD as can be seen from lanes 1-3 (CYP2C9FLD in lane 1, CYP2C9*2FLD in lane 




Figure 3.10 SDS-page gel of the purified CYP2C9FLD (lane 1), CYP2C9*2FLD (lane 2) and 
CYP2C9*3FLD (lane 3). M is the molecular weight marker with band sizes as shown. 
 
A high concentration of histidine was necessary to elute the proteins and it was then removed 
from the pooled fractions through various exchanging buffer steps. Although the CYP2C9FLD, 
CYP2C9*2FLD and CYP2C9*3FLD expressed as membrane associated proteins, they showed 
to be stable in the storing detergent free buffer. No aggregation was visible in the protein stock 
despite the high concentration of the enzyme. Table 3.3 summarises the yield of purification of 
the CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD. Similarly to the CYP2C9BMR mutants 
it appears that the SNP mutation did not alter the level of expression and purification.  
 




3.3 Spectroscopic characterisation of protein engineered human 
cytochrome P450 2C9  
 
3.3.1 The CO binding assay of CYP2C9, CYP2C9FLD, CYP2C9*2FLD, 
CYP2C9*3FLD, CYP2C9BMR, CYP2C9*2BMR, CYP2C9*3BMR 
 
The CO binding assay is a specific spectroscopic method for the identification and 
quantification of cytochromes P450. It is an assay that is based on preliminary experiments 
carried out on these enzymes at the moment of their discovery (Klingenberg 1958). Later it has 
been defined as official method for the identification and quantification of these proteins 
(Omura 1964). This test is a good indicator of the correct folding and maintenance of the cys-
iron ligand bond, which is considered responsible for the formation of the active P450 species. 
The method is based on the spectroscopic determination of the CO-bound complex of the 
Protein CYP2C9FLD CYP2C9*2FLD CYP2C9*3FLD 
Expression yield 610 nmol/L culture 595 nmol/L culture 609 nmol/L culture 
Purification yield 420 nmol/L culture 400 nmol/L culture 410 nmol/L culture 
Total percentage yield 68% 67% 67% 
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reduced P450 haem iron. The iron of the redox haem is able to bind the carbon monoxide after 
being reduced and exposed to this gas. According to the protocol (section 2.1.17), the protein in 
solution is reduced by the reducing agent dithionite and then bubbled with carbon monoxide for 
few seconds.  
Figure 3.11, 3.12 and 3.13 shows the UV-visible spectra of the purified N-terminally modified 
CYP2C9, CYP2C9FLD, CYP2C9*2FLD, CYP2C9*3FLD, CYP2C9BMR  CYP2C9*2BMR  
CYP2C9*3BMR  at the different stages of the assay: oxidised P450 resting state, reduced P450 
state after reduction with dithionite and P450-CO complex. Three main peaks define. The 
oxidised P450 resting state has a spectrum with well defined peaks such as the Soret peak at 419 
nm and the α and β band peaks at 570 nm and 535 nm respectively. The presence of all these 
peaks give confirmation of the correct folding of the protein in its low-spin state, with the haem 
cofactor correctly located within the protein helices. After reduction with sodium dithionite the 
Soret peak shifted to a lower wavelength (417 nm) indicative of the ferric/ferrous transition. 
After reduction and exposure of the protein carbon monoxide the Soret peak shifted to 450 nm 
as sign of the formation of the reduced active P450 CO-complex. The α and β bands also 
changed their spectroscopic properties and the peaks at 570 and 535 nm were replaced by a 
single peak at 550 nm. These data suggested that the purified proteins were in their holo-form 
with practically not unfolded, inactive P420 form. 
The absorbance value at 450 nm was then used to calculate the concentration of the enzyme 
present in the solution.  
 
 
Figure 3.11 Spectra of CYP2C9WT during the CO binding assay. In black is shown the spectra of the 











Figure 3.12 Spectra of CYP2C9BMR, CYP2C9*2BMR, CYP2C9*3BMR during the CO binding assay. 
In black is shown the spectra of the oxidised protein, in dash line the spectra of the dithionite reduced 










Figure 3.13 Spectra of CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD during the CO binding assay. 
In black is shown the spectra of the oxidised protein, in dash line the spectra of the dithionite reduced 
species and in gray the spectra of the CO-reduced complex. 
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3.3.2 Substrate binding affinity studies on the CYP2C9FLD and CYP2C9*3FLD 
 
As previously observed the CYP2C9*3 variant exhibits a marked decreased substrate turnover 
compared to the wild type. This reduced activity leads to alterations in in vivo pharmacokinetics 
(Haining et al., 1996; Higashi et al., 2002) and results in profound effects on the therapeutic 
outcome of clinically important drugs, such as warfarin (Higashi et al., 2002). Evidences 
suggest that the I359L mutation is located within a distal substrate binding domain (SRS5) and 
is able to alter the substrate affinity. Hummel and co-workers showed a difference in the 
spectral binding constant (KD) for flurbiprofen in presence of CYP2C9 wild type and 
CYP2C9*3 variant (Hummel et al., 2005). In order to investigate alterations in substrate affinity 
of the chimeras here considered, spectral binding studies were conducted on the CYP2C9FLD 
and CYP2C9*3FLD chimeras. As shown in figure 3.14, upon substrate binding and 
displacement of the distal water molecule, the iron spin state changes from low to high. The 
change in spin also results in a change of the absorbance spectrum of the enzyme. According to 
the substrate and the kind of bond formed, three substrate binding spectra can be identified 
(Schenkman et al., 1981). Type I binding spectra are characterized by a decrease in the 
absorbance of the Soret peak at 420nm coupled with an increase in the absorbance at around 
390nm (low spin to high spin), with an isosbestic point at around 407nm. Examples of Type I 
substrates include arachidonic acid, camphor, debrisoquinone, testosterone, ibuprofen and 
omeprazole. Type II binding spectra are caused by substrates such as aniline, cyanide and 
imidazole, and they result in an increase of the absorbance at 425-435nm and a decrease at 390-
405nm, with an isosbestic point at 419nm. Type II substrates typically tend to be inhibitors that 
contain non-bonded electrons such as a nitrogen lone pair and can ligate to the haem iron. Type 
III binding spectra are also known as “reverse Type I” as they are the specular image of Type I. 
Moreover Type III resembles Type II spectra because of an increase in the absorbance at 420nm 
and a decrease at 390nm. Unlike Type II substrates, in Type III binding spectra no ligation to 
the haem iron occurs and the spectral change is due to the displacement of the water molecule. 
This kind of binding usually occurs with substrates such as caffeine, ethanol and theophylline. 
In the case of the CYP2C9FLD and CYP2C9*3FLD, the substrate investigated for the binding 
to the haem was flurbiprofen. Figure 3.11 shows the difference spectra induced after addition of 
different concentrations of flurbiprofen to CYP2C9FLD in solution. The substrate binding 
spectra expected and then experimentally confirmed in presence of flurbiprofen was Type I 
where a decrease in the absorbance of the Soret peak at 420 nm is coupled to an increase in the 
absorbance at around 390 nm (low spin to high spin), with an isosbestic point at around 407 nm. 
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Figure 3.14 Figure showing the difference spectra induced after adding 20 µl of a 20 mM stock solution 
of flurbiprofen in a 2 µM 2C9FLD solution. The Titrations of substrate into protein were carried out in 50 
mM potassium phosphate pH 7.4 buffer containing 10 % glycerol, 500 mM sodium chloride and 0.1 % 
IGEPAL at a temperature of 28 °C 
 
The substrate binding spectra constant KD was estimated by fitting the data to the rectangular 
hyperbolic equation shown in section 2.1.18. The obtained values were 220 µM ± 30 for the 
CYP2C9FLD and 1020 µM ± 40 for the 2C9*3FLD (figure 3.15A and B). 
 
 
Figure 3.15 (A) Substrate binding curve for a 2 µM 2C9FLD solution titrated with increased 
concentration of flurbiprofen (B) Substrate binding curve for a 2 µM 2C9*3FLD solution titrated with 
increased concentration of flurbiprofen. The Titrations of substrate into protein were carried out in 50 
mM potassium phosphate pH 7.4 buffer containing 10 % glycerol, 500 mM sodium chloride and 0.1 % 
IGEPAL at a temperature of 28 °C. 
 
Differences were observed in a study on recombinant CYP2C9 and CYP2C9*3 expressed in 
Escherichia coli. In that study, KD values of 7 and 14 µM were estimated for the wild type 
CYP2C9 and the variant CYP2C9*3 in presence of (S)-flurbiprofen (Hummel et al., 2005). In 
that case the specific racemic form (S)-flurbiprofen rather than the mixture of the two (S) and 
(R)-flurbiprofen were used. The different racemic forms used could explain the reason for the 
different obtained values. 
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The second substrate investigated for CYP2C9FLD and CYP2C9*3FLD was ibuprofen. As 
previously mentioned, titration of CYP2C9 and CYP2C9*3 with ibuprofen should results as 
well in Type I substrate binding spectra. The experimental data confirmed this Type I spectra. 
Figure 3.16 shows the substrate binding curve of CYP2C9FLD and CYP2C9*3FLD titrated 
with increased concentration of ibuprofen. The extrapolated affinity binding constant KD were 
calculated to be 200 µM ± 40 and 1400 µM ± 60 for the CYP2C9FLD and 2C9*3FLD 
respectively (figure 3.16 A and B). The binding constant of the CYP2C9FLD is in agreement 
with a KD value of 170 µM observed in another study for a recombinant CYP2C9 wild-type 
(Davies et  al., 2004). No values are available in literature for the substrate binding constant of 
CYP2C9*3 with ibuprofen. 
 
 
Figure 3.16 (A) Substrate binding curve for a 2 µM 2C9FLD solution titrated with increased 
concentration of ibuprofen (B) Substrate binding curve for a 2 µM 2C9*3FLD solution titrated with 
increased concentration of ibuprofen. The Titrations of substrate into protein were carried out in 50 mM 
potassium phosphate pH 7.4 buffer containing 10 % glycerol, 500 mM sodium chloride and 0.1 
 
The substrate binding studies performed on CYP2C9FLD and CYP2C9*3FLD in presence of 
flurbiprofen and ibuprofen confirmed the expected Type I substrate binding spectra. Moreover a 
difference between the substrate binding constant of the wild type and the one of the allelic 
variant was also observed thus confirming the insertion of the right mutation in the substrate 
binding pocket. 
 
3.4 Expression, purification and spectroscopic characterisation of 
BMP, the haem domain of CYP101 
 
3.4.1 Expression and purification of BMP, the haem domain of CYP102 
 
The haem domain of the bacterial cytochrome P450 BM3 (CYP102) was expressed and purified 
to study the effect of the immobilisation process on cytochromes P450. CYP102 has been 
chosen as protein of investigation as it shows a higher structural stability than the human 
CYP450s. Moreover it is considered a surrogate for mammalian P450s as it shares 30% of 
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sequence identity with some microsomal P40s such as the fatty acid ω-hydroxylase and 35% 
with the microsomal NADPH:P450 reductase (Ravichandran et al., 1993).  
The BMP/pT7 clone used in this project was donated by Dr T.L.Poulos (Department of 
Molecular Biology and Biochemistry, University of California, Irvine, USA) and it consists of 
the 1450 base pair long haem domain of the CYP102 gene. The P450 gene fragment is 
delimited by the restriction enzymes BamHI and EcoRI .These sites are unique in the gene and 
not present in the pT7 vector.  
A large-scale expression of the bacterial P450 BMP was carried out as explained in section 
2.1.17. The time of expression applied was 24 hours and it was carried out in the Luria Bertani 
medium. The bacterial P450 BM3 has a high yield of expression in Escherichia coli cells and 
therefore it does not require a culture broth with a high content of nutrients like the Terrific 
Broth (TB) used for the human P450 isoforms. At the end of the expression the culture was 
centrifuged and 7 g of cell pellet per litre of culture was obtained.  
The BMP protein was then extracted from the cells according to the protocol described in 
section 2.1.18. The CYP102 is not associated to the membrane and therefore the BMP was 
located in the soluble protein fraction of the lysate cells without need of detergent. The protein 
rich solution was then loaded onto DEAE Sepharose anion exchange columns with different bed 
volumes. The elution was performed with buffers of progressively higher ionic strength. Elution 
profiles of the DEAE columns are reported in figure 3.17. The eluted fractions were read at the 
spectrophotometer. Samples with absorbance peaks at 420 and 280 nm were considered. When 
the ratio between the absorbance values at 420 and 280 nm were greater than 0.1, those fractions 
were pooled together and concentrated. From the SDS-Page gel it appeared that the protein 
sample still contained a contaminant with a molecular weight close to the one of the protein of 
interest. An extra purification step with a gel filtration column was performed. In this case a 
buffer with high concentration of potassium chloride was used to decrease the electrostatic 
interaction between the two proteins and favour their chromatographic separation.  
The final protein purity was estimated from either the presence of a unique band on the SDS-
PAGE gel or by calculating the purity ratio index, which is the ratio between the absorbance at 
280 nm (characteristic of polypeptide chain) and the absorbance value characteristic of the 
protein of interest (419 nm corresponding to the haem group of cytochromes P450). After gel 
filtration the BMP revealed a level of purity equal to 1.3, which is very close to the literature 
value of 1.4 for pure P450 BMP (Sevrioukova et al., 1999). Figure 3.18 shows the SDS-PAGE 
gel of the final pure BMP protein: the purified enzyme corresponds to the band running between 
the 66 and 45 KDa molecular markers. The dimension of the observed band corresponds to the 
expected molecular weight of 55 KDa of the BMP protein. Table 3.4 summarizes the final 
expression and purification yields. 
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The final stock of purified protein was then stored at -20˚C in HEPES bufferto maintain stability 







Figure 3.17 Purification steps of BMP (A) Elution profile of the first DEAE column (bed volume 
200mL). Fractions 22 to 34 were pooled, concentrated and loaded onto the second DEAE column. (B) 
Elution profile of the second DEAE column (bed volume 25mL). Fractions 20 to 35 were pooled, 


















Figure 3.18 SDS-PAGE gel of the purified BMP. Line 1: molecular weight marker with band sizes as 
shown. Line 2-4: different fractions collected from the gel filtration column. 
 
 










Expression yield 582 nmol/L culture 
Purification yield 320 nmol/L culture 
Total percentage yield 55% 
    1     2     3    4





3.5 Spectroscopic characterisation of BMP, the haem domain of 
cytochrome P450 BM3 (CYP102) 
 
3.5.1 CO binding assay of BMP 
 
The UV-VIS spectrum of the pure BMP solution showed the typical spectroscopic fingerprint of 
a b-type cytochrome (figure 3.19). The oxidised state of the enzyme exhibited a Soret peak at 
419 nm (γ band) characteristic of a low spin state iron, along with a α band at 570 nm, a β band 
at 535 nm. After reduction with sodium dithionite the Soret peak shifted to a lower wavelength 
(417 nm) indicative of the ferric/ferrous transition. The subsequent bubbling with carbon 
monoxide caused the formation of a unique peak at 550 nm and a shift of the Soret peak to 450 
nm that is characteristic of the formation of reduced P450-CO complex. 
The CO binding assay is a good indicator of the correct folding and maintenance of the cys-iron 
ligand bond, which is considered responsible for the formation of the active P450 species. As 
explained in section 1.1.3.2, weakening or distortion of this bond can cause the conversion to an 
inactive P420 species characterised by a maximum of absorbance at 420 nm. In our experiments 
the pure BMP solution showed a complete shift of the Soret band to 450 nm. 
 
Figure 3.19 CO binding assay of pure P450 BMP Black line: spectrum of oxidized BMP diluted in 50 
mM HEPES pH 8. 0. Black dashed line: spectrum of BMP after adding few crystals of sodium dithionite. 
Gray line: spectrum of BMP after gentle bubbling with carbon monoxide. The Soret peak completely 





3.5.2 Substrate binding studies 
As previously mentioned in section 1.1.2, cytochromes P450 show an iron spin state shift from 
low to high upon substrate binding and displacement of a distal water molecule. The result of 
this spin state change is a different shift of the absorbance spectra of the enzyme according to 
the substrate involved. For example cytochrome P450 BM3 interacts specifically with saturated 
and unsaturated fatty acids showing a Type I spectra that is characterized by a decrease in the 
absorbance of the Soret peak at 420nm coupled with an increase in the absorbance at around 
390nm (low to high spin). The intensity of the shift provides an estimation of the substrate 
binding constant (KD) and therefore of the accessibility of the active site.  
The characteristic low to high spin shift of the Soret absorption band has been therefore 
measured for pure P450 BMP samples in presence of a specific substrate such as arachidonic 
acid. The spectrophotometric titrations with increased concentrations of arachidonic acid 
revealed a KD of 8.99 ± 1.35 µM and a R2 of 0.98 indicating that the curve fits well the data 












Figure 3.20 Substrate binding study of BMP with Arachidonic acid. 0.4µM of BMPwt were titrated with 
a 1.5 mM stock of arachidonic acid (AA). Variations in absorbance at 397 and 419 were plotted against 
the concentration of AA.  
 








3.6 Conclusions  
The recombinant N-terminal CYP2C9FLD, CYP2C9BMR and CYP2C9 have been expressed 
successfully in a heterologous system like E.coli. As summarized in table 3.5, the yields of 
expression of the N-terminal CYP2C9FLD and CYP2C9BMR were higher than the one of the 
N-terminal CYP2C9 and thus revealed how the fusion system did not interfere with the 
expression process, but rather improved it.  
The purification protocols adopted were different among the constructs. The 2C9/pCW and 
2C9FLD/pCW genes contained four histidines at the end of their CYP2C9 and FLD genes 
respectively. The 4His-tag allowed using a Nickel chelate affinity chromatography as second 
step of the purification protocol. This method of separation uses the highly specific biological 
interactions between the His-tag enzyme and the column resin thus allowing an efficient 
elimination of non-specific contaminants. In the case of the 2C9BMR/pCW, since the multiple 
histidines were not present at the end of the gene, a hydroxyapatite resin was used. The bond 
established between the enzyme and the hydroxyapatite resin is less specific and therefore more 
protein can be lost during the washing steps. This was confirmed by the yield of purification of 
the CYP2C9BMR being lower than the constructs with the 4His-tag. However in general the 
yield of purification was in line with what observed in previous literature works (Sandhu et al., 
1993; Dodhia 2006). 
The CYP2C9*2 and CYP2C9*3 variants of the BMR and FLD chimeras did not show any 
difference in their yields of expression and purification. This result suggests that the single 
nucleotide mutations of the two variants did not influence the expression process of the gene or 
induce any major conformational changes.   
The spectra recorded during the CO binding assay confirmed that all the proteins were properly 
folded in their low-spin state, with the haem cofactor correctly located within the protein 
structure. This state was confirmed by the appearance of a peak at 450 nm, which is considered 
the maximum of absorbance of the active species. The data suggested that the purified proteins 
were in their holo-form with practically no inactive P420 form present.  
For the CYP2C9FLD the correct conformation of the substrate binding pocket was confirmed 
by the substrate binding studies in presence of ibuprofen and flurbiprofen. The substrate binding 
constants (KD) extrapolated from the fitting of the data point were in line with literature findings. 
A difference in substrate binding constant was observed between the CYP2C9FLD wild type 
and the variants 2C9*3FLD thus confirming that the single nucleotide mutation corresponding 
to the CYP2C9*3 is located within a substrate binding site and can interfer with the interaction 





Table 3.5 Comparison between the initial and final yields achieved in this study for the expression of N-
terminally modified CYP2C9, CYP2C9BMR, CYP2C9*2BMR, CYP2C9*3BMR, CYP2C9FLD, 




















(per litre of 
culture) 
Literature yield and reference (per 
litre of culture 
Purification 
yield achieved 
in this study 
Highest purification 
yield of alternative 
methods and reference 
CYP2C9 537 nmol 
600nmol (Dodhia 2006) 
500nmol (Richardson et al., 1995) 
        69% 
 
75% (Dodhia 2006) 
43 %(Sandhu et al., 1993) 
CYP2C9BMR 584 nmol 700 nmol (Dodhia 2006) 60% 60%(Dodhia 2006) 
CYP2C9*2BMR 550 nmol - 58% - 
CYP2C9*3BMR 545 nmol - 61% - 
CYP2C9FLD 610 nmol 640 nmol (Dodhia 2006) 68% 75%(Dodhia 2006) 
CYP2C9*2FLD 595 nmol - 67% - 
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4.1 Introduction  
Pioneering investigations on the electron transfer between an electrode and protein were 
performed by Heddowes and Hills, Yeh and Kuwana (Eddowes and Hills, 1977; Yeh & 
Kuwana, 1977). Since then the research on the electrochemistry of enzymes has been driven by 
both the desire to understand the electron transport process within proteins and the development 
of electrochemically based biosensors and bioreactors.  
Cytochromes P450 inspired a number of biosensing studies of the last decade because of their 
direct involvement in the metabolism of a wide spectrum of endogenous and esogenous 
substrates. 
The electroactive component of cytochromes P450 is an iron-protoporphyrin IX cofactor (haem) 
positioned within the folded polypeptide chain. As described in section 1.1.3.2, the catalytic 
activity is guaranteed by the presence of the active P450 species that is characterised by a 
specific proximale thiolate bond between the haem iron and a highly conserved cysteine residue. 
Weakening and distortion of this bond can give rise to the formation of an inactive species 
called P420. The names “P450” and “P420” originate from the maximum of absorbance of their 
reduced CO-complex at 450 and 420 nm respectively. Different conditions such as pH, ionic 
strength and salts can induce their selective formation by altering the moiety surrounding the 
haem redox centre (Imai et al.,2005).  
Over the last 30 years cyclic voltammetry has been the electrochemical technique of first choice 
for the characterisation of both the electron transfer and the catalytic properties of immobilised 
cytochromes P450 (Armstrong et al., 2000). However none of these studies provided a 
distinctive characterisation of the active and inactive species. Aim of the experiments presented 
in this chapter was to follow the electrochemical reduction of these two species in presence of 
carbon monoxide by using cyclic voltabsorptometry, a technique that combines optical and 
electrochemical data recorded simultaneously and that has been already used to characterise 
redox proteins (Astuti et al., 2004). Any optical change in the haem coordination of the 
immobilised enzyme was monitored during the potential sweep measurements so that any 
electrochemical peak could be assigned to either the active P450 form or the inactive P420 one.  
The haem domain of the bacterial cytochrome P450 BM3 (CYP102) has been chosen as subject 
of this investigation. The cytochrome P450 CYP102 is more stable than the human ones and it 
has always been considered a model for mammalian P450s because of their partial sequence 
identity (Munro et al., 2002; Ravichandran et al., 1993).  
As shown in section 3.4, the BMP/pT7 clone was successfully expressed and purified. In this 
chapter results on the immobilisation and spectroelectrochemical characterisation of pure BMP 
on semitransparent and semi-conductive tin-dioxide electrodes modified with polymers of 
different chemical properties are shown.  
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4.2 Electrochemical characterisation of the active P450 and inactive 
P420 species of BMP immobilised on glassy carbon electrodes 
A preliminary investigation into the electrochemical properties of the haem domain of the 
bacterial cytochrome P450 BM3 (BMP) immobilised on glassy carbon (GC) electrodes was 
performed. The electrodes were modified with polydiallyldimethylammonium chloride 
(PDDA), a water-soluble cationic polyelectrolyte widely used for the immobilised proteins 




Figure 4.1 Chemical structure of polydiallyldimethylammonium chloride (PDDA). 
 
The selective formation of the inactive P420 or active P450 forms was induced by changing pH. 
The active P450 form is stable at the physiological pH 7.4-8. The inactive P420 one was 
obtained by increasing the pH of the storage buffer solution to 11. The exposure of the haem 
domain to organic solvents or to a high pH has already been described as a method of inducing 
the formation of the inactive P420 species (Imai et al., 2005; Honeychurch 2006).  






Figure 4.2 UV-Vis Spectra of the haem domain of CYP102 (BMP) in its oxidized and reduced CO-
complex form. (A) Spectra of BMP in a 20mM KPi buffer pH 8 (B) Spectra of BMP left over night in a 
20mM KPi buffer pH 11. Black line: spectrum of the oxidized BMP. Red line: spectrum of BMP reduced 





The active P450 and the inactive P420 species were immobilised on the PDDA modified glassy 
carbon (GC) electrode. The cyclic voltammograms (CV) of the active and inactive forms are 
shown in figure 4.3A and 4.3B. Both CVs show a redox couple centred at -0.264 and -0.295 V 
for the P450 BMP and P420 BMP respectively. Among the two species, the inactive P420 
showed wider and better defined oxidation and reduction peaks regardless of its lower 
concentration after the pH treatment (figure 4.3B). The inactive P420 species would appear to 
be the dominating species in a cyclic voltammogram when both the active P450 and the inactive 
P420 are present. 
 
Figure 4.3 Cyclic voltammetry of BMP on PDDA modified GC electrodes. (A) Cyclic voltammogram of 
the BMP solution left in pH 8 buffer and immobilised on PDDA modified GC electrodes. (B) Cyclic 
voltammogram of the BMP solution left in pH11 buffer and immobilised on PDDA modified GC 




The two species showed two different mid point potentials that could also be influenced by the 
pH used. An influence of pH on the haem redox potential of cytochromes P450 immobilised on 
electrode surfaces has already been observed (Shukla 2005). The pH-dependent potential 
change has been assigned to a mechanism whereby protonation or deprotonation of a moiety 
close to the haem active site can accompany single electron transfer reactions. In our 
experimental conditions the mid point potential became increasingly negative (∆50 mV) as the 
pH was increased from 8 to 11.  
 
4.3 Direct spectroelectrochemistry of BMP immobilised on polymer 
modified tin-dioxide electrodes  
The experiments described in section 4.2 showed how cyclic voltammetry on its own is not able 
to address a distinctive electrochemical characterisation of the active P450 and inactive P420 
forms. Cyclic voltammetry is based on the measurement of a current signal that is proportional 
to the number of molecules either reduced or oxidized at the electrode surface at their specific 
redox potential. However when multiple species of similar redox potentials are present on the 
electrode, the recorded current signal becomes difficult to resolve as it is the sum of the signals 
coming from all the species. These observations raise therefore a question as to what the real 
nature of the species that are usually assigned to the active P450 form in a cyclic voltammogram 
is.  
So far the only way to confirm the electrochemical response of an immobilised cytochrome 
P450 species was to observe the shift of the mid point potential when the reduced species was 
complexed with carbon monoxide (CO). However this measurement only gives evidence of an 
immobilized haem protein, as it is general to the redox chemistry of a FeIII/FeII haem group 
complexed with CO and therefore is not necessarily specific to the active form of the 
cytochrome P450.  
A spectroelectrochemical technique like cyclic voltabsorptometry was then used to understand 
how to give a correct interpretation of the species appearing on a cytochrome P450 CV. This 
technique combines optical and electrochemical data recorded simultaneously during potential 
sweep measurements and it allows the measurement of visible absorption spectra associated 
with the electrochemical signal. Early spectroelectrochemical characterizations of a cytochrome 
P450 were published by Bistolas and co-workers (Bistolas et al., 2004). The study identified the 
presence of the active form of cytochrome P450cam immobilized on gold electrode modified 
with dithiopyridine. 
In this study the haem domain of the cytochrome P450 BM3 (BMP) was immobilised on tin-
dioxide electrodes modified with different polymers. Tin-dioxide is a nanostructured material 
suitable for bio-spectroelectrochemistry because of its large surface area, optical transparency 
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and superior conductivity compared to other metal oxides10-14. The modification of the electrode 
surface with a polymer was necessary to overcome the unfavourable electrostatic interaction 
between the negatively charged enzyme and the negatively charged tin-dioxide material at the 
experimentally used pH. The two polycations used to entrap the BMP and form an intermediate 
film of attraction between the investigated protein and the electrode surface were the 
polyethylenimine (PEI) and polydiallyldimethylammonium chloride (PDDA). These two 
polymers have slightly different chemical properties due to the different type and reactivity of 
the amino groups in their structure (figure 4.4). 
 
 
           (A) 
 (B) 
 
Figure 4.4 Chemical structure of polyethylenimine (PEI) (A) and polydiallyldimethylammonium chloride 
(PDDA) (B). 
 
The reason for using chemicals with slightly different properties was to change the moiety 
surrounding the sensitive haem redox centre and possibly induce either the formation of the 
active P450 species or the inactive P420 one.  
 
4.3.1 Stability of the active species of BMP  
As described in section 2.1.18, the purified BMP was stored in a 50 mM HEPES buffer pH 8 
with 20% of glycerol. The use of HEPES and glycerol as storage buffer was suggested by 
previous studies on the stability of this protein engineered enzyme (Meharenna 2001). However 
before immobilisation, it was necessary to remove both the glycerol and the HEPES that were 
observed to decrease the yield of absorption of the protein on the porous material. The HEPES 
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buffer was substituted with a low concentration of potassium phosphate buffer as previous 
works on the semi-conductive titanium-oxide (TiO2) showed a strong influence of the ionic 
strength on the immobilisation yield of different enzymes (Topoglidis, 2001).  
The active state of the BMP protein stock was checked before the immobilisation process. As 
explained in chapter 3, the CO binding assay is a specific spectroscopic method for the 
identification and quantification of cytochromes P450. It is a good indicator of the correct 
folding and maintenance of the cys-iron ligand bond, which is considered responsible for the 
maintenance of the active P450 species. The method is based on the spectroscopic determination 
of a complex between the carbon monoxide and the reduced P450 haem iron that has a 
maximum of absorbance at 450 nm when it is in its fully active state.  
A time course study on samples of BMP stored in potassium phosphate buffer pH 8 was carried 
out. Figure 4.5 shows the sample left at 4ºC in a potassium phosphate buffer at pH 8 for 30 
days. The spectra confirmed the stability of the active P450 species of BMP in the stock 
solution used for the immobilisation. 
 
Figure 4.5 UV-Vis Spectra of P450 BMP solution in 20 mM KPi pH 8 buffer and left for 30 days at 4°C. 
Black line: spectrum of oxidized BMP diluted Red line: spectrum of BMP after reduction with sodium 
dithionite and gentle bubbling with carbon monoxide. The Soret peak shifted completely from 419 nm to 
450 nm indicating the maintenance of the active P450 BMP. 
 
Moreover as the two modifiers PEI and PDDA are characterised by long hydrocarbon chains 
similar to other specific substrates of BMP like the arachidonic acid (section 3.5.2), the binding 
constant of these polycations was measured. As shown in chapter 3, the iron of the haem of 
cytochromes P450 shows a shift of its spin state from low to high upon substrate binding. This 
shift can be spectroscopically followed as a change in the absorbance spectra of the enzyme and 
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can be used to estimate the substrate binding constant (KD) and therefore the level of 
accessibility of the substrate to the active site. Type I spectra were observed when the BMP was 
titrated with its specific substrate arachidonic acid. The same protocol was applied with the 
BMP enzyme and the two polycations PDDA and PEI. 
Figure 4.6 shows the spectra collected during the titration of BMP with the PEI polycation. No 
increase in the maximum of absorbance at 390 nm was observed while the maximum of 
absorbance at 419 nm decreased at progressively higher concentration of added PEI.  
 
Figure 4.6 Difference spectra of BMP after addition of polyethylenimine (PEI). 0.4µM of BMP were 
titrated with increased concentrations of an aqueous PEI solution. Black line: 0 µM PEI; red line:  10µM; 
blue line: 20 µM; light blue line: 50µM. 
 
The absence of type I spectral shift for the BMP enzyme in the presence of PEI and PDDA 
confirmed that these polymers are not substrate of the enzyme. However the decrease in the 
absorbance spectrum at 419 nm reveals an effect of the polymers on the structure conformation 
of the protein scaffold surrounding the haem. The spectrum of absorbance at 419 nm represents 
the oxidised state of the correctly folded enzyme.  
 
4.3.2 Immobilisation of the haem domain of cytochrome P450 BM3 (BMP) on 
PDDA and PEI modified tin-dioxide
 
electrodes 
Successful immobilisation of BMP on nanostructured SnO2 electrodes was achieved after 
modifying the porous surface with polyethylenimine (PEI) or polydiallyldimethylammonium 
chloride (PDDA) polycations (figure 4.3). Some of the experiments on the PEI modified tin-
dioxide films were performed in Prof Durrant’s group (Astuti 2006). Those data are here 
illustrated for the purpose of comparison with the new set of data. 
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The pre-treatment of the tin-dioxide electrode with a polycation was fundamental to promoting 
the protein immobilisation as revealed by a brown coloration of the modified SnO2 electrode 
after immersion in the BMP solution. The role of the polycation layer was to overcome the 
unfavourable electrostatic interaction between the protein and the metal oxide film. BMP is a 
slightly acidic protein. The low isoelectric point of the enzyme and the strong acidity of the 
nanostructured SnO2 film meant that both the enzyme and the electrode surface carried a net 
negative charge in our experimental conditions at pH 8. The positively charged polycation layer 
was necessary to promote an electrostatic interaction between the enzyme and the porous 
material. Assuming that the extinction coefficient for the haem absorption band does not change 
upon binding to the electrode surface, it is possible to use this value to determine the amount of 
immobilised protein. Using an extinction coefficient of 77,500 M-1 cm-1 for the haem absorption 
band at 419nm (Modi et al., 1995), the amount of immobilised enzyme was calculated to be 1 
nanomole per cm2.  
Figure 4.7B shows the optical absorption spectrum of BMP immobilised on nanostructured 
SnO2 electrodes modified with PDDA. The film displays the spectral fingerprint of the protein 
in solution, with adsorption bands at 417, 535 and 570 nm. A comparison between the spectra of 
BMP immobilised on PEI and PDDA modified SnO2 electrodes revealed the presence of an 
extra shoulder at 398nm on the PEI modified electrode (figure 4.7A). This is indicative of the 
formation of the FeIII high spin state, which is usually observed in the presence of a bound 
substrate or upon modifications of the protein environment affecting the energy level transitions 
within the haem (Daff et al., 1997). Moreover, this low-to-high spin transition has been shown 
to cause a shift in the reduction potential of the haem to more positive values when the protein 
is in solution (Sligar et al., 1976) or immobilized on electrochemical surfaces (Kazlauskaite et 
al., 1996) in the presence of a specific substrate. This seems to suggest that the immobilization 




Figure 4.7 UV-Vis absorption spectra of BMP immobilised on nanostructured SnO2 electrodes modified 
with (A) PEI and (B) PDDA in a 0.020 M KPi buffer, pH 8.0 The SnO2 –PEI and SnO2 –PDDA film 
absorbances have been subtracted. 
 
Cytochrome P450cam in solution (Daff et al., 1997) or immobilized on an electrode 
(Kazlauskaite et al., 1996) showed a shift of its redox potential in the presence of a specific 
substrate. Instead the cytochrome P450 BM3 immobilized on DDAB modified edge-plane 
graphite electrodes did not show any change in the cyclic voltammetric peaks when lauric acid, 
palmitic acid or octane were added (Fleming et al., 2003). The same behavior was observed for 
the P450cin immobilized on the same system and titrated with specific substrates such as 
camphor and cineole (Aguey-Zinsou et al., 2003; Lei et al., 2000). In a recent study on the 
human cytochrome P450 2D6 solubilized in an aqueous dispersion of Ag nanoparticles, a spin 
shift in the presence of a specific substrate was only shown when the hydrosol was coated with 
self-assembled monolayers (SAMs) of different lengths, suggesting an adsorption-induced 
structural alteration of the active site when it is in direct contact with the metal (Bonifacio et al., 
2007).  
The shoulder at 398nm on the PEI modified electrode (figure 4.7A) is indicative of the 
formation of the FeIII high spin state, which is usually observed in the presence of a bound 
substrate or upon modifications of the protein 
The lack of this low-to-high spin transition in the presence of substrates for various immobilized 
P450 haem domains can find an explanation in our data where different immobilisation 
environments seem to influence the haem state of the enzyme so that it is already in its high spin 
state regardless of the presence of a substrate. 
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4.3.3 Spectroelectrochemistry of the haem domain of cytochrome P450 BM3 
(BMP) on PDDA and PEI modified tin-dioxide
 
electrodes 
Spectroelectrochemical experiments were performed on the BMP/PDDA/SnO2 and 
BMP/PEI/SnO2 electrodes immersed in a carbon monoxide (CO) saturated buffer. Figure 4.8 
shows the haem redox centre of the BMP/PDDA/SnO2 electrochemically reduced upon 
application of a negative potential. Upon application of the negative potential the two bands at 
535 and 570 nm shift to a unique band at 547 nm. The reduced haem then formed a complex 
with the carbon monoxide to give the characteristic shift of the γ  band of the Soret peak at 450 
nm. Scope of these experiments was to confirm the presence of a P450 redox centre and to 
follow the occurrence of its electrochemical reduction once immobilised. Moreover the 
difference spectra of the reduced CO-complex minus the reduced form of BMP show an intense 
maximum at 450 nm and minimum at 414 nm with two isosbestic points at 433 nm and 480 nm 
(figure 4.9).  
 
 
Figure 4.8 UV-Vis spectral changes for the electrochemical reduction of the BMP/SnO2 –PDDA 
electrode under application of a negative potential (-0.8V versus Ag/AgCl). The electrode was immersed 
in a 0.020 M KPi buffer solution pH 8.0 bubbled with CO for 30 minutes. Dashed line: spectrum recorded 
at time 0 (oxidized species); dotted line: spectrum recorded after 3 minutes (reduced CO-complex); solid 





Figure 4.9 The difference spectra of the oxidised minus reduced form of BMP/PDDA-SnO2 electrode 
recorded during the electrochemical reduction of the BMP/SnO2 –PDDA electrode under a negative 
potential (-0.8V versus Ag/AgCl). The different lines represent the spectra collected at different 
intermediate times from the fully oxidized to the fully reduced form. The arrow indicates the order of 
acquisition of the scans.   
 
On the other hand most of the BMP/PEI-SnO2 electrode, under the same conditions, showed a 
significant spectral shift to 420 nm that corresponds to the formation of the inactive P420 
species. Figure 4.10 shows the formation of the fully inactive species (figure 4.10A) or a 
mixture of the two species (figure 4.10B). In any case the characteristic absorption shift from 
417 nm (oxidised state) to 420 or 450 nm according to the protein state formed has 
demonstrated a successful interfacial electron transfer between the immobilised protein and the 
metal oxide material suggesting the suitability of using this semiconductor material for studying 










Figure 4.10 UV-Vis spectral changes for the electrochemical reduction of the BMP/SnO2 –PEI electrode 
upon application of a negative potential (-0.8V versus Ag/AgCl). (A) Spectra showing a unique inactive 
P420 species. (B) Spectra showing a mixture of species such as the active P450 and inactive P420. The 
different lines represent the spectra collected at different intermediate times. The arrow indicates the order 
of acquisition of the scans.   
 
The tendency of this protein to be converted to this inactive species has already been observed 
in other studies and it has been associated with the specific properties of the local environment. 
P450cam immobilized on Ag electrodes coated with self assembled monolayers (SAMs) of 
different lengths (Todorovic et al., 2006) as well as P450 BM3 dispersed in a 
didodecyldimethylammonium bromide (DDAB) solution (Udit et al., 2006) showed conversion 
of the protein to the P420 form. Different mechanisms have been proposed where the local 
environment plays a direct role in inducing the P450-P420 transition by either dehydrating the 
substrate binding cavity and decreasing the electron donor strength of the haem axial ligand or 
by interfering with the H-bonding network responsible for the stabilization of the thiolate bond. 
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In contrast the ability of PDDA polycation to maintain the active state of immobilised BMP is 
supported by a recent investigation into the electrochemical properties of this protein 
immobilised on a PDDA modified glassy carbon electrode. In particular the catalytic activity of 
the protein embedded in this polycation was proved in the presence of a substrate (Fantuzzi et 
al., 2006). 
The ease with which the Fe-S thiolate bond is altered and gives rise to the P420 state is a 
phenomenon that can be expected from proteins like the cytochromes P450 that are well known 
to possess a flexible and compressible structure (Poulos et al., 2003). One possible explanation 
of the different effects exerted by PDDA and PEI on the absorbance properties of the 
immobilized protein can be assigned to their different type and reactivity of amino groups. PEI 
contains primary and internal amino groups that can form H-bonds influencing the protein H-
bonding network as suggested for DDAB. Moreover these ammine could also react with the 
groups of the protein matrix responsible for the maintenance of the thiolate bond. On the 
contrary the cyclic structure and the high pKa of the quaternary ammonium group of PDDA 
keep it positively charged over a wide pH range and unable to form H-bonds with the protein 
matrix.  
It is interesting to observe that the correlation proposed by Todorovic between the 
immobilization-induced dehydration of the active site, the transition to high spin state and the 
conversion to P420 is in keeping with our observations where the immobilization in PEI induces 
both high spin state and P420 formation (Todorovic et al., 2006). 
The effect of the polymers on the kinetic of the electron transfer process between the P450 BMP 
and the SnO2 electrode was investigated by using chrono-absorptometry where the absorbance 
was monitored during the step potential. As previously explained, in order to measure the 
successful electron transfer between the electrode and the immobilised enzyme, the binding of 
CO to the electrochemically reduced haem iron was spectroscopically monitored as the 
appearance of the characteristic absorbance maxima at 450nm. 
The kinetic of the electron transfer process between the immobilised protein and the SnO2 
electrode was then studied applying different fixed potentials until either, the reduction and the 
subsequent CO binding, or the oxidation of the enzyme reached equilibrium. 
Potentiometric titrations were performed applying a range of potentials between 0 and -0.9 V. 
The time required to reach the equilibrium at each potential was observed to be slower 
comparing to other previously immobilised proteins (Astuti 2006). Under the application of a 
potential of -0.4 and +0.5 V the t1/2 for the complete reduction and oxidation of BMP were about 







Figure 4.11 Time dependent absorbance change at 450nm for the BMP/SnO2-PDDA electrode under the 
application of -0.4V (solid line) and +0.5V (dashed line). Experiments recorded in a 0.020 M KPi buffer 
solution pH 8.0 bubbled with CO for 30 minutes. 
 
Previous experiments on different proteins such as haemoglobin and myoglobin immobilised on 
the same system showed faster kinetics, ruling out the possibility of these kinetics being limited 
by electron transport within the nanostructured metal oxide electrode. Moreover, since the 
kinetics of electron transfer were found to be potential dependent, with the rate increasing with 
increasingly negative potentials, we can claim that they are limited by interfacial electron 
transfer rather than by CO binding kinetics. 
The weak electronic coupling of the BMP enzyme with the electrode is probably associated 
with the buried nature of the haem. Fleming and co-workers observed a similar phenomenon on 
the P450 BM3 immobilised on a DDAB modified edge-plane graphite electrode. Using Fourier 
transform ac voltammetry they observed irreversibility and slow kinetics in the electron transfer 
process to the haem domain of the immobilised protein (Fleming et al., 2005). The author 
claimed that the irreversible reduction process occurs when the protein is confined to a surface 
where it can display different orientation and therefore unfavourable electron transfer.  
All the maximum value of absorbance at 450 nm obtained after reducing the enzyme with the 
different negative potentials were then fitted to the Nernst equation. This allowed calculation of 
the reduction potentials of the protein immobilised in both systems at the equilibrium. A 
reduction potential of –0.39 ± 0.01 V was obtained for the BMP/PDDA-SnO2 electrode (figure 
4.12B), a value that is more positive compared to the – 0.57 V calculated for the same protein in 
solution (Daff et al., 1997), but that is close to – 0.36 V obtained in a recent work on the same 
 146 
enzyme immobilised on PDDA modified glassy carbon electrodes (Fantuzzi et al.,2006). 
Nevertheless it is important to underline how a similar positive shift has been observed in 
several works where the enzyme was immobilised on various surfaces differently modified. 
 
Figure 4.12 Potentiometric titration data for the BMP/SnO2 –PEI (A) and BMP/SnO2 –PDDA (B) 
electrodes obtained by monitoring the change in absorbance at 450nm in a 0.020 M KPi buffer solution 
pH 8.0 saturated with CO. (Data of the BMP/SnO2 –PEI electrode previously obtained in Prof. Durrant’s 
group). 
 
The reduction potential obtained for the BMP/PEI-SnO2 electrode was instead more negative: – 
0.58 ± 0.015 V (figure 4.12A). However, because of the aforementioned difference in the 
charge content and in the tendency of the two polymers to form H-bonds, the observed 
difference is not surprising. In haem-thiolate enzymes like P450s, the Cys ligand has to 
maintain a specific coordination in order to accept H-bonds from peptide NH groups. The 
function of this H-bonds arrangement is to regulate the haem-redox potential so that it can be 
readily reduced by redox partners (Ueyama et al., 1983; Ueyama et al., 1996). 
Moreover an effect of the charge of the polycations on the potential necessary to reduce the tin-
dioxide film has also been observed. As shown in figure 4.13, the shift observed in the 
measured potential of SnO2 and immobilised P450 is of similar magnitude and goes in the same 
direction when either PDDA or PEI were used to modify the surface. 
The different pKa values and reactivity of the amino groups of the two polymers can also affect 
their specific charge distribution and therefore their level of interaction with the localized 
charge distribution of the protein surface. This can affect the immobilization yield, the enzyme 
orientation and therefore the distance between the protein redox centre and the electrode surface 




Figure 4.13 Overlay of the cyclic voltammograms (CVs) of SnO2 –PDDA (solid line) and SnO2 –PEI 







4.3.4 Cyclic voltammetry of the haem domain of cytochrome P450 BM3 (BMP) on 
PDDA and PEI modified tin-dioxide electrodes 
Cyclic voltammetric (CV) and voltabsorptometric (CVA) experiments were performed on both 
the BMP/SnO2-PDDA and BMP/SnO2-PEI electrodes in the absence and presence of carbon 
monoxide. Figure 4.14 shows the CV of BMP/SnO2-PDDA in a CO saturated buffer at a scan 
rate of 5 mV/sec. A SnO2-PDDA electrode (protein-free) was measured as control (figure 4.15). 
A well defined reduction peak is centered at – 490 mV versus Ag/AgCl. No oxidation peak was 
observed, suggesting a lack of oxidation of the enzyme during the reverse scan. The lack of 
oxidation can be related to both the slow oxidation kinetic of the enzyme and the semi-
conducting properties of the tin-dioxide particles.   
 
 
Figure 4.14 Cyclic voltammogram (CV) of the BMP/SnO2 –PDDA measured at scan rates of 5mV/s in a 




Figure 4.15 Cyclic voltammogram (CV) of the SnO2 –PDDA electrode measured at a scan rate of 5mV/s 
in a 0.020 M KPi pH 8.0 saturated with CO. 
 
 
The corresponding spectra collected simultaneously to the potential cycle show the formation of 
only one species, the active P450 (figure 4.16). 
 
Figure 4.16 Spectra collected simultaneously to the CV recorded for the BMP/SnO2 –PDDA electrode. 
Different absorbance spectra were collected at different potentials: thin solid line at -0.2V, dotted line at -




Combining the spectroscopic and electrochemical data it is possible to obtain the cyclic 
voltabsorptomogram (CVA) of a species of interest by plotting the optical absorbance at a 
specific wavelength versus the applied potentials. The cyclic voltabsorptometric (CVA) data for 
the BMP/SnO2-PDDA are shown in figure 4.17. By calculating the first derivative of this CVA 
it is possible to obtain a differential cyclic voltabsorptommogram directly comparable to the 
original CV (Topoglidis et. al; 2003). Figure 4.18 shows the overlay of the CV and DCVA for 
the BMP/SnO2-PDDA electrode with a reduction peak centered at – 440 mV in agreement with 
the – 490 mV extrapolated from the CV. No oxidation peak is observed in accordance with the 
CV. According to the absorption spectra (figure 4.16), this reduction peak is entirely assigned to 
the P450 active form.  
 
 
Figure 4.17 Cyclic voltabsorptommogram (CVA) of the BMP/SnO2–PDDA electrode corresponding to 




Figure 4.18 Overlay of the cyclic voltabsorptommogram (CVA) at 450 nm (dashed line) and cyclic 
voltammogram (CV) (solid line) of the BMP/SnO2 –PDDA electrode. 
 
Figures 4.19A and 4.19B show the CV and DCVA at 450 and 420 nm recorded for the 
BMP/SnO2-PEI electrode. The CV shows two reduction peaks, a larger one centered at – 390 
mV and a minor one at – 550 mV (figure 4.19A). The oxidation peak is here observed, but 
because it is not present in the corresponding CVA (figure 4.19B), it can be associated to a 









Figure 4.19 (A) cyclic voltammogram (CV) recorded for the BMP/SnO2 –PEI electrode. (B) Overlay of 
the cyclic voltabsorptommogram (CVA) at the wavelengths of 450 (solid line) and 420 nm (dashed line) 
recorded for the BMP/SnO2 –PEI electrode. (Data collected previously in Prof. Durrant’s group). 
 
Figure 4.20 shows the spectra of the species reduced under application of the cyclic potential 
variation: a mixture of two species is revealed, a major peak at 420 nm and a minor one at 450 
nm.  
The DCVA relative to the two wavelengths of 450 and 420 nm  of figure 4.19B presents a peak 
at – 600 mV corresponding to the species at 450 nm and another one at – 500 mV for the 




Figure 4.20 Spectra collected simultaneously to the CV recorded for the BMP/SnO2 –PEI electrode.  
 
Table 4.1 Summary of the potential of the reduction peaks appeared in the CVs and DCVAs for the 






The values of the potential calculated from the DCVA are in qualitative agreement with the 
reduction potentials calculated for the protein in solution, where the inactive P420 form has a 
less negative potential comparing with the active P450 form (Omura et al., 1964). The use of 
optically transparent SnO2 was therefore particularly useful for the BMP/SnO2-PEI electrode 
because it allowed the identification of the species reduced during the scan. In particular, while 
the cyclic voltammogram showed a main reduction peak centered at –0.39 V, the corresponding 
absorption spectra revealed the presence of a mixture of two species namely the active P450 
species and the inactive P420. As shown by the spectra and the DCVA, the greater contribution 
to this reduction peak comes from the inactive P420 form. In the CV the reduction of the P450 
species could be represented either by the small reduction peak at – 0.55 V or hidden under the 
tail of the adjacent broad peak centered at –0.39 V (figure 4.19A).  
Moreover from the analysis of the CV of figure 4.19A and the corresponding absorbance 
spectra of figure 4.20, there is not a direct correlation between the amount of the immobilized 
 P450 / PDDA P450 / PEI P420 / PEI 
Reduction peak on CV - 490 mV - 550 mV - 390 mV 
Reduction peak on DCVA - 440 mV - 600 mV - 500 mV 
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species and the number of electroactive molecule reduced during the scan, suggesting the P420 
dominates the first electron transfer event. Biotechnological applications of cytochrome P450 
rely on the catalytic activity of the immobilized enzyme driven by the applied potential. It is 
therefore crucial to determine which values of the potential correspond to the active form of the 
enzyme to allow success in driving the catalytic reaction.  
 
4.3.5 NADPH consumption studies on BMP P420 species in solution  
Cytochromes P450 are redox enzymes able to perform their catalytic activity through the 
consumption of two electrons taken from a NADPH cofactor. In the previous section 4.3.4 the 
P420 form of the enzyme was shown to be thermodynamically favoured as it was reduced at 
more positive potential values and therefore it had more time for its complete reduction during 
the time of scan. The fact that in a cyclic voltammetric experiment the P420 form is the 
dominating species for the first electron transfer event, can open further questions on a possible 
contribution of this inactive species to the catalytic current associated to the second electron 
transfer event occurred in presence of a substrate.  
A study of the ability of the cytochrome P450 BM3 (CYP102) in the P420 form in solution to 
use the natural cofactor NADPH as source of electrons necessary for the catalytic cycle was 
performed. The P420 species was induced by increasing the pH and the NADPH consumption 
was followed.  
Figure 4.21 shows the rates of NADPH consumption for the active and inactive species of BMP 
protein in presence and absence of substrate. 
Even if the conditions of the enzyme in solution are different from those when the protein is 
immobilized we observed that the P420 species was not able to take electrons from NADPH in 
both the absence and the presence of a specific substrate. The conditions of the enzyme in 
solution are different from those when the enzyme is immobilised where the distance for the 
tunnelling is shorter and the over-potential applied is much higher than the thermodynamic 
barrier. However from these observations we can conclude that the contribution of the inactive 
P420 form to the catalytic process should be very limited although it seems to be the dominating 
species in the cyclic voltammogram. 
Therefore from the results we can conclude that, even though the P420 species dominates the 





















Figure 4.21 Rate of NADPH consumption for the cytochrome P450 BM3 (CYP102). Blue line: rate of 
NADPH consumption for P450 BM3 in the absence of substrate in a pH 7.4 buffer. Black line: rate of 
NADPH consumption for P450 BM3 in the presence of substrate in a pH 7.4 buffer. Red line: rate of 
NADPH consumption for P420 BM3 in the presence of substrate in a pH 11 buffer. 
 
4.3.6 Enzymatic characterisation of the active P450 and inactive P420 species of 
cytochrome BMP immobilised on PEI modified tin-dioxide electrodes 
An enzymatic characterisation of the two P450 and P420 species of the BMP enzyme 
immobilised on the PEI modified tin-dioxide electrodes was carried out using 
chronoamperometry. The aim of these chronoamperometric experiments on the BMP 
immobilised on PEI modified SnO2 electrode was to distinguish the catalytic turnover in the 
presence of a substrate for the two single species when present at the same time on the electrode 
surface. The BMP/SnO2–PEI configuration was chosen for being able to induce the formations 
of a mixture of the active and inactive species. 
A fixed potential necessary to reduce the enzyme was applied for 30 minutes in the presence of 
a substrate. The substrate chosen for these experiments was p-nitrophenol, a compound that was 
used to enzymatically characterise the haem domain of cytochrome P450 BM3 immobilised on 
a PDDA modified glassy carbon electrode (Fantuzzi et al., 2006). The product that is formed 















Figure 4.22 Chemical structure of p-nithrophenol (PNP) and p-nitrocatechol (PNC) 
 
According to the spectro-electrochemical data, the two potentials of -400 and -600 mV 
corresponding to the two species were applied to the immobilised BMP in the presence of PNP. 
These potentials should be sufficient for the selective reduction of either the active P450 species 
or the inactive P420 one formed during the potential scan. 
The protein free PEI modified film was shown to give on its own a contribution to the product 
formation. Different conditions such as time of measurement, temperature and presence of 
superoxide dismutase and catalase were tested to limit this contribution. Table 4.2 shows the 
results of the experiments performed following the best optimised conditions. As shown from 
the data no clear and different catalytic contribution of the two species was observed. The high 
contribution made by the protein free film on the total amount of product formed could still be 
the cause of this difficulty in measuring small differences in the catalytic activity of the two 
species. Because of the photo-induced reactivity of the film further experiments would be 
necessary to minimize the amount of product formed by the film on its own. After the 
stabilisation of the film a detailed investigation into the catalytic properties of the active and 
inactive species of the immobilised BMP/PDDA/ SnO2 electrode will be achieved.  
 
Table 4.2 Product formed (p-nitrocatechol PNC) for the BMP/PEI-SnO2 electrode in presence of a 
specific substrate such as p-nitrophenol (PNP). 
 
Applied potential Product formed (mM) 
-600 mV 1.85 ± 0.9 

















The distinctive electrochemical reduction of the active and inactive species of BMP, the haem 
domain of the bacterial cytochrome P450 BM3 (CYP102), was performed by using cyclic 
voltabsorptometry, a technique that combines optical and electrochemical data recorded 
simultaneously.  
The use of a semi-conductive and optically transparent material such as tin-dioxide allowed to 
spectroscopically follow the formation of the P420 and P450 species, and to investigate their 
individual electrochemical behavior. Electrodes with different levels of the two species were 
successfully obtained by modifying the porous material with different polycations such as 
PDDA and PEI. The easy conversion of the active P450 species to the inactive P420 one in 
polycations with slightly different chemical properties stressed the importance of chosing the 
right immobilization conditions for developing a catalytically active P450 based amperometric 
sensor. The data presented here demonstrate how, differently from what is commonly thought, 
when both the P450 and P420 species are present on the electrode, the inactive P420 dominates 
the cyclic voltammogram. However the study on the level of NADPH consumed by the inactive 
P420 species in presence of substrate seems to indicate that the overall contribution of this 
species to the catalytic process is very limited. 
Because of the importance and novelty of the electrochemical findings of this preliminary 
spectroelectrochemical investigation, the data presented in this chapter have been published in 





























of the immobilised N-




















5.1 Introduction  
 
The development of an in vitro system able to induce the P450 metabolic reaction has enormous 
potentials for the delivery of high-impact biosensors or bioreactors. While developing such 
systems, key points that need to be established are the effective electron transfer communication 
between the immobilised P450 and the electrode as well as the active state of the immobilised 
enzyme. As learnt from chapter four, the effective electron transfer communication can be 
studied by following the electrochemical response of the reduced and oxidised haem iron redox 
centre. Furthermore confirmation of the presence of an immobilised FeII/FeIII redox species can 
be attained by means of an electrochemical CO binding assay of the immobilised P450 enzyme. 
Nevertheless, it is necessary to stress how the information obtained on the shift in the reduction 
potential of the immobilised species upon addition of carbon monoxide it is only limited to the 
presence of an iron redox centre and it does not give any further indications on the active P450 
or inactive P420 state of the immobilised enzyme.  
Instead the only way to confirm the final active state of the enzyme, if spectroscopic techniques 
are not combined to the electrochemical measurement, is to confirm the electrocatalytic 
conversion of a substrate through the measurement of the final product.  
Because the catalytic activity of the immobilised enzyme is crucial to the construction of the 
sensor, all possible factors that can influence the active state need to be taken into consideration. 
As indicated in chapter four the physical properties of the environment surrounding the haem 
redox centre is a factor that can have a strong influence on the conformational changes and 
therefore active state of the immobilised enzyme (Panicco et al., 2008).  
Taking into account all these considerations, the present chapter moved the attention to the main 
scope and character of the project, which is the electrochemical characterisation of the human 
cytochrome P450 2C9 for the development of a P450 based amperometric sensor. At first the 
investigation was limited to the N-terminal modified CYP2C9 that represents the simplest 
system between the available constructs. The electrode material chosen for starting the 
investigation was glassy carbon, which has the advantage of ease of use; it has good 
conductivity and is a well known electrode surface for the electrochemical characterisation of 
redox proteins such as cytochromes P450 (Bistolas et al., 2005). As several studies of redox 
proteins immobilised on carbon electrodes have shown, improved electron transfer can be 
achieved by modifying the electrode surface with surfactants or poly-ions. Therefore, the same 
approach used in chapter four was applied in this chapter. The N-terminally modified CYP2C9 
was immobilised on glassy carbon electrodes modified with either 
polydimethlydiallylammonium chloride (PDDA), the polymer that in chapter four showed the 
best results for CYP102, or didecyldimethylammonium bromide (DDAB), a surfactant that has 
been already used in the literature for CYP2C9. Aim of the investigation was to characterise and 
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compare the electrochemical and electro-catalytic properties of the human CYP2C9 once 
immobilised on a simple electrode system on two different electrode modifiers.  
 
5.2 Cyclic voltammetry of CYP2C9 immobilised on PDDA and DDAB 
modified glassy carbon electrodes 
 
The N-terminally modified CYP2C9 was immobilised on polydimethlydiallylammonium 
chloride (PDDA) and didecyldimethylammonium bromide (DDAB) modified glassy carbon 
electrodes according to the protocol described in section 2.2.5. As explained in chapter 3, the N-
terminal modification of the CYP2C9/pCW was introduced to remove the binding anchor to the 
membrane. In a previous study on the characterisation of the CYP2C9 construct used in this 
project, the modification at the N-terminus has shown not to alter the structural conformation 
and the substrate binding pocket of the purified enzyme (Dodhia et al., 2006). 
The technique used for the electrochemical characterisation of CYP2C9/pCW was cyclic 
voltammetry that is one of the most versatile for the study of electro-active species (section 
2.2.1.1). In a cyclic voltammetric experiment the working electrode potential is ramped linearly 
up to a set potential and then inverted back to close a cycle. The current at the working electrode 
is plotted versus the applied voltage to give a cyclic voltammogram trace. The important 
parameters of a cyclic voltammogram are the magnitude of the anodic peak current (ipa), the 
cathodic peak current (ipc), the anodic peak potential (Epa) and the cathodic peak potential 
(Epc). 
Figure 5.1 shows the cyclic voltammogram (CV) of CYP2C9 immobilised on PDDA modified 
glassy carbon (GC) electrodes at 0.1V/sec of scan rate in anaerobic conditions. The electrolytic 
solution contained potassium phosphate and potassium chloride salt at a concentration to 
guarantee the electrochemical conductivity and the stability of the enzyme. The pH of the 






Figure 5.1 Cyclic voltammograms of N-terminally modified CYP2C9 immobilised at poly 
dimethydiallyl ammonium chloride (PDDA)-modified glassy carbon electrodes. The CV was recorded in 
deoxygenated 50 mM potassium phosphate pH 7.4 containing 500 mM potassium chloride at a scan rate 
of 1 V.s-1 at 25 °C. 
 
The ratio between polymer and protein was adjusted to obtain a significant electrochemical 
response. The CYP2C9 embedded in a 10 % wt PDDA solution did not show any signal. A pair 
of stable redox peaks centred at -0.054 V ± 0.004 was instead observed when the PDDA 
concentration was lowered to 3.5 % wt. This potential value corresponds to the Emid, which is the 
midpoint of the anodic (Epa) and cathodic (Epc) peak potentials. No redox waves were observed 
from the bare glassy carbon or from the protein-free PDDA modified GC electrode (figure 5.3 
A). The lack of response in the control electrodes suggests that the observed signal can only be 
attributed to the electrochemical response of the CYP2C9* 
The absence of an electrochemical response from the CYP2C9 immobilised in a high 
concentration of PDDA polymer underlines the possibility of its direct or indirect effect on the 
redox properties of the enzyme.  
Figure 5.2 shows the cyclic voltammogram of the CYP2C9 immobilized on DDAB modified 
GC electrode at 0.1V/sec of scan rate in oxygen-free conditions. The concentration of DDAB 
used was the same reported in previous studies (Fantuzzi et al., 2004). A redox couple was 
observed at -0.033 V ± 0.004, a more positive potential compared to the one observed in the 
PDDA film. No redox waves were observed for the DDAB modified GC electrode in the 
absence of protein (figure 5.3) thus confirming that the redox response was coming from the 
immobilised haem redox centre. Table 5.1 summarizes all the electrochemical parameters 




Figure 5.2 Cyclic voltammograms of N-terminally modified CYP2C9 immobilised at 
didecyldimethylammonium bromide (DDAB) modified glassy carbon electrodes. The CV was recorded 
in deoxygenated 50 mM potassium phosphate pH 7.4 containing 500 mM potassium chloride at a scan 




Table 5.1 Electrochemical parameters extrapolated from the cyclic voltammetric experiments on 






 Emid which is the midpoint of the anodic (Epa) and cathodic (Epc) peak potentials  
  ‡ 
∆E which is the peak-to-peak separation (Epa-Epc)  





Enzyme modification Emid (V)*  vs NHE ∆E (V)‡ ipc/ipa• 
CYP2C9/PDDA/GC – 0.054 ± 0.004 0.041± 0.008 0.72± 0.08 
CYP2C9/DDAB/GC – 0.033 ± 0.004 0.063± 0.008 0.72± 0.01 
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Figure 5.3 Cyclic voltammograms of the protein-free didecyldimethylammonium bromide 
(DDAB) modified glassy carbon electrodes (A) and protein-free polydimethydiallyl ammonium chloride 
(PDDA) modified glassy carbon electrodes (B). The CV was recorded in deoxygenated 50 mM potassium 
phosphate pH 7.4 containing 500 mM potassium chloride at a scan rate of 1 V.s-1 at 25 °C. 
 
The cathodic-to-anodic peak current ratio was 0.72 for both the CYP2C9/PDDA/GC and the 
CYP2C9/DDAB/GC. This value is consistent with a quasi-reversible electrochemical response.  
Table 5.2 shows the list of studies carried out on CYP2C9 and other human P450s immobilized 
on carbon electrodes modified with PDDA or DDAB. All the Emid values reported fall in a range 
between +0.098 and -0.097 V. Two studies on the N-terminally modified His tagged-CYP2C9 
immobilised on DDAB/EPG electrode reported an Emid of – 0.041 V (Johnson et al., 2005) and ≅ 
-0.080 V (Shukla et al., 2005). The mid point potentials here observed for the 
CYP2C9/DDAB/GC and CYP2C9/PDDA/GC electrodes are close to these values.  
 
 
Table 5.2 Published studies on different human cytochrome P450 isoforms immobilised on carbon and 
gold electrodes modified with polymers or surfactants.  
Reference Surface/Modification CYP450 Emid (V) vs NHE ks (s-1) 
Johnson 2005 EPG/DDAB   CYP2C9 -0.041 - 
Shukla 2005 EPG/DDAB   CYP2C9 ≅ -0.080 - 
Fantuzzi 2004 GC/DDAB CYP2E1 -0.085 ± 0.005 
+0.060 ± 0.005 
1 
2 
Fantuzzi 2004 GC/PDDA (PDDA 10wt%) CYP2E1 -0.085 ± 0.005 
+0.060 ± 0.005 
1 
2 
Dodhia 2006 GC/PDDA  (PDDA 10wt%) CYP3A4 -0.097 ± 0.011 378 
Joseph 2003 AU/MPS/PDDA (PDDA 20wt%) CYP3A4 +0.098 ± 0.005 - 
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The 21mV of difference between the measured Emid of the CYP2C9/DDAB/GC and 
CYP2C9/PDDA/GC electrodes is not surprising if compared to the wide range of values 
obtained for different human cytochromes P450 and different immobilization methods. Table 
5.3 shows all the Emid values reported in different studies on the electrochemical characterisation 
of the immobilised bacterial P450cam (table 5.3). The range of Emid values registered for the same 
enzyme is between + 0.022 and -0.139V. From the table it is clear how the immobilisation 
process and the immobilisation environment are the main factors responsible for defining the 
redox potential of the immobilised enzyme.  
 
Table 5.3 Published studies on the bacterial P450cam in solution and immobilised on carbon and clay 
electrodes differently modified.  
Reference Surface/Modification CYP450 Emid (V vs NHE) 
Zhang 1997 DDAB/carbon electrode CYP450cam +0.022 
Lvov 1998 MPS-(PEI/PSS)/carbon electrode CYP450cam -0.006 
Iwuoha 1998 DDAB/BSA/glutaraldehyde/carbon el CYP450cam -0.019 
Munge 2003 PEI/ carbon electrode CYP450cam -0.074 
Zhang 1997a DMPC/ carbon electrode CYP450cam -0.121 
Lei 2000 Clay CYP450cam -0.139 
Fisher 1985 Solution (potentiometry) CYP450cam -0.303 
 
Another observation which is common to all these reduction potentials is that they are all 
consistently more positive than those obtained from potentiometric titrations of the same 
enzymes in solution (Sligar et al., 1979). 
Nevertheless there are also studies in which the immobilisation method did not change the 
redox potentials. The CYP2E1 immobilised on PDDA and DDAB modified glassy carbon 
electrodes showed the same potential value of -0.085 V for both configurations (Fantuzzi 2004). 
The different response exerted by two different P450s treated in the same experimental 
conditions could suggest an isoforms specific behaviour. Structural differences in the substrate 
binding cavity of different cytochromes P450 could be claimed as being mainly responsible for 
the observed phenomenon. The deposited crystal structures of CYP2C9 have revealed a quite 
spacious substrate binding site easily accessible to multiple binding sites. It is probably this 
large way of access that could leave the internal redox centre configuration more exposed to 
interactions with the external environment. The reported case of CYP2C9 being particularly 
sensitive to certain amount of acetonitrile is an example of this effect (Tang et al., 2000). 
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Another phenomenon that could affect the mid point potential of the immobilised enzymes is 
the specific charge of the film component enzyme (Fleming et al., 2006).  
Integration of the anodic peak area in the voltammograms showed an average surface coverage 
(Γ) of 1.18x10-10 mol/cm2 and 1.19x10-10 mol/cm2 for the CYP2C9/PDDA/GC and 
CYP2C9/DDAB/GC respectively. This coverage should correspond to about 20 layers of 
electro-active protein, but this remains an approximate estimation because of the semi-porous 
and not totally flat structure of the glassy carbon material. 
Cyclic voltammetry of cytochrome P450 allows examination of not only the first one-electron 
reduction event of the P450 catalytic cycle, but also other associated chemical reactions, such as 
the effect of the binding of a substrate on the redox potential of the enzyme. Figure 5.4 shows 
the overlay of the cyclic voltammograms of CYP2C9/DDAB/GC before and after addition of 
substrate. Diclofenac and S-warfarin were chosen as substrates to investigate (figure 5.4A and 
5.4C). A control experiment in which the solvent acetonitrile used to dissolve S-warfarin was 




















Figure 5.4 Cyclic voltammograms of N-terminally modified CYP2C9 immobilised at 
didecyldimethylammonium bromide (DDAB) modified glassy carbon electrodes. Black line: CV recorded 
in measuring buffer. Grey line: CV recorded in measuring buffer after the addition of substrate or solvent 
(total volume added 5µL). (A) CV recorded before and after addition of 250µM of (S)-warfarin 
solubilised in acetonitrile. (B) CV recorded before and after addition of acetonitrile (C) CV recorded 
before and after the addition of 250µM of diclofenac solubilised in aqueous measuring buffer. Measuring 
buffer: deoxygenated 50mM potassium phosphate pH 7.4 containing 500 mM potassium chloride. All 







The Emid of the enzyme immobilized on DDAB showed a 0.016 V shift towards more negative 
values when 250µM of S-warfarin were added. The addition of an equal volume of acetonitrile 
only induced a small positive shift of +0.004 V. In the case of diclofenac a smaller and quite 
negligible shift of 0.009 V towards more positive values was recorded.  
In the case of CYP2C9 immobilized on PDDA modified glassy carbon electrodes a negative 
shift was observed in the presence of both S-warfarin and acetonitrile, while diclofenac showed 
a negative shift of -0.004V. Table 5.4 summarizes all the observed experimental values. 
 
Table 5.4 Measured Emid shift for the CYP2C9/DDAB/GC and CYP2C9/PDDA/GC electrode after 




Substrate/Solvent Emid shift (V) 
CYP2C9/DDAB/GC (S)-warfarin/AcCN -0.016 ± 0.003 
 AcCN +0.004 ± 0.003 
 Diclofenac/H2O +0.009 ± 0.003 
CYP2C9/PDDA/GC (S)-warfarin/AcCN -0.020 ± 0.007 
 AcCN -0.019 ± 0.007 
 Diclofenac/H2O -0.004 ± 0.007 
 
 
According to early potentiometric studies on P450cam (CYP101) (Sligar et al., 1976), P450BM3 
(CYP102) (Daff et al., 1997) and P450scc (CYP11A1) (Light et al., 1981) in solution and 
voltammetric works on P450cam immobilised on graphite electrodes the binding of substrate to 
the iron haem should be associated with a shift of the Emid to more positive values (>100mV). 
This change should be associated to a substrate-dependent thermodynamic switch.  
However, subsequent voltammetric studies on other P450s did not confirm this theory and 
neither our data. The CYP2C9 immobilised on DDAB modified EPG did not show any 
consistent shift in presence of S-warfarin, diclofenac, tolbutamide and sulfaphenazole. Only a 
small shift was observed in the presence of torsemide (Johnson et al., 2005). Shukla and co-
workers did not observe any change in the Emid of CYP2C9 immobilised on EPG electrodes 
after addition of known substrates (Shukla et al., 2005). The same situation was obtained for 
P450cin (Aguey-Zinsou et al., 2003) and P450BM3 (Fleming et al., 2003).  
Several hypothesis have been formulated on the lack of interaction between the substrate and 
the active site. The substrate-binding cavity adjacent to the haem active site film could be 
occupied and blocked by the film component. Another hypothesis is that the substrate could 
reach the substrate-binding cavity through being sequestered by the film. Finally it could be that 
the substrate binds correctly but the already large positive increase in the Emid because of 
interactions with the membrane (low dielectric environment, more hydrophobic, water 
exclusion) could mask any further increase related to the substrate. Alternatively, as observed in 
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chapter 4, the environment surrounding the immobilised enzyme could induce structural 
changes and formation of the inactive P420 species. 
The redox peak current was scanning rate-dependent thus demonstrating a good electron 
transfer and a surface-controlled process between the CYP2C9 and the modified GC electrodes.  
The difference ∆Ep between the peak potential of the anodic and cathodic peaks (∆Ep = Epa – 
Epc) is an interesting experimental parameter. The ∆Ep experimentally calculated at the scan 
rate of 1Vs-1 were 41± 8 and 63± 8 mV for the CYP2C9 embedded in PDDA and DDAB 
respectively. For ideal, reversible, surface redox behaviour the ∆Ep should be zero and 
independent of sweep rate. However most of the experimentally reported, nearly reversible 
surface redox systems are characterized by finite values of ∆Ep (Armstrong et al., 2000). The 
distance between the theoretical and experimental values of ∆Ep is also supported by the half-
peak-width (∆E1/2) of the surface redox waves. The ∆E1/2 should be 91/n mV under ideal 
conditions where the adsorbates do not interact between each other. The present studies have 
yielded ∆E1/2 values of 199 and 174 mV for the reduction and oxidation peaks of the 
2C9/PDDA/GC electrode and 220 and 195 mV for the reduction and oxidation peaks of the 
2C9/DDAB/GC electrode. The broadness of the oxidation and reduction peaks could be due to a 
dispersion of the potential values resulting from different protein orientations or multiple 
species (Fleming et al., 2003). 
Once concluded that the electrochemical process was surface-controlled and not diffusion-
controlled, the heterogeneous electron transfer constant (ks) was determined according to 
Laviron’s theory for diffusionless thin layer voltammetry (Laviron, 1979).  
Laviron formulated a general expression for the voltammogram of a diffusionless system from 
which the rate constant and the transfer coefficient of the reaction can be calculated. In order to 
confirm the diffusionless regime, the peak currents of the oxidation and reduction peaks were 
plotted against the scan rate. It resulted that the relationship between the two parameters was 
linear up to 40 V/sec, after which they become linear with the square root of the scan rate 
(diffusive system). This is characteristic of thin film electrochemistry, indicative of finite 
diffusion of the protein within the film. Thus up to 40 V/sec the system van be treated as surface 
confined. Within this diffusionless regime the ratios of the total charge under the cathodic and 
anodic peaks approach unity for both proteins, indicating a chemically reversible system.  
The plots of the peak-to-peak separation (∆E) versus the logarithm of the scan rate for the 
CYP2C9/DDAB/GC and CYP2C9/PDDA/GC is shown in figure 5.5 and 5.6 respectively. The 
CYP2C9 immobilised in the two different films showed slightly different kinetics of electron 
transfer. The CYP2C9 immobilised in the PDDA polycation showed a faster electron transfer 
kinetics than the CYP2C9/DDAB/GC electrode whose plots of the oxidative and reductive plots 




Figure 5.5 Trumpet plot for the CYP2C9/DDAB/GC response. The response from the CYP2C9 
immobilised on DDAB modified glassy carbon electrode is shown. The reductive (black dots) and 
oxidative (red dots) peak potentials are plotted against the logarithm of the scan rate.  
 
 
Figure 5.6 Trumpet plot for the CYP2C9/PDDA/GC response. The response from the CYP2C9 
immobilised on PDDA modified glassy carbon electrode is shown. The reductive (black dots) and 
oxidative (red dots) peak potentials are plotted against the logarithm of the scan rate.  
 
 
Within the diffusionless regime, the theory of Laviron was used to estimate the standard rate 
constant ks. Assuming a transfer coefficient (α) of 0.5, ks at 10 V/sec were 82 ± 11 s-1 and 189 ± 
38 s-1 for the CYP2C9/DDAB/GC and CYP2C9/PDDA/GC respectively.  
In both the immobilization systems used the electron transfer rate was faster than that calculated 
for the P450 enzymes in solution (≅ 0.01s-1). Although it is not fully understood, the enhanced 
electron transfer rate observed for haem proteins in surfactant films has been attributed to the 
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surfactant blocking adsorption of macromolecular impurities to the electrode surface, which 
would otherwise create an insulating layer and hinder ET (Rusling 1998). 
Similar values were obtained with different isoform and different modifications. A previous 
work on CYP2C9 immobilised on DDAB/PGE electrodes revealed an electron transfer rate of 
150 s-1 that increased to 165 s-1 in more basic conditions (pH 8.2) and decreased to 139 s-1 by 
moving to more acid pH values (pH 6.0) (Johnson et al., 2005). An electron transfer constant of 
650 ± 50 s-1 was reported for the haem domain of cytochrome P450 BM3 immobilised on 
pyrene-wired BPG electrodes (Udit et al., 2004). CYP3A4 wild type immobilised on PDDA 
modified glassy carbon electrodes showed a ks value of 378 ± 10 s-1. The electron transfer of 
FeIII haem photochemical reduction has been calculated to be in the range between 280 and 3300 
s-1 (Sevrioukova et al., 2000). 
The effect of the presence of S-warfarin substrate on the electron transfer rate of CYP2C9 
immobilised in different environments was also studied. Table 5.5 shows the variation in the 
electron transfer rate measured for the two investigated configurations. A decrease in the ks 
value was obtained for both the CYP2C9 immobilised on DDAB and PDDA modified glassy 
carbon electrodes when S-warfarin was added to the reaction solution.  
 
Table 5.5 List of ks values calculated for the CYP2C9/DDAB/GC and CYP2C9/PDDA/GC in presence 
and absence of substrate. 
 
Enzyme modification substrate ks (s-1) 
CYP2C9/DDAB/GC None 82 ± 11 
 (S)-
warfarin 
49 ± 7 
CYP2C9/PDDA/GC None 189 ± 38 
 (S)-
warfarin 
93 ± 6 
 
In solution the substrate-free P450cam showed a slower rate of the first electron transfer than 
the substrate-bound P450cam. This difference in the electron transfer is explained in terms of 
larger reorganisation energy required by the six-coordinated substrate-free complex to be 
converted to the five-coordinated reduced substrate-free complex (Honeychurch et al., 1999). In 
our case the protein is immobilised on the surface and as already observed before not even a 
positive shift in the Emid potential has been seen when substrate has been added. The change of 
electron transfer here observed could be therefore assigned more to a rearrangement of the 





5.3 Chronoamperometry of CYP2C9 in presence of substrate for the 
determination of the product formed  
 
Cyclic voltammetry of CYP2C9 immobilised on PDDA and DDAB modified glassy carbon 
electrodes were carried out in oxygen saturated buffer. Both the PDDA and DDAB systems 
were sensitive to the presence of oxygen in the buffer as shown by the large catalytic current 
due to electrocatalytic reduction of oxygen to hydrogen peroxide by the reduced haem iron 
(Estavillo et al., 2003). 
As the haem domains of CYP2C9 immobilised in both PDDA and DDAB were able to catalyse 
the reduction of molecular oxygen, substrate turn-over studies were performed as described in 
section 2.2.9. The substrate chosen for the catalytic investigation was S-warfarin, which is a 
specific substrate of the human CYP2C9 isoform. Experiments on the microsomial fraction of 
the human liver have shown that S-warfarin is mainly metabolized to 7OH-warfarin by 
CYP2C9 (Kaminsky et al., 1997) (figure 5.7). 
 
 
Figure 5.7 Chemical structures of (S)-warfarin and the hydroxylated product S-7-hydroxywarfarin. 
 
The chronoamperometric experiments were carried out in the presence of the specific substrate 
S-warfarin and the product formed was identified by analysing the electrochemical reaction with 
high-performance liquid chromatography (HPLC). The chromatographic conditions used are 
described in section 2.2.9. In order to identify and quantify the product formed, a standard of the 
7-hydroxywarfarin was injected and analysed under the same conditions. Figure 5.8 shows the 




Figure 5.8   Standard curve used to quantify the amount of 7-hydroxy warfarin formed. Shown is the 
change in peak area at different concentration of 7-hydroxy diclofenac (µM). 
 
The change in current upon application of a fixed negative potential of -550mV was monitored 
in the presence of oxygen and substrate S-warfarin. A higher current was observed for the 
CYP2C9/DDAB/GC electrode.  
At the end of the experiment the electrolytic solution of reaction was injected into a HPLC 
system for the identification of the product formed. The expected product was the 7-OH 
warfarin, the main metabolite formed by this human isoform (Kaminsky et al., 1997). Figure 5.9 
shows the overlay of the chromatograms of the reaction sample, the product standard and the 






Figure 5.9 HPLC chromatograms. Overlay of the reaction of 2C9/DDAB/GC electrode with (S)-warfarin 
(black line), protein-free control DDAB/GC electrode with (S)-warfarin (dash line) and 7-hydroxy 
warfarin standard solution (grey line). Peak number 1 represents the Internal Standard Salycilic acid, peak 
number 2 the 7-hydroxywarfarin, peak number 3 the (S)-warfarin. 
 
 
Table 5.6 shows the amount of 7-OH warfarin formed in the reaction cell and the S-warfarin 
turnover. The percentage of coupling of the reaction has been estimated as a ratio between the 
total experimental current consumed and the current consumed to produce the amount of 
product measured.  
 
Table 5.6 Catalytic parameters of the CYP2C9 immobilised on DDAB and PDDA modified glassy 
carbon electrodes (the values have been subtracted of the amount of 7-hydroxy warfarin formed by the 
protein-free electrode). The percentage of coupling has also been calculated from the amount of current 









warfarin/min/pmol P450 % coupling 
CYP2C9/DDAB/GC 2.16 ± 0.30 4.28 ± 0.59 8.96 ± 0.85 
CYP2C9/PDDA/GC 1.59 ± 0.14 3.17 ± 0.28 7.41 ± 0.46 
 
 
The S-warfarin catalytic turnover and the percentage of coupling of the reaction appeared to be 
higher for the CYP2C9 immobilized in the surfactant DDAB. The enzyme seems to be more 
active when it is embedded in the surfactant film rather than when it is embedded in the 
polycation.  
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The previously mentioned influence of the electrode modifier on the conformational changes of 
the protein seems to be confirmed by the catalytic activity experiments.  The PDDA polymer 
and the DDAB surfactant are both positively charged but their structure and chemistry are quite 
different (figure 5.10).  
 
 
Figure 5.10 Chemical structures of polydimethlydiallylammonium chloride - PDDA (A) and 
didecyldimethylammonium bromide - DDAB (B). 
 
 
The DDAB is an amphiphilic surfactant that forms a multi-bilayer film simulating the biological 
membrane of the enzyme. The enzyme is therefore entrapped in a fluid and permeable layer 
formed by the hydrophobic tails of the molecule (figure 5.11). 
 
 
Figure 5.11 Representation of a multi-bilayer of didecyldimethylammonium bromide molecules (DDAB) 
entrapping an enzyme molecule on an electrode.   
 
 The PDDA is instead a polyelectrolyte positively charged that because of its polymeric 
structure and viscosity tends to form a more mechanically stable film. It is interesting to observe 
that similarly to this polymer, the chemical structures of most of the specific substrates of 
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CYP2C9 contain aromatic rings. It could be hypothesized that once the polymer enters into the 
large active site cavity interact with the multiple ligand binding sites thus inducing significant 
conformational change on the highly conserved chain of hydrogen bonds that guarantee the 
catalytic activity and redox properties of the enzyme.  
Figure 5.12 shows the hydrophobic cleft of peptides involved in the multiple substrate binding 
sites of CYP2C9. 
 
 
Figure 5.12 Aminoacids forming the hydrophobic substrate binding cavity of CYP2C9 as solved in the 
deposited crystal structure of the flurbiprofen-bond CYP2C9 (1R90).   
 
 
 5.4 FT-IR characterisation of differently modified CYP2C9 
electrochemical surfaces  
 
As previously hypothesized the altered electrochemical response and decreased catalytic activity 
of the CYP2C9 immobilised on the PDDA polymer could be due to conformational changes 
induced by the film components on the polypeptide chain. The secondary structure of CYP2C9 
embedded and immobilised on an electrode surface was investigated by Fourier transform 
infrared spectroscopy. In particular the specular reflection of light at high grazing angles of 
incidence has been applied to enhance the infrared signal of the immobilised film.  
Spectroscopy is among the first techniques to have been used to study the structural properties 
of cytochromes P450 (Rein et al., 1984). The first application of infrared spectroscopy applied 
to a cytochrome P450 dates from 1976 and from there on a number of studies on different 
cytochromes P450 have been published. 
Infrared spectroscopy measures transitions between vibrational states of molecules, which are 
induced by irradiating the sample with infrared light. The infrared spectrum originates from the 
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plot between the intensity of light absorption and the frequency of the light. A molecule has a 
unique infrared spectrum with peaks at specific frequencies which correspond to the vibrational 
frequencies of specific functional groups or bonding arrangments. The typical infrared spectrum  
of haem proteins has dominant bands between 1700 and 1400 cm-1 originated from the protein, 
while the weak bands at 1950 cm-1 and close to the dominant protein bands belong to the carbon 
monoxide ligand, the protonated carboxy groups from the protein and the haem group. 
The specific vibrations arising from the peptide group are listed in table 5.7. The band taken in 
consideration in this work is Amide I band, which is the distinctive infrared band of proteins 
and it appears beween 1700 and 1600 cm-1, with a maximum intensity at around 1674-1654. 
 





Assignment (main contributions) 
Amide A 3250-3300 N-H stretch in resonance with amide II overtone 
Amide I 1600-1700 
Mainly C=O stretching, slightly coupled with C-N, CCN 
deformation, N-H bending 
Amide II 1550 N-H bending coupled with CN stretching 
Amide III 1230-1330 N-H bending, C-N stretching 
Amide IV 625-767 OCN bending, coupled with other modes 
Amide VI 640-800 Out-of-plane N-H bending 
Amide VII ≈ 200 Skeletal torsion 
 
The Amide I band results from the stretching vibration of the peptide C=O group. The fact that 
C=O group is involved in various secondary structure motifs via hydrogen bonding to the 
peptide N-H group, the Amide I band contains a multitude of single bands with different 
frequencies. An estimate of the secondary structure composition can be achieved by calculating 
the relative areas of the single bands extrapolated from the fitting of the peak. It is necessary to 
assume that the extinction coefficient for the C=O stretch vibration is the same in all hydrogen 
bonding structures.  
Preliminary experiments have been performed on the CYP2C9/DDAB and CYP2C9/PDDA 
mixture deposited on a glassy carbon surface at the scope to identify any effect of the film 
components on the structural conformation of the enzyme. However, because of the non 
atomically flat surface of this carbon material which is instead characterised by cavities across 
its solid glassy state, the infrared signal coming from the film electrode did not have a 
significant intensity. Evaporated gold electrodes on silicon slides were then used as solid 
support to immobilise the protein film mixtures. Gold electrodes obtained for evaporation on 
 177 
solid flat support are known to have an atomically flat surface that renders them good substrates 
for the specular reflection of an incident beam of light.  
The recorded spectra of the immobilized protein were enhanced and a Gaussian fit of the 
observed peaks was carried out. According to a review on studies on the FT-IR spectra of P450s 
in solution, the spectra of five different cytochromes P450 have been compared and nine 
common sub-bands can be identified (table 5.8).  
 
Table 5.8 Summary of the fit data of the amide I band averaged for 5 different CYPs (CYP101, CYP102, 
CYP111, CYP2B4, CYP11A1 (Jung 2008). 
 
 
Secondary structure Wavenumber (cm-1) Standard deviation 
βeta sheet 1 1614.99 2.90 
βeta sheet 2 1623.69 1.94 
βeta sheet 3 1632.24 1.71 
310helix/unordered 1640.63 1.47 
α helix 1 1648.52 0.66 
α helix 2 1656.09 0.82 
turn 1 1664.10 1.59 
turn 2 1673.52 1.73 
turn 3 1683.20 3.05 
 
 
The nine peaks typical of the secondary structure of cytochromes P450 have been identified in 
the experimentally recorded spectra and the relative areas of the single bands extrapolated from 
the fitting of the peak. A total relative abundance of the main secondary structures was then 
calculated.  
Figure 5.13 shows the enhanced FT-IR spectrum of a CYP2C9/PDDA/Au electrode. Table 5.9 








Figure 5.13 Enhanced and Gaussian fit curvature of the Amide I band of the CYP2C9 enzyme 
immobilised on PDDA modified gold electrode. 
 
Table 5.9 Summary of the fit of the data corresponding to the amide I band of the CYP2C9 embedded in 








(PDDA:2C9 = 1:3) 
2C9/PDDA 
(PDDA:2C9 = 1:2) 2C9/DDAB 
β sheet 9.6 19.15 ± 2.49 25.75 ± 2.28 21.77 ± 1.40 
310helix/unordered 47.7 11.43 ± 1.58 15.70 ± 1.72 12.03 ± 1.22 
α helix 42.7 39.52 ± 1.78 26.14 ± 1.85 33.87 ± 1.86 
Turn  29.89 ± 2.71 32.41 ± 2.04 32.32 ± 1.98 
 
 
As it can be seen from the results, different percentages of PDDA were used in the protein 
mixture to simulate the conditions in which no electrochemical response was observed from the 
CYP2C9 enzyme. In general a higher percentage of β-sheet was observed compared to the X-
ray crystal structure, but this is expected as the FT-IR tends to enhance the signal of the β-sheets 
while the X-ray the one of the α helix.  Nevertheless a higher percentage of β-sheets and 
unordered secondary structure components were observed when a higher concentration of 
PDDA was present in the protein mixture. This behaviour is in line with what observed 





5.5 Conclusions  
The electrochemical characterisation of the N-terminal modified CYP2C9 was performed on 
PDDA or DDAB modified glassy carbon electrodes. Successful results were obtained in terms 
of electrochemical communication as a couple of well defined redox peaks were observed in 
both configurations. Nevertheless an effect of the chemical modifier on the reduction potential 
of the enzyme was observed, as the Emid of the CYP2C9 embedded in PDDA resulted to be 
more positive than the one embedded in DDAB. However a variation of the Emid according to 
the immobilisation method used is not something unusual as shown by the different of values 
observed for the same enzyme immobilised in different set-up (Johnson et al., 2005; Shukla et 
al., 2005).  
The determination of the electron transfer constant for the immobilised CYP2C9 showed higher 
ks values when the protein was immobilised on the PDDA modified glassy carbon electrode. 
Considering the buried nature of the haem within the folded polypeptide, an increase in the 
electron transfer could mean a more exposed haem redox centre. The higher exposure could be 
due to conformational changes induced by the polycation on the structural folding of the 
enzyme. The fact that there is an effect induced by this polymer on the human CYP2C9 is also 
confirmed by the fact that the concentration of PDDA used to modify the electrode needed to be 
adjusted in order to have an electrochemical response. At high PDDA concentrations no 
response was observed from the immobilised CYP2C9. 
The electro-catalytic activity of the enzyme in the presence of the specific substrate S-warfarin 
showed that the CYP2C9 immobilised on PDDA modified glassy carbon electrode possessed a 
lower enzymatic activity and a lower percentage of coupling for the catalytic reaction when 
compared to the CYP2C9 immobilised on DDAB. To investigate if this decrease was caused by 
an effective distortion of the CYP2C9 structure induced by the polymer an FT-IR investigation 
on the secondary structure of the immobilised enzyme was performed. Results confirm this 
effect on the CYP2C9 when embedded in high concentrations of the PDDA. 
By looking at the different chemical properties of the two molecules, the DDAB surfactant 
assumes a membrane-like structure that undoubtedly has higher affinity for the human P450s, 
an enzyme that in its native environment is bound to a membrane. On the contrary the PDDA 
polymer creates a much more rigid film that possibly constrains the structure of the flexible 
CYP2C9* Moreover the known wide substrate binding cavity of the CYP2C9 could give easy 
access to the PDDA molecules whose chemical structure contains aromatic rings similar to 
those present in most of the known CYP2C9 substrates. For these reasons it cannot be excluded 
that the PDDA either entering the active site cavity or interacting with the hydrophobic patches 
present in the substrate pocket alters the hydrogen bonding network crucial to the redox 
properties and the catalytic activity of the immobilised enzyme. 
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An interesting observation stems from these data: for each isoform careful analysis and 
selection of the best immobilization conditions is required and generalisation cannot be drawn 
for the whole P450 family. This is demonstrated by the fact that the human CYP2C9 and the 
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6.1 Introduction  
 
The results observed in chapter five would indicate that between the two investigated methods 
of immobilisation, the DDAB/GC configuration is the most suitable for the electrochemical and 
electro-catalytic characterisations of the N-terminally modified CYP2C9. For this reason the 
same immobilisation approach was used with the previously expressed and purified chimeras, 
both the wild type and the allelic variants of the CYP2C9 isoform. In such a way a direct 
comparison between the electrochemical and electro-catalytic performances of the CYP2C9, 
CYP2C9BMR and CYP2C9FLD constructs will be available. The scope of these fusion proteins 
is to have constructs in which the haem domain of the P450 is genetically fused to an external 
redox module simulating the role of the human cytochrome P450 reductase (CPR). When the 
CYP2C9 is immobilised on an electrode, the electrons are exchanged directly between the haem 
redox centre and the electrode surface. However in this condition it is difficult to control the 
number of electrons and the rate at which they are transferred to the haem when a negative 
reduction potential is applied. The catalytic cycle involves the sequential transfer of two 
electrons to the haem and their productive use is strictly controlled by the kinetic constants of 
each individual step. Having a fusion protein where the haem domain is genetically fused to an 
intermediate electron transfer system would regulate the flow of electrons that reach the 
catalytic centre. Such regulation could improve the final catalytic efficiency of the enzyme.  
The CYP2C9FLD, CYP2C9BMR and their corresponding allelic variants CYP2C9*2 and 
CYP2C9*3 have been electrochemically and electro-catalytically characterised in order to 
assess if the immobilised constructs were able to conform to the in vivo and in vitro literature 
findings where the polymorphic variants exhibit a reduced metabolism towards the widely used 
anti-coagulant drug (S)-warfarin.  
 
6.2 Cyclic voltammetric studies on the CYP2C9BMR and 
CYP2C9FLD chimeras and their corresponding allelic variants 
 
6.2.1 Electrochemical characterisation of the CYP2C9BMR, CYP2C9*2BMR AND 
CYP2C9*3BMR on glassy carbon electrodes 
 
The electrochemical properties of the CYP2C9BMR construct and its two allelic variants 
CYP2C9*2BMR and CYP2C9*3BMR were investigated. As explained in chapter 3, the 
CYP2C9BMR construct derives from the fusion between the N-terminally modified human 
CYP2C9 and the reductase domain of the bacterial CYP102 (BMR), which contains an AvrII 
site in its codon sequence. Previous studies demonstrated how the presence of the bacterial 
reductase (BMR) improved the solubility of the whole construct without interfering with the 
folding, the haem incorporation and the substrate binding of the CYP2C9 (Dodhia et al., 2006).  
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All the catalitically self-sufficient chimeras in which the haem and the external reductase 
domain are fused in a unique polypeptide chain have been immobilised on glassy carbon 
electrodes. The aim of the construct is to have a system in which the linked reductase would 
modulate the transfer of electrons from the electrode to the haem redox centre thus improving 
the catalytic performance of the immobilised enzyme. 
The CYP2C9BMR, CYP2C9*2BMR and CYP2C9*3BMR were then immobilised on a DDAB 
(didecyldimethylammonium bromide) modified glassy carbon electrodes according to the 
protocol described in section 2.2.5.  
The use of a synthetic surfactant as modifier of the electrode surface was suggested by the 
results explained in chapter 5. Similarly to chapter 5 the electrochemical properties of the 
immobilised enzyme were investigated by using cyclic voltammetry that follows the electron 
transfer between the electrode and the immobilised redox protein as change in current after 
applying a cyclic range of potentials. The parameters extrapolated from the cyclic 
voltammograms were again the magnitude of the anodic peak current (ipa), the cathodic peak 
current (ipc), the anodic peak potential (Epa) and the cathodic peak potential (Epc). 
All the electrochemical measurements were recorded at < 2ppm oxygen level. Anaerobic 
conditions were necessary to focus on the study of the first one electron transfer event of the 
immobilised redox species. In the presence of oxygen the immobilised CYP2C9 would undergo, 
after the first reduction, the formation of the first FeII-dioxygen complex and the whole catalytic 
cycle. 
The range of potentials applied was chosen according to the values at which the redox centres of 
the CYP2C9 haem domain and the BMR reductase domain are reduced. An initial potential 
(0.55V) was changed in a linear manner up to a pre-definite limit (-0.6V) and then reversed to 
the initial value (0.55V) at defined scan rates. The method required optimisation of protein 
concentration in order to obtain a good electrochemical signal. 
The electrolytic solution used contained a high concentration of potassium chloride salt to 
guarantee the conductivity within the electrochemical cell and the monomeric state of the 
engineered enzyme (Dodhia et al., 2006).  
Figure 6.1 shows the cyclic voltammetric measurement (CV) performed on CYP2C9BMR, 
CYP2C9*2BMR and CYP2C9*3BMR immobilised on DDAB modified glassy carbon 
electrodes at 0.1 V/sec of scan rate in anaerobic conditions. 
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Figure 6.1 Cyclic voltammograms of CYP2C9BMR (A), CYP2C9*2BMR (B) and CYP2C9*3BMR (C) 
on a DDAB modified glassy carbon (GC) electrode. The cyclic voltammograms were recorded in the 
absence of oxygen at 20 °C in 50 mM potassium phosphate pH 7.4 containing 500 mM potassium 
chloride at a scan rate of 0.1 V.s-1. 
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Two reversible redox couples were observed for all the investigated chimeras. A first redox 
couple centred at more positive potentials was observed at –46 ± 3, –40 ± 1 and –44 ± 4 mV for 
the CYP2C9BMR/DDAB/GC, CYP2C9*2BMR/DDAB/GC and CYP2C9*3BMR/DDAB/GC 
respectively. A second Faradaic couple centred at -237 ± 3, –214 ± 2 and – 214 ± 4 mV was 
instead observed for the CYP2C9BMR/DDAB/GC, CYP2C9*2BMR/DDAB/GC and 
CYP2C9*3BMR/DDAB/GC respectively. All these potential values were calculated versus the 
saturated calomel electrode (SCE) and then normalised versus the normal hydrogen electrode 
(NHE) for a direct comparison with literature values. As shown in figure 5.3 the same 
experiment was performed on a protein-free DDAB modified glassy carbon electrode and no 
redox response was observed. This result confirms how the observed electrochemical signal 
corresponds to the redox centre of the immobilised enzyme.  
According to a previous study on the redox properties of the immobilised cytochrome 
P450BM3 (CYP102), the redox couples observed in each CV of figure 6.1 should correspond to 
the redox centres of the two domains of the chimeras. The couple of peaks centred at more 
positive potentials represents the human CYP2C9, CYP2C9*2 and CYP2C9*3 haem domain, 
while the couple centred at more negative potential values corresponds to the flavinic cofactors 
(FAD/FMN) of the BMR reductase domain (Fleming et al., 2003). Similarly to the present 
study, Fleming and co-workers immobilised the P450 BM3 on an edge-plane pyrolytic graphite 
electrode modified with DDAB. The protein immobilisation occurred upon immersion of a pre-
formed DDAB film in a CYP102 solution. Two redox couples centred at about –8 and –146 mV 
versus NHE were observed and assigned to the CYP102 haem domain and FAD cofactor.  
To further confirm the nature of the second redox couple, a CV of an FMN containing protein 
immobilised in the same conditions was performed. Figure 6.2 shows the CV of the 
FMN/DDAB/GC electrode where a redox couple centred at -227 mV can be observed. This 
reduction potential is very close to the one observed for all the second peaks of the immobilised 




Figure 6.2 Cyclic voltammogram of a FMN redox centre on a DDAB modified glassy carbon (GC) 
electrode. The cyclic voltammogram was recorded in the absence of oxygen at 20 °C in 50 mM potassium 
phosphate pH 7.4 containing 500 mM potassium chloride at a scan rate of 0.1 V.s-1. 
 
 
A progressive decrease in the current signal of the second peak corresponding to the reductase 
domain of the construct was observed after multiple cyclic scans. The change in peak intensity 
could be assigned to either the denaturation of the protein at the electrode surface or the 
reorganisation of the CYP2C9BMR-DDAB film at the electrode/solution interface. The 
reductase domain could take an initial preferential orientation close to the surface and then 
rotate far away from the surface at an unfavourable electron transfer position (Fleming et al., 
2003). 
Table 6.1 contains a list of all the electrochemical parameters extrapolated from the CVs. The 
peak-to-peak separations are higher than those observed for the N-terminally modified CYP2C9 
immobilised on DDAB/GC electrodes (table 5.1). The higher distance between the reduction 
and oxidation peaks could be due to the co-presence of more than one redox centre in the bigger 
chimera and therefore a higher number of possible orientations on the surface. The cathodic-to-
anodic peak current ratios were 0.9, 0.6 and 0.7 for the CYP2C9BMR, CYP2C9*2BMR and 







Table 6.1 List of electrochemical parameters extrapolated from the cyclic voltammetric experiments 





 Emid which is the midpoint of the anodic (Epa) and cathodic (Epc) peak potentials  
  ‡ 
∆E which is the peak-to-peak separation (Epa-Epc)  
  • ipc/ipa which is the cathodic-to-anodic peak current ratio 
 
Integration of the I-E curve gives the number of electrons transferred and hence direct 
calculation of the electrode coverage. Integration of the anodic peak area in the voltammograms 
showed an average surface coverage (Γ) of 3.10x10-11, 2.91x10-11 and 3.11x10-11 mol/cm2 for the 
CYP2C9BMR/DDAB/GC, CYP2C9*2 BMR/DDAB/GC and CYP2C9*3 BMR/DDAB/GC 
respectively. These areas correspond to an immobilised film of about 5 multi-layers of enzyme 
though it is necessary to remember the porous structure of the glassy carbon.  
Experiments at different scan rates were performed to check the linearity between the peak 
current and the scan rate. Straight lines were fitted for both the oxidation and reduction peak 
current points thus revealing a good electron transfer and a surface controlled process between 
the enzymes and the electrode surfaces (figure 6.3). The linearity of the plots gave evidence that 
all the wild type and allelic variants of the BMR chimeras were successfully immobilised onto 
the electrode surface. 
Enzyme modification Emid (V)*  vs NHE ∆E (mV)‡ ipc/ipa• 
CYP2C9BMR/DDAB/GC – 0.046 ± 0.003 0.092 ± 0.006 0.9 
 
– 0.237 ± 0.004   
CYP2C9*2BMR/DDAB/GC – 0.040 ± 0.001 0.080 ± 0.001 0.6 
 
– 0.214 ± 0.004   
CYP2C9*3BMR/DDAB/GC – 0.044 ± 0.004 0.087 ± 0.008 0.7 




Figure 6.3 Plot of the peak height vs. scan rate (V/s) for the 2C9BMR (A), CYP2C9*2BMR (B) and 
CYP2C9*3BMR (C) immobilised on DDAB modified glassy carbon electrodes. Experiments recorded in 




In the literature the presence of a P450 FeIII/FeII redox couple has been confirmed by cyclic 
voltammetric experiments in a CO saturated buffer. CO is known to bind specifically as a sixth 
ligand to the reduced haem iron of cytochromes P450, causing a shift of the peaks towards more 
positive values. Positive shifts in the midpoint potential of the haem iron, upon binding carbon 
monoxide have been reported for the CYP102 (P450
 
BM3) immobilised at DDAB modified 
edge plane pyrolytic graphite electrodes, the haem domain of CYP102 immobilised at 
DDAB/PSS (polystyrene sulphonate) modified base plane graphite electrodes and the human 
CYP2C9 immobilised at DDAB modified edge plane pyrolytic graphite electrodes (table 6.2). 
 
Table 6.2 List of studies on the cyclic voltammetric characterisation of cytochromes P450 in the presence 
of carbon monoxide. ∆E is the shift of the mid point potential of the haem redox centre when the cyclic 











However, as explained in chapter 4, the shift of the mid point potential in the presence of CO is 
only indicative of the presence of a haem redox centre and it does not give any information on 
the P450 active or P420 inactive state of the immobilised enzyme.  
Taking into account all these considerations, cyclic voltammetric experiments in a CO saturated 
buffer were performed and a shift of the mid point potential towards more positive values was 
observed for all the variants. An increase of the mid point potential of approximately 90, 81 and 
63 mV was observed for the CYP2C9BMR, CYP2C9*2BMR and CYP2C9*3BMR respectively 
(figure 6.4). These results confirmed the electron exchange between the protein and the 
electrode, the origin of the observed response from the haem domain of the immobilised 
cytochrome P450 and the correct incorporation of the haem within the folded polypeptide chain. 
Moreover the fact that only the redox couple centred at more positive potential shifted in the 
presence of CO is a further confirmation of its haem domain identity.  
Enzyme modification 
∆E  in the 
presence of carbon 
monoxide (mV) 
Reference 
CYP102/DDAB/EPPG  +50 Fleming et al., 2003 
CYP102/DDAB/PSS/ EPPG +55 Udit et al., 2005 





Figure 6.4 Cyclic voltammograms of the CYP2C9BMR (A), CYP2C9*2BMR (B) and CYP2C9*3BMR 
(C) on a DDAB modified glassy carbon electrodes. Experiments recorded in the absence of oxygen and in 
the presence of CO at 20°C in 100mM potassium phosphate pH 7.4 at a scan rate of 0.1 V/s. 
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The haem redox couples of the CYP2C9BMR, CYP2C9*2BMR and CYP2C9*3BMR were all 
sensitive to the presence of oxygen in the buffer, as can be seen from figure 6.5. The large 
catalytic current observed in fully oxygenated buffer is due to the electrocatalytic reduction of 























Figure 6.5 The effect of oxygen on the cyclic voltammograms of CYP2C9BMR (A), CYP2C9*2BMR 
(B) and CYP2C9*3BMR (C) immobilised on DDAB modified glassy carbon electrodes. All CVs were 
recorded at a scan rate of 0.1 V.s-1 at 25 °C in 50 mM potassium phosphate pH 7.4 containing 500 mM 
potassium chloride.  
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6.2.2 Electrochemical characterisation of the CYP2C9FLD, CYP2C9*2FLD AND 
CYP2C9*3FLD on glassy carbon electrodes 
 
The direct electrochemistry of CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD was 
performed following the same approach described in section 6.2.1. The CYP2C9FLD construct 
was obtained through the fusion of a N-terminally modified human CYP2C9 and flavodoxin, a 
small electron transfer protein from Desulfovibrio vulgaris. The 3 amino acid linker (Pro-Arg-
Ser) and the unique Avr II restriction site were the same used for the construction of 
CYP2C9BMR chimera. Similarly to the N-terminal modified CYP2C9, the CYP2C9FLD 
contained modifications to remove the N-terminal membrane anchor and favour the holo protein 
expression. The genetic fusion of the CYP2C9 haem domain with the soluble flavodoxin had 
the scope to improve the solubility of the whole construct and to have a module able to regulate 
the flow and transfer of electrons from the electrode to the P450 redox centre. The 
CYP2C9FLD chimera also has a six residue C-terminal histidine tag to facilitate the purification 
process. 
Cyclic voltammetry was the technique of choice for investigating the electrochemical properties 
of the immobilised enzymes. The CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD were 
immobilised on DDAB (didecyldimethylammonium bromide) modified glassy carbon 
electrodes. The protocol used for the immobilisation of the proteins was the same applied to the 
BMR chimeras. Different protein concentrations were used and tested to obtain a good 
electrochemical signal. The use of DDAB as immobilisation matrix was suggested by the results 
discussed in chapter 5 where the CYP2C9 showed improved catalytic performance and less 
conformational changes compared to other modifiers. 
The electrochemical characterisation was performed in anaerobic conditions at < 2ppm oxygen 
level to follow the first reduction of the haem iron during the catalytic cycle (section 1.12). The 
cyclic range of potentials applied was the same of the BMR chimeras between 0.55V and –
0.6V.  
Figure 6.6 shows the cyclic voltammograms recorded for the CYP2C9FLD, CYP2C9*2FLD 
and CYP2C9*3FLD immobilised on the DDAB modified glassy carbon electrodes. Table 6.3 
shows the list of the electrochemical parameters experimentally calculated. The parameters 
extrapolated from the CV are the magnitude of the anodic peak current (ipa), the cathodic peak 









Figure 6.6 Cyclic voltammograms of the CYP2C9FLD (A), CYP2C9*2FLD (B) and CYP2C9*3FLD (C) 
on a DDAB modified glassy carbon electrodes. Experiments recorded in the absence of oxygen and in the 
presence of CO at 20°C in 100mM potassium phosphate pH 7.4 at a scan rate of 100mV/s. 
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Table 6.3 Electrochemical parameters extrapolated from the cyclic voltammetric experiments on 









 Emid which is the midpoint of the anodic (Epa) and cathodic (Epc) peak potentials  
  ‡ 
∆E which is the peak-to-peak separation (Epa-Epc)  
  • ipc/ipa which is the cathodic-to-anodic peak current ratio 
 
Integration of the anodic peak area in the voltammograms showed an average surface coverage 
(Γ) of 7.42x10-11, 1.01x10-10 and 9.56x10-11 mol/cm2 for the CYP2C9FLD/DDAB/GC, 
CYP2C9*2FLD/DDAB/GC and CYP2C9*3FLD/DDAB/GC respectively. This coverage 
corresponds to about 15 multi-layers of enzyme immobilised on the surface. 
As already stated all the electrode responses were dominated by one reversible redox couple 
centred at –39mV for the 2C9FLD, -44 mV for the 2C9*2FLD and –50 mV for the 2C9*3FLD. 
All these potentials were calculated versus the saturated calomel eletrode (SCE) and then 
normalised versus the normal hydrogen electrode (NHE).  
The second redox couple corresponding to the flavodoxin domain of the 2C9FLD chimera was 
not observed. The hypothesis that the peaks corresponding to the flavodoxin are buried under 
the oxidation and reduction peaks of the haem domain is ruled out by the cyclic voltammogram 
of the FMN redox centre containing enzyme shown in the previous section (figure 6.2). The 
orientation of the enzyme on the surface could be responsible for the lack of this signal. DDAB 
is a cationic surfactant comprising a positively charged dimethyl-ammonium head group 
capable of electrostatic interaction with negatively charged surface residues at the GC surface, 
and a hydrophobic didodecyl tail group moiety capable of mimicking the environment of a 
biological membrane. The positively charged head groups are likely to strongly adsorb on the 
negatively charged glassy carbon surface, leaving the hydrophobic tails on the opposite side 
available for interaction with the hydrophobic 2C9 haem domain. The small flavodoxin could 
therefore be positioned at a distance from the surface that could comprise the effective electron 
transfer. 
Moreover another theory is that the orientation of the protein on the surface is influenced by the 
three positively charged histidine of the His-tag located at the end of the flavodoxin domain for 
purification purposes. The repulsion between the positively charged tag and the positively 
Enzyme modification Emid (V)*  vs NHE ∆E (V)‡ ipc/ipa• 
CYP2C9FLD/DDAB/GC – 0.039 ± 0.011 0.082 ± 0.025 0.8 
CYP2C9*2FLD/DDAB/GC – 0.044 ± 0.030 0.134 ± 0.015 1 
CYP2C9*3FLD/DDAB/GC – 0.050 ± 0.036 0.102 ± 0.037 1 
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charged DDAB could orient the chimera in a way that the FLD domain is positioned at a certain 
distance from the surface and therefore not able to exchange electrons with the surface. 
As shown in chapter 5, the cyclic voltammetric experiment performed under the same condition 
on a protein-free DDAB modified electrode did not show any redox peaks (figure 5.3). The 
observed signal can only be associated with the redox centre of the immobilised haem domain.  
In terms of protein immobilisation, the CVs performed at different scan rates allowed 
investigation of whether the enzyme is actually immobilised or not onto the electrode surface. 
The linearity of the plots of the change in current (I) versus the scan rate (υ) for both the 
oxidation and reduction peaks confirmed a surface controlled electron transfer process between 
the enzymes and the electrode. The results confirmed the successful immobilisation of all the 





















Figure 6.7 Plot of the peak height vs. scan rate (V/s) for the 2C9FLD (A), CYP2C9*2FLD (B) and 
CYP2C9*3FLD (C) on a DDAB modified glassy carbon electrode. Experiments recorded in the absence 
of oxygen at 20°C in 100mM potassium phosphate pH 7.4 at different scan rates (50mV/s to 20 V/s). 
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To confirm that the observed response was originated by the haem domain of the immobilised 
CYP2C9FLD chimeras, cyclic voltammograms were recorded in a carbon monoxide saturated 
buffer. As previously mentioned, this assay has so far been used to identify the presence of a 
FeII/FeIII species. When correctly incorporated, the reduced haem iron binds the CO as a sixth 
ligand, forms a complex and gives a shift of the mid point potential towards more positive 
values (Fleming et al., 2003; Udit et al., 2005; Johnson et al., 2005). The expected positive shift 
was observed in the mid point potential of all the chimeras. Change in potentials of +80 mV, 
+75 mV and +70 mV were observed for the 2C9FLD, 2C9*2FLD and 2C9*3FLD respectively 
(figure 6.8). However as explained in chapter 5 this change in potential is only indicative of the 
presence of a redox FeII/FeIII centre and it does not give information about the active P450 or 






















Figure 6.8 Cyclic voltammograms of the CYP2C9FLD (A), CYP2C9*2FLD (B) and CYP2C9*3FLD (C) 
on DDAB modified glassy carbon electrodes. Experiments recorded in the absence of oxygen and in the 
presence of CO at 20°C in 100mM potassium phosphate pH 7.4 at a scan rate of 100mV/s. 
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The haem redox couples of the CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD were all 
sensitive to the presence of oxygen in the buffer, as can be seen from figure 6.9, and the large 
catalytic current observed in fully aerated buffer is due the electrocatalytic reduction of oxygen 























Figure 6.9 The effect of oxygen on the cyclic voltammograms of CYP2C9FLD (A), CYP2C9*2FLD (B) 
and CYP2C9*3FLD (C) immobilised on DDAB modified glassy carbon electrodes. All CVs were 
recorded at a scan rate of 0.1 V.s-1 at 25 °C in 50 mM potassium phosphate pH 7.4 containing 500 mM 
potassium chloride.  
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6.3 Rotating disk electrodes measurements: determination of the 
number of electrons used in dioxygen reduction  
 
During the seven steps of the catalytic cycle of cytochromes P450, the initial P450 resting state 
form is converted to a final high valent iron-oxo complex. The final reactive intermediate, also 
called “Compound I”, is responsible for the conversion of a substrate to its corresponding 
product. The life time of this iron-peroxy species is fundamental to guarantee an efficient 
product turnover and avoid secondary undesired uncoupling reactions.  
In the absence of substrate the full conversion of the catalytic intermediates to the “Compound 
I” requires four electrons and leads to the formation of water from dioxygen molecules. When 
the number of electrons utilized in the dioxygen reduction is lower than four, this is an 
indication of anomalies in the completion of the catalytic cycle. These anomalies can be 
represented by uncoupling reactions that can take place at specific points of the catalytic cycle 
causing formation of undesired products and waste of electrons (chapter 1) 
By identifying the number of electrons consumed by the three chimeras when they react with 
oxygen, it is possible to evaluate the catalytic performances of the haem redox centre before the 
addition of substrate.  
The number of electrons (n, eq mol-1) transferred in faradaic reactions like the reduction of the 
haem redox centre of cytochromes P450 can be measured at Rotating Disk Electrode (RDE) by 
applying the Koutechy-Levich equation (Treimer et al., 2002). Applications of rotating disk 
electrodes to study the electrode kinetics and mechanisms are well documented and include a 
number of advantages. The rate of mass transport of reactants to a RDE surface is controlled 
precisely by fixing the rotational velocity (ω) of the electrode. Moreover the electrode current 
quickly achieves steady-state values and it is insensitive to incidental vibrations of the 
apparatus.  
A pre-requisite to perform electrochemical experiments at RDE is to have a robust protein film 
resistant to mechanical stress like high-speed rotations. 
Experiments were performed on CYP2C9/DDAB/GC, CYP2C9FLD/DDAB/GC and 
CYP2C9BMR/DDAB/GC electrodes, but, since the film showed to be unstable at high rotation 
speed, an alternative method of immobilisation was then applied. Following a published 
method, the CYP2C9, CYP2C9BMR and CYP2C9FLD were immobilised on a film resulting 
from the combination of a surfactant and a polyanion, the didodecyldimethylammonium 
polystyrenesulfonate (DDAPSS) (Udit et al., 2006). 
Figure 6.10 shows the cyclic voltammograms (CVs) recorded at pH 7.4 for the 
CYP2C9/DDAPSS/GC, CYP2C9BMR/DDAPSS/GC and CYP2C9FLD/DDAPSS/GC 
electrodes.  
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Table 6.4 summarizes the midpoint potentials measured in an oxygen-free environment for all 
the CYP2C9/DDAPSS/GC, CYP2C9BMR/DDAPSS/GC and CYP2C9FLD/DDAPSS/GC 
electrodes. 
The Emid extrapolated from the CVs were –21 ± 4, –39 ± 5 and –33 ± 4 V for the 
CYP2C9/DDAPSS/GC, CYP2C9BMR/DDAPSS/GC and CYP2C9FLD/DDAPSS/GC 
electrodes respectively. These values correspond to the haem FeII/FeIII redox centre as confirmed 
























Figure 6.10 Cyclic voltammograms of the CYP2C9BMR (A), CYP2C9 (B) and CYP2C9FLD (C) on 
DDAPSS modified glassy carbon electrodes. Experiments were recorded in the absence of oxygen at 
20°C in 100mM potassium phosphate pH 7.4 at a scan rate of 0.1 V/s. 
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Table 6.4 Electrochemical parameters extrapolated from the cyclic voltammetric experiments on 










The comparison between the Emid of all the constructs immobilised in the DDAPSS and DDAB 
surfactants showed how the CYP2C9FLD and CYP2C9WT maintain the same reduction 
potential in both immobilisation systems. The change in counter-ion from Br¯ to PSS¯ did not 
significantly alter the Emid of these two chimeras. Instead the CYP2C9BMR showed a change in 
its reduction potential. However the lack of the peak corresponding to the FMN cofactor 
indicates a change in the orientation of the CYP2C9BMR on the surface. The bigger dimension 
and the different charge distribution of the BMR domain compared to the FLD domain probably 
render the 2C9BMR more sensitive to counter ion with different electro-negativity like Br- and 
PSS-. 
Electrolysis on the CYP2C9/DDAPSS/GC, CYP2C9BMR/DDAPSS/GC and 
CYP2C9FLD/DDAPSS/GC electrodes was then performed by applying a fixed potential of -
0.65V at different rotation rates. The limiting current or steady-state current was measured at 
each rotation rate. According to the Levich equation for a fast-electron transfer process when 
solely the mass transfer process controls the reduction of the redox species at the surface 
electrode, the relationship between the limiting current and rotation speed can be visualized as 
plot of il (limiting current) versus ω1/2 (rotation speed) and should be a straight line. 
Figure 6.11 shows the Levich plots for all the CYP2C9/DDAPSS/GC, 
CYP29BMR/DDAPSS/GC and CYP2C9FLD/DDAPSS/GC electrodes.  
Enzyme modification Emid (V)*  vs NHE 
(oxygen-free) 
Emid (V)*  vs NHE 
(oxygen saturated) 
CYP2C9BMR/DDAPSS/GC – 0.021 ± 0.004 - 0.013 ± 0.006 
CYP2C9FLD/DDAPSS/GC – 0.039 ± 0.005 -0.060 ± 0.003 




Figure 6.11 Levich plots for the CYP2C9FLD (A), CYP2C9BMR (B) and CYP2C9WT immobilised on 
DDAPSS modified glassy carbon electrodes. The individual points and broken lines represent the 
experimental data and lines derived from the fitting of the experimental data. Experiments recorded on a 
rotating disk electrode in the presence of oxygen at 20°C in 100mM potassium phosphate pH 7.4 at 
different scan rates. The doted line is the trend line showing the non linearity of the points. 
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The experimental data points show that for all the constructs the limiting currents appear to 
level off at high rotation rates. The non linear trend of the data points indicated that the 
dioxygen reduction is limited by a second event occurring at the electrode surfaces. In this case 
the electron transfer is not the limiting step but a second event is the kinetics of oxygen 
reduction. For this reason it is necessary to use the Koutechy-Levich equation which is an 
elaboration of the previous one for slow electron transfer processes. The Koutechy-Levich plots 
for all the CYP2C9/DDAPSS/GC, CYP2C9BMR/DDAPSS/GC and 
CYP2C9FLD/DDAPSS/GC electrodes are shown in figure 6.12 and they are represented as 
































Figure 6.12 Koutechy-Levich plots for the CYP2C9FLD (C), CYP2C9BMR (B) and CYP2C9WT (A) 
immobilised on DDAPSS modified glassy carbon electrodes. The individual points, solid lines and 
broken lines represent experimental data, lines derived from the fitting of the experimental data and 
theoretical lines. Experiments recorded on a rotating disk electrode in the presence of oxygen at 20°C in 
100mM potassium phosphate pH 7.4 at different scan rates. iL is the measured limiting current and ω the 




The Koutechy-Levich plots were linear for all the CYP2C9/DDAPSS/GC, 
CYP2C9BMR/DDAPSS/GC and CYP2C9FLD/DDAPSS/GC electrodes, with slopes yielding 
an n value or number of electrons consumed of 2.22 ± 0.19, 1.04 ± 0.26 and 3.53 ± 0.17. Table 
6.5 summarizes the calculated parameter.  
 
 
Table 6.5 The number of electrons used in dioxygen reduction by CYP2C9BMR, CYP2C0FLD and 







The intercepts of the Koutechy-Levich plots were used to calculate the kinetic currents (ikin) that 
limit the electrode reaction. These currents vary linearly with protein concentration and can be 
used to extrapolate the second-order rate constant that governs the current-limiting reaction 
(kobs): 
ikin = nFA[O2]ΓP450kobs 
(where ΓP450 is the surface concentration of protein). Values of kobs equal to 6.3x109, 9.6x108 and 
2.6x109 s-1 were obtained for the CYP2C9BMR, CYP2C9FLD and CYP2C9WT respectively. 
As explained in chapter 1, the catalytic reduction of oxygen by P450 contains three potential 
reactions, normally addressed as uncoupling reactions that use different numbers of electrons. 
The reduction of oxygen to superoxide radicals uses one electron, the reduction of oxygen to 
hydrogen peroxide uses two electrons and the formation of water requires four electrons. The 
measurement of the number of electrons used per catalytic cycle gives an indication of which of 
these roots is preferentially taken by a specific construct. 
The CYP2C9BMR consumed only one electron per cycle and therefore it looks like its cycle 
has been stopped to complex 3 that can then autoxidate back to complex 1 and form oxygen 
radicals. The CYP2C9WT consumed two electrons per cycle and therefore it looks like its cycle 
has been stopped to complex 5 that then protonates and forms hydrogen peroxide. The 
CYP2C9FLD appears to be the construct with the higher probability to reach compound I. The 
consumption of 3.5 electrons could mean that while one portion of the immobilized enzyme 
dissociates the iron-peroxy species to peroxide, the other portion converts this intermediate to 
Compound I, which is then reduced by a further two electrons to water. It can be concluded that 
an increase in the number of electrons utilized in the dioxygen reduction is indicative of longer 
lived iron-peroxy species (Dodhia et al., 2008; Udith et al., 2005). The longer life of this iron-
Enzyme modification Number of electrons consumed 
CYP2C9BMR/DDAPSS/GC 1.04 ± 0.26 
CYP2C9FLD/DDAPSS/GC 3.53 ± 0.17 
CYP2C9WT/DDAPSS/GC 2.22 ± 0.19 
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peroxy species means that among all studied constructs the CYP2C9FLD is the one with more 
chances to convert a reacting substrate to product. 
However since this assumption is based on the reaction of the enzyme with dioxygen and not 
with substrate, electrocatalysis in the presence of a substrate were performed. A fixed reduction 
potential was applied for a certain period of time after addition of S-warfarin. The obtained 
electrolytic solution was then injected into an HPLC system to separate, identify and quantify 
the expected 7-OH warfarin product formed.  
Table 6.6 summarizes the results of the cataytic experiments. An estimation of the coupling was 
given as ratio between the current consumed during the experiment and the current 
corresponding to the amount of product formed. The results confirmed the previous assumptions 
as the CYP2C9FLD was confirmed to be the construct with the higher catalytic activity and the 
CYP2C9BMR the one with the lower.  
 
Table 6.6 The amount of 7-hydroxy warfarin formed by CYP2C9FLD/DDAB/GC, 
CYP2C9WT/DDAB/GC CYP2C9BMR/DDAB/GC electrodes (the values have been subtracted of the 




As the results gave evidence of the better catalytic performance of CYP2C9FLD compared to 
the other available constructs, the CYP2C9FLD chimera was selected for further investigations.  
 
6.4 pH dependence studies on the FLD chimeras 
 
The influence of pH on the haem redox potential was measured on the CYP2C9, CYP2C9*2 
and CYP2C9*3. A pH-dependent potential change has already been observed for haem-
containing proteins immobilized at electrode surfaces. This potential shift is in accordance with 
a mechanism whereby protonation or deprotonation accompany the reduction event. In 
particular, for a reversible one-electron transfer coupled to a single proton transfer, a change of 
–59 mV per pH unit is expected. In our experimental conditions the mid point potential became 
increasingly more negative as the pH was increased from 5 to 10. Straight lines with slopes of 





Coupling efficiency  
(%) 
CYP2C9FLD/DDAPSS/GC 2.16 ± 0.78 7.39 ± 2.66 1.47 ± 0.47 
CYP2C9WT/DDAPSS/GC 1.37 ± 0.01 6.60 ± 0.01 0.87 ± 0.23 
CYP2C9BMR/DDAPSS/GC Not detectable Not detectable Not detectable 
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44, 40 and 46 mV per pH unit were observed for the 2C9FLD, 2C9*2FLD and 2C9*3FLD 




Figure 6.13 Plots of the midpoint potentials versus pH. The graphs represent the pH-dependence of the 
midpoint potentials measured for the CYP2C9FLD (A), CYP2C9*2FLD (B) and CYP2C9*3FLD 
constructs. The data have then been fitted to a linear equation. 
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The ferrous P450 protonation site remains to be established, but, as suggested in another study 
on the direct electrochemistry of enzymes from the cytochrome P450 2C family, it must be a 
strong base as there is no variation from linearity up to the highest pH examined (Shukla et al., 
2005). Protonation of amino acid residues close to the haem or protonation of the haem 
propionate group can be cause of the pH dependent haem redox potentials. Given to the 
apparent high pKa of the reduced form of each protein, hydroxide appears a possible candidate 
base that is produced under reduction. It is possible that this hydroxide is released from the 
distal (sixth) coordination site upon reduction to give a five-coordinate ferrous haem that is 
protonated, but remains ligated, i.e., affording a six-coordinate aqua-ferrous haem (Shukla et al., 
2005). 
From the data it appears that the single nucleotide mutations of the allelic variants do not have 
any effect on the aminoacids close to the haem redox centre and responsible for the pH-
dependent shift.  
 
6.5 Enzymatic studies on the FLD chimeras 
 
6.5.1 Titrations in the presence of a specific substrate 
 
In the previous sections the successful electron transfer between the immobilized enzymes and 
the electrode has been characterised. The CYP2C9FLD has been identified as one of the most 
efficient construct in terms of catalytic activity. Further investigations on the activity of the 
CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD variants immobilised on an electrode have 
been carried out to assess if the different catalytic activity observed in vivo between the 
polymorphic variants was also observed in an in vitro immobilised system. These data would 
confirm the feasibility of building a P450 based amperometric sensor for the selection of drugs 
according to their different level of interaction with the polymorphic variants of CYP2C9.  
As shown in other studies, cyclic voltammetry and amperometry can be used to study the 
catalytic behaviour of immobilised P450 enzymes (Joseph et al., 2003; Fantuzzi et al., 2004). In 
these studies the addition of a specific substrate had an effect on the electroactivity of the 
immobilised P450. Voltammograms showed a markedly increase in the catalytic reduction 
current upon addition of substrate. The increase in catalytic current reflects an increase in the 
turnover of dyoxygen and suggests that the substrate is metabolized by the reduced P450 
enzyme, which is in turn re-oxidated for the next catalytic cycle. A similar substrate 
concentration-dependent change in current can be observed using amperometry, a technique that 
monitors change in current when applying a fixed potential. If the reaction for these substrates 
follows Michaelic-Menten kinetics, apparent Km values can be calculated from the voltammetric 
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and amperometric data. Changes in reduction currents dependent on substrate concentration 
represent the amperometric sensor transduction. 
As previously mentioned, Joseph and co-workers applied this approach on the human CYP3A4 
immobilized on polycation modified gold electrodes. The apparent Km of different substrates 
was measured and the product formation was confirmed by LC-MS analysis.  
Since during its catalytic cycle the cytochrome P450 reduces oxygen to hydrogen peroxide, 
superoxide dismutase and catalase were added to control the contribution of reactive oxygen 
species to the formation of metabolites (Joseph et al., 2003). 
In another work on CYP2E1 either adsorbed on polycation or surfactant modified glassy carbon 
electrodes, the catalytic activity of the immobilized enzyme was confirmed after spectroscopical 
identification of the product. To test the ability of the system to work as an amperometric 
sensor, the modified gold electrode was titrated with p-nitrophenol showing a response in a 
Michaelis-Menten fashion (Fantuzzi et al., 2004). 
A similar approach was then applied to the 2C9FLD, 2C9*2FLD and 2C9*3FLD immobilised 
on the DDAB modified electrode. As expected in the oxygenated buffer the reduction peak 
increased and the oxidation peak disappeared.  
However the electrochemical signal disappeared after repetitive scans (figure 6.14). Either the 
mechanical desorption of the protein film or the denaturation of the protein structure caused by 















Figure 6.14 Repetitive cyclic voltammograms recorded on a 2C9FLD DDAB modified glassy carbon 
electrode in an oxygenated 100mM potassium phosphate buffer pH 7.4 at 20°C at a scan rate of 0.1V/s. 
The gray line represents the first CV recorded, while the black line represents the tenth scan.   
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In order to control the formation of the hydrogen peroxide and radicals, experiments were 
repeated in the presence of catalase and superoxide dismutase either added in the electrolytic 
buffer or co-immobilised in the protein layer. No improvement was observed and therefore the 
mechanical instability of the protein layer was considered as the main responsible for the 
decrease in the measured current signal. 
In order to improve the mechanical stability of the protein surfactant film a layer of Nafion was 
deposited above the protein layer. Figure 6.15 shows the structure of the sulfonated 
tetrafluorethylene copolymer Nafion, a compound that can take a micellar structure when 









Figure 6.15 Chemical structure of Nafion, a sulfonated tetrafluorethylene copolymer with ionic 
properties as a result of incorporating perfluorovinyl ether groups terminated with sulfonate groups onto a 
tetrafluoroethylen (Teflon) backbone. 
 
 
Figure 6.16 shows how the current of the 2C9FLD/Nafion/DDAB/GC electrode remained stable 
after several scans (figure 6.16B). A CV of the Nafion/DDAB/GC electrode was measured to 











Figure 6.16 (A) Cyclic voltammograms recorded on a 2C9FLD/DDAB/GC electrode (grey line) and 
DDAB/GC electrode (black line) in an oxygenated 100 mM potassium phosphate buffer pH 7.4 at 20°C 
at a scan rate of 0.05 V/s. (B) Repetitive CVs recorded in the same buffer and at the same scan rates. 
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However, the Nafion in its micellar conformation has a porous structure whose charge can 
decrease the permeability of positively charged molecules. According to numerous studies, the 
physical and chemical properties of these structures can be tailored by incorporating quaternary 
ammonium bromide salts (Moore et al., 2004). The quaternary ammonium salts can exchange 
their cations with the protons of the sulfonic acid groups thus modifying the size and mass 
transport capacity of the layer. 
Different quaternary ammonium salts were then mixed to the nafion solution and their effect on 
the membrane accessibility was tested by using two electroactive compounds: the positively 
charged hexaammine ruthenium III chloride and the negatively charged potassium ferricyanide 
(Takehara et al., 1994). Both these compounds are able to give an electrochemical signal which 
is proportional to the uncovered surface of the glassy carbon electrode. As shown in figure 6.17, 
before adding the salts, the untreated Nafion/GC electrode was completely impermeable to the 
positively charged ruthenium and permeable to the negatively charged ferricyanide. After 
treating with tetraethylammonium bromide the membrane changed its properties and become 


















Figure 6.17 (A) Cyclic voltammograms recorded on a Nafion/GC electrode in a Potassium ferricyanide 
buffer (B) Cyclic voltammograms recorded on a Nafion/GC electrode in a 0.1M Hexaammine ruthenium 
III chloride buffer (C) Cyclic voltammograms recorded on a Nafion/tetraethylammonium bromide GC 
electrode in a Potassium ferricyanide buffer (D) Cyclic voltammograms recorded on a 
Nafion/tetraethylammonium bromide GC electrode in a Hexaammine ruthenium III chloride buffer. All 




Once the permeability of the film has been modified, increasing concentrations of different 
substrates were added to the reduced CYP2C9FLD/Nafion/DDAB/GC electrode. Diclofenac, 
tolbutamide and S-warfarin were tested but no consistent and reproducible results were 
obtained.  
Nevertheless, electrolysis with saturating concentration of diclofenac was tested. A fixed 
negative potential was applied for 30 minutes and a saturating concentration of diclofenac was 
added into the electrocatalytic solution. At the end of the experiment the reaction solution was 
injected into an LC-MS system to investigate if the CYP2C9/Nafion/DDAB/GC electrode was 
able to metabolise the drug and form its corresponding metabolic product. The presence of the 
4-hydroxy diclofenac, which is the expected physiological product of diclofenac hydroxylation 
by CYP2C9, was confirmed (figure 6.18). The identity of the ion with m/z 312 was confirmed 
by multiple fragmentations (figure 6.19). 
 
Figure 6.18 LC-MS analysis of the electrolysis reaction of the sample electrode 
(2C9FLD/Nafion/DDAB/GC) and control electrode (Nafion/DDAB/GC) with diclofenac. (A)  Selected 
ion trace chromatograms at m/z 312 for the sample reaction. (B) Selected ion trace chromatograms at m/z 
312 for the control reaction. The electrolysis was performed by applying a fixed potential of -0.65V for 
30 minutes in presence of diclofenac. Analysis preformed on an IT-TOF (Shimadzu) instrument and C-18 








Figure 6.19 Spectral tree of MS1 spectrum with m/z of 312.02. (A) Spectrum of the peak corresponding 
to the 4-OH diclofenac. (B) First fragmentation: MS2 of the ion m/z 312.02. (C) Second fragmentation: 
MS3 of the parent ion m/z 231.046. (D) Chemical structure of the 4-OH diclofenac (exact mass: 312.02) 
and its two fragments (exact mass: 167.01 and 195.04). 
 
However even if the immobilised protein resulted to be more stable and catalytically active, it 
was difficult to control the effective concentration of substrate permeated through the film. For 
this reason the 2C9FLD/Nafion/DDAB/GC set-up remains problematic if the final aim is to 
have a system for the full metabolic characterization of new chemical entities.  
 
6.5.2 Chronoamperometry in the presence of a specific substrate 
 
In the previous sections the CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD immobilised on 
DDAB modified glassy carbon electrodes showed to be catalytically active towards molecular 
oxygen. The catalytic activity towards substrates was then tested on the 
CYP2C9FLD/DDAB/GC, CYP2C9*2FLD/DDAB/GC and CYP2C9*3FLD/DDAB/GC 
electrodes.  
Substrate turn-over studies using the protein modified electrodes were carried out as described 
in section 2.2.9. The CYP2C9FLD/DDAB/GC, CYP2C9*2FLD/DDAB/GC and 
CYP2C9*3FLD/DDAB/GC electrodes were reduced after applying a fixed negative potential 
for 30 minutes in the presence of S-warfarin, which is a well known specific substrate for the 
human CYP2C9 (Kaminsky et al., 1997). 
This substrate is frequently used to characterise the in vitro hydroxylase activity of the human 
CYP2C9 and its two allelic variants CYP2C9*2 and CYP2C9*3. Moreover to exclude the direct 
participation of radicals and hydrogen peroxide on the formation of the substrate, catalase and 
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superoxide dismutase were added in catalytic amounts (1-2 units) in the reaction buffer and also 
co-immobilised with the protein. 
Table 6.7 summarizes the amounts of 7-OH warfarin formed by all the investigated chimeras in 
the experimental conditions indicated above. The amount of electroactive species at the 
electrode surface was measured as described in section 2.2.9. The amount of product formed by 
the protein-free DDAB modified glassy carbon electrode was subtracted from the total amount 
of product identified. 
 
Table 6.7 The amount of product formed (pmoles per pmole of P450) by the N-terminally modified 




Enzyme modification Vmax / pmol 7-hydroxy 
warfarin/min/pmol P450 % coupling 
CYP2C9FLD/DDAB/GC 18.23 ± 1.29 12.67 ± 2.33 
CYP2C9*2FLD/DDAB/GC 12.42 ± 2.17 20.82 ± 8.23 
CYP2C9*3FLD/DDAB/GC 2.73 ± 1.07 5.32 ± 2.03 
 
 
The turnover of the CYP2C9 allelic variants reflected what expected from literature data in vivo. 
The two main allelic variants CYP2C9*2 and CYP2C9*3 generally show a lower catalytic 
activity and they are known to induce serious adverse drug reactions with low therapeutic index 
drugs such as (S)-warfarin, acenocumarol and tolbutamide.  In vitro studies associate 
CYP2C9*3 with an intrinsic clearance of substrate lower than the one observed for the 
CYP2C9*2 (Yamazaki et al., 1998a; Yamazaki et al., 1998b; Rettie et al., 1999; Yasar et al., 
2001). Similar findings were observed in this set of experiments where the CYP2C9*3 showed 
a sixfold decrease in the apparent Vmax which is very close to the fivefold decrease observed in 
other studies on recombinant CYP2C9 (Haining et al., 1996). Similarly, in a study on 
microsomal fractions containing CYP2C9 and CYP2C9*3, the metabolic transformation of S-
warfarin has shown that the Vmax decreased its value from 220 ± 7 to 67 ± 4 (Yamazaki et al., 
1998b). 
The catalytic activity of the CYP2C9*2 was also affected. The Vmax of the 
2C9*2FLD/DDAB/GC decreases of one third compared to the CYP2C9. This value is in line 
with another study on liver microsome, but lower from what observed in others (Yamazaki et 
al., 1998a). However considering that the decreased activity of the CYP2C9*2 has been 
correlated with an altered interaction of the haem domain with the P450 reductase (Crespi et al., 
1997) it is not surprising to have small differences in our system where the haem domain is 
instead genetically fused to a small protein acting as a reductase. 
An estimation of the coupling efficiency was also given as ratio between the experimentally 
measured current and the current corresponding to the product formed. It is interesting to 
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observe a drastic decrease of the coupling efficiency in the CYP2C9*3 variants. A similar 
observation has been done on a study on recombinant CYP2C9*3 expressed in Escherichia coli 
cells as a reconstitute system with the human cytochrome P450 reductase. The substrate tested 
was naproxen. Also in that case an increased percentage of uncoupling reactions were seen for 
the CYP2C9*3 as disproportionate formation of the desmethylnaproxen product and H2O2 (Wei 
et al., 2007). The hypothesis of an increased amount of uncoupling reactions in the CYP2C9*3 
variants would contrast the original hypothesis of an altered substrate binding due to the 
location of the mutation within a substrate binding site of the enzyme. Nevertheless this 
hypothesis was already put in doubts from the deposition of the crystal structure of the CYP2C9 
where it appeared that the I359L is not involved in substrate binding (Wester et al., 2004). For 
the 2C9*2FLD/DDAB/GC the percentage of coupling appeared to be even higher than the wild 
type.  
  
6.6 Conclusions  
 
The electrochemical characterization of the CYP2C9BMR/DDAB/GC, 
CYP2C9BMR/DDAB/GC and their corresponding allelic variants was successfully carried out. 
All the constructs and variants showed well defined redox peaks in their cyclic voltammogram. 
The Emid calculated on the wild types CYP2C9BMR/DDAB/GC and CYP2C9BMR/DDAB/GC 
were similar to each other as well as to the one of the CYP2C9/DDAB/GC measured in chapter 
5. A slightly more negative value was observed for the CYP2C9BMR/DDAB/GC electrode, but 
in that case a second peak corresponding to the FMN redox centre of the BMR domain was 
observed thus indicating a different orientation of the chimera on the surface.  
The CYP2C9*2 and CYP2C9*3 variants of the CYP2C9BMR and CYP2C9FLD chimeras were 
also characterized and no significant differences in the Emid value were observed. The 
similarities observed would indicate that the single nucleotide mutation did not affect the 
reduction potential of the construct. 
As previously mentioned, the CO binding effect on the reduction potential shift of the haem was 
performed as a pure indication of the presence of a FeII/FeIII redox centre on the surface. All the 
constructs analysed showed a shift of their reduction potential towards more positive values and 
they confirmed the identity of the electroactive species immobilised.  
Differences into the electro-catalytic activity efficiency were then investigated between 
CYP2C9, CYP2C9BMR and CYP2C9FLD. A study on the number of electrons consumed by 
the three wild type chimeras in presence of oxygen and absence of substrate was performed at 
rotating disk electrodes in the catalytic cycle. In the catalytic cycle, Compound I is the final 
reactive iron-peroxy species responsible for the insertion of a hydro group in the substrate. The 
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application of the Koutechy-Levich equation to elaborate the experimental data revealed that in 
absence of substrate the CYP2C9FLD has a higher probability to form Compound I when 
compared to the other constructs. In order to confirm these findings the effective conversion of 
S-warfarin to its product 7-OH warfarin was carried out and the product formed quantified. 
CYP2C9FLD was found to be the construct with the higher amount of product formed for each 
molecule of enzyme in a minute. Also the percentage of coupling of the reaction towards S-
warfarin was measured and it resulted to be higher in the CYP2C9FLD construct. 
Subsequent attempts of testing the CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD 
electrodes as amperometric sensors by determining changes in the catalytic current induced by 
the addition of substrate failed. The deposited film showed a strong instability probably due to 
desorption or degradation of the immobilized enzyme.   
The system was therefore tested as a bio-catalyser. Saturating concentrations of S-warfarin were 
added and a fixed negative potential was applied for thirty minutes. The quantification by HPLC 
of the product formed revealed differences in the catalytic activity of the CYP2C9*2FLD and 
CYP2C9*3FLD constructs. The trend in the decrease of the activity for both the 
CYP2C9*2FLD and the CYP2C9*3FLD was in line with what observed in literature data and 
confirmed how the enzyme is able to maintain its enzymatic properties when immobilized. Even 
though the use of the CYP2C9/DDAB/GC as a sensor did not show to be promising, the 
information obtained from the electrochemical characterization confirmed the feasibility of 
developing a sensor based on immobilized cytochromes P450 once the right conditions for the 
mechanical stabilization of the layer and maintenance of the active state of the enzyme are 
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7.1 Introduction  
The conclusions from chapter six pointed out how a key feature for the development of a 
cytochrome P450 based sensor is the stability of the immobilised protein film. In the case of the 
DDAB modified glassy carbon electrode, the protein is adsorbed on the carbon surface for a 
mixture of hydrophobic and electrostatic interactions between the amino acid side –chains of the 
protein and the methyl and hydroxyl groups of the surface. These interactions are not strong 
enough to keep the protein adhered to the surface especially when multi-layers of protein with 
various distances from the surface are formed. Changing the electrode material to a surface 
capable of forming strong covalent bonds between the protein and the electrode surface is a 
possible way to improve the stability of the deposited protein layer. With this in mind 
CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD were immobilised on gold electrodes 
modified with a self assembled monolayer (SAM) of molecules functionalised with specific 
groups for the formation of covalent bonds with specific amino acids presents on the exposed 
surface of the polypeptide chain. Moreover in this system the protein interacts only with the 
superficial groups of the modified electrode and it is not completely embedded in a polymer 
where, as observed in the previous chapters, multiple interactions can induce conformational 
changes and modification of the active state of the enzyme. 
Once the best conditions to achieve a uniform and stable protein/SAM layer were established, 
the electrochemical characterisation of the electrodes was carried out. Furthermore, the system 
has then been tested as amperometric sensor where the change in current induced by the 
addition of incrementing concentration of substrate has been monitored and plotted to 
extrapolate enzymatic parameters towards a specific drug. The investigation has been then 
extended to the allelic variants CYP2C9*2FLD and CYP2C9*3FLD with the aim of 











7.2 Characterisation of the gold surface 
Gold is considered one of the most studied substrates for the electrochemical applications 
because of its high electrical conductivity, easy malleability and inertia to atmospheric oxygen 
and most chemicals (table 7.1). 
 
Table 7.1 List of the electrical conductivity of some elements usually used in electrochemical surfaces. 
 








Biological materials like metalloproteins can be bound and electrochemically characterised on 
gold surfaces. However proteins directly bound to unmodified gold electrodes tend to denature 
because of the formation of strong interactions between the metal and the polypeptide chain. To 
avoid these structural distortions the electrode surface can be modified with molecules able to 
form a protective intermediate layer between the enzyme and the bare gold. Aim of these layers 
also called “Self Assembled Monolayers” (SAM) is to avoid the direct contact of the enzyme 
with the surface, to guarantee and modulate the transfer of electrons and to avoid aspecific 
reactions of contaminants with the metal surface.  
Since the gold binds thiols with high affinity, most of the ligands that form SAMs are 
alkanethiols (Nuzzo et al., 1983). In the ligand the thiol is also called “head group” and it 
defines the specific affinity for the gold surface. Opposite to the thiol group, a specific chemical 
functionality can form interactions with defined functional groups of the polypeptide chain. In 
this way the SAM provides a convenient, flexible and simple system for tailoring the interfacial 
properties of the metal.  
In the next section the approaches that have been used in this study to achieve the formation of a 






7.2.1 Formation of a stable CYP2C9FLD alkanethiol modified gold electrode  
A key point for the formation of a stable, compact and well organised SAM is the cleanliness of 
the bare gold electrode. This pre-requisite is sometimes difficult to achieve as the bare surface 
of the gold metal tends to adsorb organic materials readily. The quick absorption of 
contaminants is due to their effect to reduce the surface tension (surface free energy) at the 
interface between the metal and the surrounding environment (Parsons et al., 1990).  
Most of the published methods for the cleaning of gold electrodes involve the oxidation of the 
Au metal surface.  These include electrochemical oxidation, immersion into a strong oxidizing 
solution such as “piranha” or exposure to reactive oxygen plasma. The experiments presented in 
this section have been performed on polycrystalline gold substrates prepared via controlled 
resistive evaporation on silicon wafer. Because of the thin thickness of the gold layer, the 
electrodes could not be treated with the “piranha” solution, but instead they were repetitively 
washed with organic solvents and then plasma cleaned. 
Figure 7.1 shows the cyclic voltammogram of a gold electrode after the cleaning procedures 
described in section 2.2.6. The figure shows the characteristic CV shape of a clean gold surface 
cycled between a potential range of +0.2 and +1.5 V in sulphuric acid solution. 
 
 
Figure 7.1 Cyclic voltammogram of a bare polycrystalline gold electrode scanned between +0.2 and 
+1.5V in a 0.5M sulphuric acid solution.  
 
However a problem associated with the oxygen plasma treatment is the production of gold 
oxides, Au2O3 on the gold surface. Many have investigated the effects of the metal surface 
oxidative pre-treatment upon the SAM formation, but whether the Au2O3 affects the SAM 
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quality remains uncertain. Therefore in order to avoid interferences in the SAM formation, the 
plasma cleaned gold electrode was left in ethanol for 20 minutes, as this is a good method to 
reduce the gold oxide (Ishida et al., 1997). 
The self assembled monolayer used in this study was a mixture of six and seven carbons long 
alkanethiols. Mixtures of alkanethiols of different lengths are widely used for the formation of a 
densely packed crystalline monolayer. Strong molecular interactions (van der Waals forces) are 
formed between the long carbon chains so that the longer the chain length, the more ordered the 
monolayer (Strong et al., 1988; Bain et al., 1989a). During the process of deposition, an initial 
disordered monolayer is formed in the first few minutes. Over the next several hours of 
incubation, van der Waals forces on the carbon chains help packing the long alkanethiol into a 
well-ordered, crystalline layer (Dubois et al., 1992). During this long phase of settlement, 
contaminants eventually present on the surface are replaced, solvents are expelled from the 
monolayer, and defects are reduced by lateral diffusion of the alkanethiols (Bain et al., 1989b). 
The final result is a hexagonal-packing arrangement that develop a natural curvature of 30° 
from the normal surface to maximize the molecular interactions between the carbon chains 
(Bain et al., 1989a).  
The “mixed monolayer” used in this work consisted of the 6-hexanethiol and the 7-mercapto 
heptanoic acid. The use of alkanethiols with different functional groups is a conventionally used 
method. Having only one of the two alkanethiols functionally modified reduces the chances of 
undesired reactions to occur. The presence of multiple groups like COOH and OH can induce 
cross-linkage via H-bonding and the formation of multilayers of SAMs. Furthermore, a steric 
hindrance can occur between neighbour head-groups disturbing the formation of a compact 
SAM (Bain et al., 1989b).  
Temperature and time of incubation are two factors that can influence the homogeneity of the 
SAM monolayer. Two different temperatures and times of incubation were therefore tested. 
Quantitative analysis of the coverage was evaluated by cyclic voltammetric investigations in the 
presence of the redox couple K3Fe(CN)6. The redox activity of this probe is inhibited as the 
monolayer becomes more compact with time. On a bare gold surface the electroactive 
K3Fe(CN)6 shows two well defined reversible and symmetric peaks. The two redox peaks 
become progressively more asymmetric as soon as a fully covered monolayer is formed on the 
surface. Figure 7.3 shows the CV of a bare gold electrode immersed in an electrolytic solution 
containing the ferricyanide probe. The two well defined and reversible redox peaks indicate a 
free access of the ferricyanide probe to the surface.  
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Figure 7.3 Cyclic voltammogram of a bare gold electrode. The experiment was recorded in an electrolyte 
solution containing 0.2 M K3Fe(CN)6 and 0.1 M aqueous KCl at a scan rate of 100mV/s and 20°C. 
 
 
The deposition of the SAM monolayer was achieved after immersing the cleaned electrode in an 
ethanolic solution of the two alkanethiols. Since temperature can improve the binding kinetics 
of the monolayer, a pre-treatment of the electrodes at high temperature (60˚C) followed by a 
long term room temperature incubation showed an increase in the level of insulation of the gold 
surface.  It appeared that the longer the incubation, the more insulating was the electrode (figure 




Figure 7.4 Cyclic voltammogram of a cleaned gold electrode treated with 6-hexanethiol and 7-mercapto 
heptanoic acid in ethanol for 24 hours. The electrode was heated at 60˚C for the first 20 minutes of the 
incubation. The experiments were recorded in 0.2 M K3Fe(CN)6 / 0.1 M aqueous KCl at a scan rate of 





Figure 7.5 Cyclic voltammogram of a cleaned gold electrode treated with 6-hexanethiol and 7-mercapto 
heptanoic acid in ethanol for 48 hours. The electrode was heated at 60˚C for the first 20 minutes of the 
incubation. The experiments were recorded in 0.2 M K3Fe(CN)6 / 0.1 M aqueous KCl at a scan rate of 
100mV/s and 20°C. 
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Achieving a good level of insulation of the electrochemical surface was an important step to 
limit the number of defects that could favour not only direct contact and denaturation of the 
protein, but also electrochemical reduction of oxygen to give a-specific current masking the 
response of the species of interest. 
After having found the best conditions for immobilisation, the protein was then covalently 
attached to the insulated electrode through formation of an amide bond between the free amines 
located on the amino acid sequence and the terminal carboxylate group of the 7-mercapto 
eptanoic acid. The bond occurs after an intermediate reaction with two components that catalyze 
and stabilise the final reaction between the carboxylic group of the SAM and the amine group of 
the protein. In the reaction sequence first the N-(3-dimethylamino)propyl-N′-ethylcarbodiimide 
hydrochloride (EDC) binds the carboxylic group. Then EDC is replaced by the N-
hydroxysuccinimide (NHS) ester that activates the carboxyl group to form an O-urea derivative. 
The protein immobilisation occurs by displacement of the NHS group by lysine residues in the 
protein (Patel et al., 1997). However since at the experimentally used pH the lysine are 
protonated, it is usually the NH2 group of the N-terminal that form the bond. In particular these 
lysines are those located at the N-terminus of the polypeptide as the pH used guarantees their 
protonation.  
Figure 7.6 shows the carbodiimide coupling reaction provided by EDC and promoted by NHS.  
 
Figure 7.6 Schematic representation of the carbodiimide coupling reaction between N-(3-
dimethylamino)propyl-N′-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS). 
 
 
The deposition of the protein on the modified electrode was the last step in the preparation of 
the amperometric sensing system and it was successfully achieved by following the protocol 
described in section 2.2.6. 
The aim of the system will be to measure the small changes in current following the 
metabolization of specific drugs by the enzyme.  Because of the expected small changes in 
current, it is particularly important to limit the background current signal coming from 
undesired reactions occurring at the electrode surface. For this reason before using the system 
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for its final goal, the stability of the background signal was investigated and specific 
experiments were performed to improve it.  
In the previous experiments the insulation of the electrode was maximized and the numbers of 
pinholes were minimized. Nevertheless, the background signal was found to drift following 
potential scanning. Protein aggregates on the electrode surface could responsible for this 
observed drift.  
In order to eliminate these aggregates multiple washes were performed in a phosphate buffer 
with high concentration of sodium chloride. The electrode was then left in the same buffer to 
favour the desorption of the excess of protein. 
Different incubation times and temperatures were tested. As shown in figure 7.7 more stable 
current signal was obtained after the electrodes was left in the electrolyte buffer at 4˚C for more 




Figure 7.7 Current signal measured at the potential of -0.450 V for CYP2C9FLD/C6C7/Au electrodes 
incubated in electrolytic buffer (EB) for different period of times. Black dots: electrode left for two hours 
in EB at 4°C. Red dots: electrode left for two hours in EB at 4°C. Blue dots: electrode left for two hours 
in EB at 4°C.The current was measured during cyclic voltammetric experiments perfomed in electrolyte 









7.3 Cyclic voltammetric studies on the CYP2C9FLD chimeras and 
their corresponding allelic variants 
 
Chapter 6 showed how the CYP2C9FLD construct immobilised on DDAB modified glassy 
carbon electrode had the highest catalytic activity compared to the CYP2C9BMR and N-
terminally modified CYP2C9 constructs. Moreover results on the CYP2C9*2FLD and 
CYP2C9*3FLD reflected literature findings where the two allelic variants are expected to have 
a reduced substrate turnover compared to the wild type isoform. For these reasons this chapter 
focuses on the FLD chimeras CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD and these are 
electrochemically characterised once immobilised on alkanethiols modified gold electrodes. 
Cyclic voltammetry was the technique of choice to investigate the electrochemical properties of 
the immobilised enzymes. As previously described in section 2.5, this method is able to follow 
the electron transfer between an electrode and an immobilised redox protein as a change in 
current after applying a cyclic range of potentials.  
All the electrochemical measurements were recorded at < 2ppm oxygen to focus on the first 
electron transfer event of the catalytic cycle. The voltammetric cycles were performed at a range 
of potentials between -0.75 and +0.25 V. The window of applied potentials was chosen 
according to the reduction potential of the CYP2C9 haem and FLD domain. The potential range 
never exceeded -0.75 V as below this value an electrochemical desorption of the immobilised 
layer was expected.  
The electrolytic solution contained a high potassium chloride salt concentration to guarantee 
both the conductivity of the electrochemical assembly and the monomeric state of the 
immobilised enzyme (Dodhia et al., 2006).  
Figures 7.8, 7.9 and 7.10 show the cyclic voltammograms of the CYP2C9FLD/C6C7/Au, 
CYP2C9*2FLD/C6C7/Au and CYP2C9*3FLD/C6C7/Au electrodes measured under anaerobic 
conditions. In order to see an electrochemical response the speed of the scan rate was adjusted 
to low values. A couple of redox peaks was only seen when the speed of the scan rate was 
slowed to 5mV/sec.  
One redox couple probably corresponding to the FeIII/II redox transition of the heam cofactor 
was observed at -0.079 ± 0.011, -0.088 ± 0.004 and -0.098 ± 0.008 V for the CYP2C9FLD, 
CYP2C9*2FLD and CYP2C9*3FLD respectively. These potential values were calculated 
versus saturated calomel electrode (SCE) and then normalised versus the normal hydrogen 





Figure 7.8 Cyclic voltammograms of the CYP2C9FLD gold electrodes modified with mixed monolayer 
C6C7. Experiments recorded in the absence of oxygen at 20°C in 50mM potassium phosphate, 500mM 




Figure 7.9 Cyclic voltammograms of the CYP2C9FLD gold electrodes modified with mixed monolayer 
C6C7. Experiments recorded in the absence of oxygen at 20°C in 50mM potassium phosphate, 500mM 





Figure 7.10 Cyclic voltammograms of the CYP2C9FLD gold electrodes modified with mixed monolayer 
C6C7. Experiments recorded in the absence of oxygen at 20°C in 50mM potassium phosphate, 500mM 
KCl, pH 7.4 at a scan rate of 5mV/s. 
 
 
Table 7.2 shows the list of the electrochemical parameters experimentally calculated. Important 
parameters taken in consideration from the CV are the magnitude of the anodic peak current 
(ipa), the cathodic peak current (ipc), the anodic peak potential (Epa) and the cathodic peak 
potential (Epc). 
 
Table 7.2 Electrochemical parameters extrapolated from the cyclic voltammetric experiments on 











 Emid which is the midpoint of the anodic (Epa) and cathodic (Epc) peak potentials 
‡ 
∆E which is the peak-to-peak separation (Epa-Epc) 
• ipc/ipa which is the cathodic-to-anodic peak current ratio 
 
 
Enzyme modification Emid (V)*  vs NHE ∆E (V)‡ ipc/ipa• 
CYP2C9FLD/DDAB/GC -0.079 ± 0.011 0.210 0.20 
CYP2C9*FLD/DDAB/GC -0.088 ± 0.004 0.210 0.20 
CYP2C9*3FLD/DDAB/GC -0.098 ± 0.008 0.175 0.10 
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The same experiment was performed on a protein-free C6C7 modified gold electrode (figure 
7.11). No redox couples were observed in the control electrode thus confirming that the peaks 
observed in figure 7.8, 7.9 and 7.10 correspond to the haem domains of the CYP2C9FLD, 
CYP2C9*2FLD and CYP2C9*3FLD constructs.  
 
 
Figure 7.11 Cyclic voltammograms of the protein-free gold electrodes modified with mixed monolayer 
C6C7. Experiments recorded in the absence of oxygen at 20°C in 50mM potassium phosphate, 500mM 
KCl, pH 7.4 at a scan rate of 5mV/s. 
 
 
As already observed for the CYP2C9FLD/DDAB/GC electrodes described in chapter 6, also 
here the second redox couple corresponding to the flavodoxin domain of the 2C9FLD chimera 
normally occurring at more negative potentials was not observed.  
The formal mid point potential values (Emid) listed in table 7.1 are more positive than those 
reported in the literature for different human cytochromes P450. Published literature data on 
CYP2C9 and other human isoforms immobilised on gold electrodes modified with different 










Table 7.3 List of studies and mid point potential values (Emid) observed for different human P450 and 











It is evident how each method of immobilisation influences the mid point potential of the same 
enzyme. The Emid measured for a recombinant CYP2C9 immobilised on gold electrodes 
modified with a mixture of alkanethiols of different length showed the most negative value 
(Yang et al., 2009). The mid point potential calculated in this set of experiment is instead more 
close to what observed by Joseph and co-workers on CYP3A4 immobilised with alternate layers 
of PDDA polymer (Joseph et al., 2003).  
The previously discussed influence of the FLD domain on the reduction potential of the enzyme 
was also confirmed in previous investigations. Results on a comparison between the 
electrochemical performances of CYP3A4FLD/Cys-Mal/Au and CYP3A4/Cys-Mal/Au 
electrodes showed a more positive potential for the construct with the FLD domain probably 
due to a favorable orientation of the immobilised enzyme (Dodhia et al., 2008).  
No significant difference in the formal potentials has been observed between the CYP2C9FLD 
and the two corresponding allelic variants. This suggests that the single nucleotide mutations of 
the CYP2C9*2 and CYP2C9*3 did not influence the reduction potential of the enzymes. 
 
 
7.4 Enzymatic studies on the fld chimeras 
 
7.4.1 (S)-warfarin metabolism electrocatalysed by immobilised CYP2C9  
 
The electrocatalytic characterisation of the immobilised CYP2C9 allelic variants is necessary to 
build a P450 based amperometric sensor able to detect the different levels of interaction 
between the CYP2C9 allelic variants and specific substrates. Experiments were then performed 
to study the electrochemically driven CYP2C9-mediated enzyme kinetics of S-warfarin. As in 
chapter 6, S-warfarin has been chosen for this investigation as the CYP2C9 catalyses the 7-
hydroxylation of S-warfarin better than that of R-warfarin. Moreover literature data have shown 
Enzyme modification Emid (V)*  vs NHE References 
CYP2E1/Cys-Mal/Au -0.177 ± 0.005 Fantuzzi 2004 
CYP3A4/ Cys-Mal/Au -0.157 ± 0.017 Dodhia 2008 
CYP3A4FLD/ Cys-Mal/Au -0.136 ± 0.010 Dodhia 2008 
CYP2C9/C8C11/Au -0.240 Yang 2009 
CYP3A4/ MPS/PDDA/Au +0.098± 0.005 Joseph 2003 
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this substrate to be a probe used to characterise differences between the metabolic activity of the 
CYP2C9 wild type and its two main allelic variants CYP2C9*2 and CYP2C9*3 (Kaminsky et 
al., 1997).  
Figure 7.12 show the cyclic voltammogram of the CYP2C9FLD/C6C7/Au electrode obtained in 
anaerobic (dash line) and aerobic (black line) conditions.  
 
 
Figure 7.12 Cyclic voltammograms of 2C9FLD/C6C7/Au electrodes in nitrogen saturated (dash line) and 
oxygen saturated (solid line) buffer. Experiments recorded at 20°C in 50mM potassium phosphate, 
500mM KCl, pH 7.4 at a scan rate of 5mV/s. 
 
 
In absence of oxygen, a couple of reversible peaks is observed centered at -0.079 V vs NHE. In 
the presence of oxygen, the oxidation peak disappears and the current of the reduction peak 
increases with a main peak centered at -0.45V vs SCE (figure 7.15). The result confirms how in 
the presence of oxygen the reduced FeII binds the oxygen molecule and starts the catalytic cycle 
with further reduction and conversion of oxygen to water, hydrogen peroxide and oxygen 
radicals. When both oxygen and a suitable substrate are present, metabolite production should 
be observed as well as an increase in the electron consumption because of both the uncoupling 
reactions and the metabolite formation (Estavillo et al., 2003). 
The large catalytic current observed in figure 7.15 was observed for all the 
CYP2C9FLD/C6C7/Au, CYP2C9*2FLD/C6C7/Au and CYP2C9*3FLD/C6C7/Au electrodes. 
The increase of the catalytic current in the presence of oxygen demonstrated the ability of the 
enzymes to metabolise oxygen and therefore the natural progression of the electrons through the 
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catalytic cycle. The metabolic activity towards a specific substrate was then tested and 
electrocatalysis in the presence of S-warfarin were performed.  
The electrocatalytic experiments were performed by immersing the CYP2C9FLD/C6C7/Au, 
CYP2C9*2FLD/C6C7/Au and CYP2C9*3FLD/C6C7/Au electrodes in an oxygenated 
electrolytic buffer containing saturating concentrations of S-warfarin for CYP2C9. A fixed 
reduction potential of -0.550 V was applied for 30 min and during the experiment the solution 
was stirred to ensure a constant concentration of oxygen at the interphase of the electrode. The 
potential applied was decided according to the reduction potential value estimated from the 
cyclic voltammograms. The aim of this applied potential was to guarantee the full reduction of 
the immobilised enzyme during the entire period of the experiments. At the end of the 
controlled electrolysis, the reaction solution was injected into a high-performances liquid 
chromatographer to determine the presence and quantify the concentration of the 7-OHwarfarin 
product formed.  
Figure 7.16 shows the chromatographic trace of the reaction obtained from the incubation of the 
CYP2C9*2FLD/C6C7/Au electrode with S-warfarin (black line). The trace overlaid (gray line) 
represents the electrolytic reaction obtained from the incubation of the protein-free C6C7/Au 
electrode with S-warfarin. Comparison of the two traces in figure 7.13 shows that a small 
amount of 7-hydroxy warfarin was also produced by the control electrode. Reactive oxygen 
species formed during the catalytic cycle can have a minor role in the formation of this small 
amount of metabolite. As previously explained, in order to control the potential formation of 
hydrogen peroxide and oxygen radicals originated from uncoupling reactions, catalase and 




Figure 7.13 Overlay of the HPLC chromatograms of the electrolytic reaction between 
CYP2C9FLD/C6C7/Au and (S)-warfarin (solid line), the electrolytic reaction between C6C7/Au and (S)-
warfarin (gray line), the 7OH-warfarin standard (dash line). The electrolytic reactions were perfomed 
upon application of a negative potential of -550mV for 30 minutes. Peak 1 corresponds to the internal 
standard salicylic acid, peak 2 to the product 7-hydroxy warfarin and peak 3 to the substrate (S)-warfarin. 
 
 
After 30 minutes of electrolysis in the presence of S-warfarin the turnover of the products 
formed were 15.75 ± 2.40, 6.85 ± 2.20 and 2.17 ± 0.12 pmol of 7-OH warfarin/min/pmol P450 
for the CYP2C9FLD/C6C7/Au, CYP2C9*2FLD/C6C7/Au and CYP2C9*3FLD/C6C7/Au 
electrodes respectively. These values represent the Vmax which is the maximum enzyme velocity 
extrapolated at saturating concentrations of substrate.  
Once the ability of the sensor to metabolise a substrate was established, the amperometric 
electrode was then tested as amperometric sensor. At this aim electrochemical titrations were 
performed. During each experiment different concentrations of a known substrate were added, 
the immobilised enzyme was reduced by applying a cyclic scan between 0 and -0.65V and the 
change in catalytic current was monitored at -0.45V. The potential value at which the current is 
monitored was decided according to the reduction potential value obtained from the cyclic 
voltammetric characterisation. The change in the current signal at -0.45V was plotted versus the 
concentration of substrate added. The end point of the titration corresponds to the point at which 
the rate of conversion of the substrate to product reached saturation.  
Preliminary experiments were carried out on the wild type, the CYP2C9FLD/C6C7/Au. A first 
electrochemical titration was performed on diclofenac, which is a known substrate of the wild 
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type CYP2C9, but it has not been seen to induce different metabolic behaviour in the allelic 
variants (Kirchheiner et al., 2003).  
The red dots in figure 7.14 represent the change in current at -0.45V after different 
concentrations of diclofenac were added to the CYP2C9FLD/C6C7/Au electrode.  The net 
current measured upon substrate addition was substracted of the value of current measured 
before substrate addition. An initial increase in the absolute value of current upon substrate 
addition was followed by a saturation of the signal. This is consistent with the behaviour of an 
enzyme in Michaelis-Menten conditions. The initial increase of current consumed and then the 
establishment of a saturation of the signal are indicative of a successful titration experiment. 
The net current measured upon substrate addition was subtracted of the value of current 
measured before substrate addition. The change in current consumed reflects an increase in the 
turnover of dyoxygen affected by the substrate and suggests that substrate is metabolized by the 
P450 enzyme, which is in turn regenerated for the next catalytic cycle. 
The black dots of figure 7.14 represent the change in current at -0.45V after different 
concentrations of diclofenac were added to the protein-free C6C7/Au electrode. The stability of 
the current in the control electrode excluded the possibility of interferences from aspecific 
reactions at the electrode surface or from an effect of the cyclic scans on the electrode charge. 
The fitting of the data point revealed a typical Michaelis-Menten behaviour that is expected for 
enzymatic metabolic reactions and in the case of this immobilised system represents the 
amperometric sensor transduction. From the fitting of the curve a Km value was extrapolated, 
which is the concentration of substrate at which half of the Vmax is achieved.  This constant is 
often associated with the affinity of the enzyme for a substrate as it is a measure of the substrate 
concentration required for effective catalysis. A value of 0.34 ± 0.08 was obtained which is in 




Figure 7.14 Titration of CYP2C9/C6C7/Au with diclofenac. Plot of the normalised change in catalytic 
current (measured at -0.45V of potential) versus the concentration of diclofenac added. The current was 




The response of the CYP2C9FLD/C6C7/Au, CYP2C9*2FLD/C6C7/Au and 
CYP2C9*3FLD/C6C7/Au towards S-warfarin was then tested. Figure 7.15 shows the plots of the 
change in current versus the concentration of the substrate added. From the fitting of the curves 
Michaelis-Menten constants were calculated for all the variants. The CYP2C9FLD/C6C7/Au, 
CYP2C9*2FLD/C6C7/Au and CYP2C9*3FLD/C6C7/Au electrodes showed Km values of 6.24 ± 


















Figure 7.15 Titrations of CYP2C9FLD/C6C7/Au (A), CYP2C9*2FLD/C6C7/Au (B) and 
CYP2C9*3FLD/C6C7/Au (C) electrodes with (S)-warfarin. Plot of the normalised change in catalytic 
current (measured at -0.45V of potential) versus the concentration of diclofenac added. The current was 





Table 7.4 summarizes the kinetic parameters calculated for all the immobilised CYP2C9 
variants. The CYP2C9*2 and CYP2C9*3 showed progressively higher Km values thus revealing 
lower specificity towards the drug as expected from the literature (Yamazaki et al., 1998a; 
Yamazaki et al., 1998b).  
 




Km             
(µM of        
S- warfarin) 
Vmax   
(pmol of 7-hydroxy 
warfarin/min/pmol 
P450) 
CYP2C9FLD/C6C7/AU 0.84 ± 0.05 15.75 ± 2.40 
CYP2C9*2FLD/C6C7/AU 1.76 ± 0.76 6.85 ± 2.20 
CYP2C9*3FLD/C6C7/AU 6.24 ± 0.95  2.17 ± 0.12 
 
Table 7.5 summarizes enzymatic parameters published for in vitro characterizations of the 
catalytic activity of CYP2C9 and its allelic variants towards warfarin.  
 
Table 7.5 List of publication and enzymatic parameters measured for recombinant human CYP2C9, 




(µM of        
S- warfarin) 
Vmax 





(Baculovirus–Insect cells) 6 ± 0.43 212 ± 7.4 
CYP2C9*3 
(Baculovirus–Insect cells) 30 ± 4.30  41 ± 3.9 
Haining et al., 
1996 
CYP2C9 
(Yeast cells) 11.6 ± 0.9 133.3  ± 6.1 
CYP2C9*3 
(Yeast cells) 92.3 ± 5.5 180.5 ± 8.0 
CYP2C9*2 
(Yeast cells) 12.5  ± 0.7 165.6 ± 5.2 
Sullivan-Klose 
et al., 1996 
CYP2C9 
(HepG2 cells) 4.1 ± 0.6 421 ± 21 
Rettie et al., 
1992 
CYP2C9 
(liver microsomes) 22-32 5.8-8 
CYP2C9*2 
(liver microsomes) 35-18 3.8-4.5 
CYP2C9*3 




(liver microsomes) 18±2 220 ± 7 
CYP2C9*2 
(liver microsomes) 22±1 110 ± 3 
CYP2C9*3 






The values calculated on the CYP2C9FLD/C6C7/Au electrode fall within the published range 
which is 6-420 for the Vmax and 4-32 for the Km. (Yamazaki et al., 1998a; Yamazaki et al., 
1998b). 
Regarding the CYP2C9*2FLD/C6C7/Au and CYP2C9*3FLD/C6C7/Au electrodes, it is 
interesting to analyse how much the enzymatic activity was decreased in respect to the wild 
type. Table 7.5 summarizes and compare the drop of the enzymatic activity in literature and in 
this work. From the in vitro data on microsomes containing CYP2C9, CYP2C9*2 and 
CYP2C9*3 variants, it results that the enzymatic activity decreases of a certain percentage. The 
same amount is confirmed in this set of experiments for the recombinant CYP2C9, CYP2C9*2 
and CYP2C9*3 immobilised on SAM modified gold electrode. Nevertheless it is necessary to 
point out the difficulty in finding an exact numerical correspondence between the observed and 
the published values. From table 7.5 it is clear how the enzyme source and the environment 
strongly influence the enzymatic activity. In any case having found that the trend of the 
enzymatic activity for the CYP2C9*2FLD/C6C7/Au and CYP2C9*3FLD/C6C7/Au follows the 
literature findings represents a successful results for the developed sensing system. 
From the data obtained in this set of experiments, the same investigation performed in chapter 6 
on the percentage of coupling of the different variants was carried out. The coupling has been 
calculated as ratio between number of electrons consumed and number of electrons necessary to 
produce the found amount of product. Table 7.6 summarizes the values and it appears that both 
the CYP2C9*2FLD/C6C7/AU and CYP2C9*3FLD/C6C7/AU shows a strong reduction of 
coupling compared to the CYP2C9FLD/C6C7/AU.  
 
Table 7.6 Percentage of coupling calculated for the CYP2C9FLD/C6C7/Au, CYP2C9*2FLD/C6C7/Au 
and CYP2C9*3FLD/C6C7/Au electrodes. 
 
Enzyme modification % coupling 
CYP2C9FLD/C6C7/AU 4.17 ± 0.94 
CYP2C9*2FLD/C6C7/AU 1.68 ± 0.51 
CYP2C9*3FLD/C6C7/AU 0.57 ± 0.08 
 
In the case of the variants immobilized on the DDAB modified glassy carbon electrode, only the 
CYP2C9*3FLD/C6C7/GC showed a decrease in the percentage of coupling. The new findings 
are more in line with a previous study mentioned in chapter 6 where the altered substrate 
turnovers of both the CYP2C9*2 and CYP2C9*3 are assigned to alteration in the P450 catalytic 
cycle (Wei et al., 2007). It seems that once immobilised on the SAM modified gold electrode 
where no polymers or modifiers are in direct contact with the protein scaffold, the enzymatic 
behaviour of the enzyme reflects more what observed in vitro with the protein free in solution. 
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7.5 Conclusions  
 
A detailed investigation on the deposition of a homogeneous and insulating alkanethiol layer on 
gold electrodes was successfully carried out. The reason for achieving a fully covered surface 
was to avoid the direct interaction between the metallo-protein and the electrode surface. 
Generally the direct interaction between a bare gold and a metallo-protein is so strong to induce 
a modified structure from that of the native form. The metallo-protein tends to aggregate on the 
electrode surface causing a blockage and lack of voltammetric response. Moreover direct 
electrochemical reduction of oxygen and other contaminants at the available exposed gold 
surface would mask and interfere with the catalytic current signal of the enzyme. The 
electrochemical signal in oxygenated buffer upon deposition of the SAM and CYP2C9FLD 
protein on the gold surface was found to be stabilized by incubating the electrode in to the 
buffer prior to the measurements.  
The cyclic voltammetric experiments on the CYP2C9/C6C7/Au, CYP2C9*2/C6C7/Au and 
CYP2C9*3/C6C7/Au electrodes confirmed the presence of an immobilised redox species from 
the appearance of a couple of redox peaks on the cyclic voltammogram. The Emid values of the 
CYP2C9/C6C7/Au, CYP2C9*2/C6C7/Au and CYP2C9*3/C6C7/Au were slightly more negative 
than those calculated for the same enzymes immobilised on DDAB modified glassy carbon 
electrodes. However a change in the reduction potential values according to the immobilisation 
method used has been widely observed in literature.  
No significant difference in the formal potentials of the CYP2C9FLD and its two corresponding 
allelic variants has been observed. The same behaviour was already observed on the DDAB 
modified method and thus further confirms how the single nucleotide mutations of the 
CYP2C9*2 and CYP2C9*3 does not influence the reduction potential of the enzymes. 
The enzymatic characterisation of the CYP2C9/C6C7/Au, CYP2C9*2/C6C7/Au and 
CYP2C9*3/C6C7/Au electrodes was then carried out in the presence of S-warfarin. 
Electrocatalytic titrations upon addition of increasing concentrations of substrate were 
performed and a Michaelis-Menten behaviour was observed from the plot of the variation of the 
measured current versus the concentration of substrate added. Enzymatic parameters were 
extrapolated and Km values in line with literature findings were observed. The same was 
observed for the Vmax of the enzyme measured from the amount of product formed after 
saturating concentration of substrate were added. Similarly to what previously observed for the 
glassy carbon electrodes the immobilised allelic variants showed changes in the coupling 













Immobilisation of the 




















The successful response of the CYP2C9/C6C7/Au was then transposed to a prototype bio-chip 
developed by Nanobiodesign Ltd. As materials cost is a crucial factor for the construction and 
manufacturability of a bio-chip the electrode material was changed from evaporated gold on 
silicon to sputtered gold on PET.  
 
8.2 Developing a P450 based amperometric sensor 
 
8.2.1 CYP2C9 biochip design 
 
An enzyme-electrode is a miniaturised chemical transducer that works by combining an 
electrochemical process (amperometric, potentiometric) to the activity of an enzyme. The 
function of the enzyme is to provide selectivity by virtue of its biological affinity for a particular 
substrate molecule. 
The biotechnology industry has tried to miniaturize this concept in order to develop biochips 
applied to different research areas including proteomics, genomics and pharmaceuticals. The 
intersection between these biotechnological areas and the semiconductor industry has open the 
way to the development of biosensors of microscopic dimension called bio-chips. These chips 
are meant as miniaturized laboratories where thousands of biochemical reactions can occur. 
These tools are useful to quickly screen large numbers of biological analytes for different 
purposes. Pharmaceutical companies can use these sophisticated devices to speed up important 
processes such as the development of drugs and the accurate diagnosis and understanding of 
biological mechanisms. 
The aim of this project was to characterise the immobilised cytochrome P450 2C9 and its two 
main allelic variants to be used in the development of protein bio-chips for the metabolic 
characterisation of new chemical entities. In particular preliminary investigations have been 
carried out on a first prototype developed and designed in collaboration with Nanobiodesign ltd, 
a spin-off company of Imperial College London. 
The array tested in this set of experiments is made of polypropylene and contains 8 wells with a 
sputtered gold working electrode, a screen printed silver chloride reference electrode and a 
screen printed carbon paste counter electrode. Figure 8.1 shows a scheme of the three electrodes 






Figure 8.1 A schematic representation of the main components of the three electrodes potentiostatic 







Figure 8.2 Picture of the plastic eight wells single usage array designed by Nanobiodesign ltd. The array 






8.2.2 Cyclic voltammetry and enzymatic characterisation of the cyp2c9 biochip 
 
A preliminary electrochemical characterisation of the CYP2C9FLD construct immobilised on 
alkanethiols modified sputtered gold electrodes was carried out using cyclic voltammerty. The 
protocol used for the SAM deposition, protein immobilisation and stabilization was the same 
described in the previous section. The electron transfer between the electrode and the 
immobilised redox protein was monitored as a change in current after applying a cyclic range of 
potentials. All the electrochemical measurements were recorded at < 2ppm oxygen level to 
follow the first electron transfer event of the immobilised redox species.  
The window of potentials applied to the 2C9FLD immobilised on the alkanethiol modified 
sputtered gold electrodes was shorter than the one applied to the same enzyme immobilised on 
the alkanethiol modified evaporated gold electrodes. A shorter window of potentials was 
necessary to avoid the electrochemical desorption and detachment of the screen-printed 
materials. Cyclic scans were performed between -0.65 and 0 V. 
The experimental conditions used were the same applied for the evaporated gold electrodes 
described in the first part of the chapter. Figure 8.3 shows the cyclic voltammogram of the 
CYP2C9FLD immobilised on C6C7 modified screen-printed gold electrodes. Similarly to the 
evaporated gold used in the previous section, the CYP2C9FLD immobilised on sputtered gold 
electrodes showed a reversible electrochemical response when a scan rate of 5mV/sec was 
applied. A single redox couple corresponding to the FeIII/II redox transition was observed at -
0.178 ± 0.016 V. All the potential values were calculated versus the silver chloride electrode 
and then normalised versus the normal hydrogen electrode (NHE).  
The same experiment was performed on a protein-free C6C7 modified screen-printed gold 
electrode and no electrochemical response was shown (figure 8.3). The lack of electrochemical 
response from the control electrode confirms the identity of the oxidation and reduction peaks 
observed in figure 8.3 as being the haem domain of the human CYP2C9FLD.  
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Figure 8.3 Cyclic voltammograms of the CYP2C9FLD immobilised on the sputtered gold electrodes of 
the array modified with a C6C7 alkanethiol monolayer. The black line represents the CV of the 
CY2C9FLD/C6C7/Au electrode. The red line corresponds to the protein-free C6C7/Au electrode. 
Experiments recorded in the absence of oxygen at 20°C in a 50mM potassium phosphate, 500mM KCl, 
pH 7.4 buffer at a scan rate of 5mV/s. 
 
 
The mid point potential value observed is more negative than what observed on the evaporated 
gold electrode. Table 8.1 summarizes the main electrochemical parameters calculated from the 
cyclic voltammetry of CYP2C9FLD immobilised on the sputtered gold electrode.  
 
Table 8.1 Electrochemical parameters extrapolated from the cyclic voltammetry of CYP2C9FLD 







 Emid which is the midpoint of the anodic (Epa) and cathodic (Epc) peak potentials 
‡ 
∆E which is the peak-to-peak separation (Epa-Epc) 
   
To test the ability of the array to determine the metabolic profile of unknown drugs, a series of 
known drug substrate specific to CYP2C9 have been used. Electrochemical titrations were then 
performed as described in the previous section. The electrochemically driven CYP2C9-
mediated enzyme kinetics of S-warfarin, diclofenac, fluoxetine, flurbiprofen, ibuprofen, 
piroxicam, tolbutamide and dextromethorphan was measured.  
Enzyme modification Emid (V)*  vs NHE ∆E (V)‡ 
CYP2C9FLD/C6C7/Au -0. 178 ± 0.016 0.200 
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As previously explained, the reduction peak of an active cytochrome P450 shows a marked 
increase in its catalytic current in the presence of oxygen as the haem iron is reduced, 
complexed with oxygen and metabolised to water, hydrogen peroxide or oxygen radicals 
through the three uncoupling shunts of the catalytic cycle. When a suitable substrate is added, 
metabolite production is observed together with a further increase of the electron consumption 
because of both uncoupling reactions and metabolite formation.  
Figure 8.4 shows the results of the titrations in terms of fittings of the data points obtained after 
the addition of each substrate. The apparent Km values extrapolated from the fittings as well as 















Figure 8.4 Titrations of CYP2C9FLD immobilised on the C6C7 modified sputtered gold of the arrays with 
different substrates. The data have been plotted as normalised change in catalytic current (measured at -
0.45V) versus concentration of the specific substrates added. The current was measured during cyclic 








Table 8.2 Electrochemical parameters extrapolated from the cyclic voltammetry of CYP2C9FLD 
immobilised on the sputtered gold of the electrochemical array illustrated bio-chip.  
 
Substrate Measured Km (µM) Literature Km (µM) Reference 
Warfarin 1.30  ±  0.57 0.8-5.8 Yamazaki et al., 1998 
Diclofenac 4.29  ±  2.38 1.8-8 Mancy et al., 1999 
Fluoxetine 4.27  ± 1.52 9.7 Ring et al., 2001 
Flurbiprofen 13.59  ± 5.10 19.4 Tracy et al., 2002 
Ibuprofen 17.49  ±  6.80 38 Andersson et al., 2004 
Piroxicam 36.13 ± 7.08 30.5 Tracy et al., 2002 
Tolbutamide 84.69  ±  6.70 145-192 Iwata et al., 1998 
Dextromethorphan 109.07 ± 10.61 222-343 Yu et al., 2001 
Naproxen 117.07 ± 31.31 116-307 McGinnity et al., 1999 
Melatonin 203.70  ± 23.34 282 Facciola et al., 2001 
 
 
All the calculated apparent Km fall within the published range of Km values. Each data point was 
subtracted of the background current signal. The background current signal was obtained after 




When the same protocols used in chapter 7 were transferred on the bio-chip, similar results were 
obtained especially in terms of electrochemical response in the presence of substrate. 
Electrocatalytic titrations in the presence of different specific substrates were performed and Km 




































The main aim of this thesis was to provide fundamental knowledge for the creation of an 
amperometric sensor for drug metabolism studies based on human cytochrome P450 2C9 and its 
main allelic variants, the CYP2C9*2 and CYP2C9*3. The detailed conclusions for each part of 
the project are reported at the end of each chapter. Here are summarised the general conclusions 
that are very encouraging. 
 
The fusion proteins CYP2C9BMR and CYP2C9FLD chosen for the investigation did not 
interfere with the expression and purification processes, but rather improved them. The 
preliminary spectroelectrochemical characterisation of the bacterial BMP revealed important 
findings regarding the state of an immobilised P450. It was clarified that the environment in 
which the immobilised protein is embedded is fundamental to define its active or inactive state 
and that, when both the active P450 and inactive P420 species are present on the electrode, the 
inactive one dominates the cyclic voltammogram. Similar observations were confirmed when 
the project was moved to the human CYP2C9 immobilised on PDDA and DDAB modified 
glassy carbon (GC) electrodes. The chemical properties of the modifier used had an effect on 
the reduction potential, electron transfer and conformational of the immobilised enzyme. 
Moreover among all the available constructs, the CYP2C9FLD showed the highest catalytic 
efficiency in terms of both the probability of forming the metabolically active P450-Compound 
I and the effective conversion of the substrate S-warfarin to its hydroxylated product.  
 
Taking in consideration all these information the experiments were directed onto the enzymatic 
characterisation of the allelic variants CYP2C9*2FLD and CYP2C9*3FLD. The DDAB 
modified glassy carbon electrode configuration showed the same metabolic response towards S-
warfarin as in in vitro experiments in solution, but also a mechanical instability of the protein 
layer. The CYP2C9FLD, CYP2C9*2FLD and CYP2C9*3FLD were therefore covalently 
immobilised onto alkanethiol modified gold electrodes and the system was tested as both bio-
catalyser and amperometric sensor. The results obtained were very encouraging as it was 
possible to measure enzymatic parameters like Km and Vmax in line with literature data. The same 
results were successfully confirmed when the same conditions were transferred to a prototype 
array of eight wells. The results pave the way to the future development of an amperometric 
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